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This thesis reports on the use of neopterin and 7,8-dihydroneopterin as biomarkers of 
inflammation in advanced atherosclerosis and the use of spectral CT imaging to assess the 
features and morphology of vulnerable atherosclerotic plaque. New non-invasive imaging 
modalities are being explored as current methods for the diagnosis of cardiovascular disease 
cannot be used for subclinical atherosclerosis. Specifically, non-invasive tools are required to 
assess plaque vulnerability, the main cause of stroke or heart attack. Neopterin has shown 
promise as biomarker for cardiovascular disease, with both prognostic and diagnostic 
capabilities. However, despite its known utility as a marker, little is understood about how the 
neopterin measured in blood plasma or serum relates to the underlying condition and how it 
relates to plaque vulnerability. Furthermore, it is generally unknown how the parent 
compound 7,8-dihydroneopterin becomes oxidised in biological systems. 
In this thesis, live excised carotid plaques from symptomatic patients provided a unique 
experimental system to test the effects of oxidants and inflammatory stimulants on the 
inflammatory biomarkers neopterin and 7,8-dihydroneopterin. Activating macrophages in the 
plaque produced a response that is inversely proportional to the volume of calcification in the 
tissue. The antioxidant and radical scavenging properties 7,8-dihydroneopterin were explored 
using a key oxidant, superoxide. Neopterin was found to be a central product of the complex 
reaction. Baseline 7,8-dihydroneopterin and neopterin values in plaque compared to plasma 
demonstrated that the plasma values do not necessarily reflect the antioxidant capacity or 
inflammatory status of the plaque tissue. However, there appears to be good correlation 
between immune cell activity in plaque and plasma lactate values. Calcification, 
haemorrhage, and lipid cores were identified using MARS spectral CT. Development of a 
low-density lipoprotein- based nanoparticle for the identification of macrophages within in 
plaque had limited success, with more work needed to improve the uptake in a cell model 
before use in a tissue sample. 
The results of this thesis demonstrate that spectral imaging has the capability to assess 
features of plaque vulnerability such as calcium deposition, lipid pools and intraplaque 
haemorrhage. This has the potential to improve patient diagnosis if this can be translated to 
   
ii 
 
human use. Furthermore, 7,8-dihydroneopterin and neopterin are modulated by changes in 
oxidant levels and immunological stimulation in atherosclerotic tissue, improving support for 
the case for adding these markers to panel of biomarkers for cardiovascular disease. Further 
research into how plasma levels of both compounds relative to in situ plaque production 
impacts patient outcomes would provide insight into the role of antioxidant capacity in 
plaque vulnerability and atherosclerosis.
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The development of tools to assess subclinical cardiovascular disease is essential to improving 
the health outcomes for millions of people. At present identifying subclinical or asymptomatic 
atherosclerosis in patients is problematic and often not attempted due to the invasive nature of 
the tests required. Instead, subclinical patients are treated based on a risk score. Undetected 
atherosclerosis is a concern, as cardiovascular disease is the cause of approximately 33% of 
deaths each year in New Zealand (Heart Foundation New Zealand), and can also have serious 
impact on patients’ quality of life.  
The aim of this thesis is to explore aspects relating to the diagnosis and detection of subclinical 
atherosclerosis using excised carotid plaque tissue from symptomatic patients. This thesis 
examines the link between neopterin, a known marker of cardiovascular disease, and the plaque 
tissue. This is achieved through a combination of biochemical assessments and spectral 
imaging of plaque tissue. In addition, this thesis broadens the understanding of the biomarker 
neopterin by examining the oxidative effect of superoxide on the parent compound, 7,8-
dihydroneopterin. This research explores potential imaging targets in advanced atherosclerotic 








Despite there being extraordinary breadth and depth to the literature relating to atherosclerosis, 
the disease is still not well understood. Here, the scope of this review is to establish the 
relevance of atherosclerosis in the New Zealand setting, to briefly explore the current methods 
of diagnosis and detection and their limitations, assess the role of inflammation as this 
specifically relates to macrophages in atherosclerotic plaque, and to examine potential 
biomarkers related to inflammation in atherosclerosis and new imaging modalities for detection 
of the disease. 
1.3 Cardiovascular Disease and Atherosclerosis 
Cardiovascular disease is the broad term given to the various inter-related pathologies that 
affect the heart and arteries (P. M. Ridker & Antman, 1999). Pathologies encompassed by this 
term include myocardial infarction, ischemic stroke, heart failure, and arrhythmia (Dhamoon, 
Sciacca, Rundek, Sacco, & Elkind, 2006). Atherosclerosis is one of the underlying processes 
that cause the conditions related to cardiovascular disease. It is the formation of plaque in the 
artery wall which eventually produces the symptoms of cardiovascular disease, e.g. high blood 
pressure, narrowing or stenosis of the artery (Narasimhulu et al., 2016).  
Plaques form from an early age, beginning as fatty streaks due to an accumulation of lipid-rich 
material (Gu & Zhang, 2015). Monocytes, a macrophage precursor cell, infiltrate the arterial 
wall in early atherosclerosis (Ulrich, Heine, Gerhart, Kohler, & Girndt, 2008; Xu et al., 2015; 
Yamashita et al., 2000). Once resident, macrophages promote inflammation through the 
generation of oxidants and the release of inflammatory cytokines (Biessen & Wouters, 2017). 
Macrophages continue the progression of an atherosclerotic lesion by taking up toxic oxidized 
low-density lipoprotein (oxLDL) in an uncontrolled manner, causing foam cell formation and 
eventual cell necrosis (Howell et al., 2011; Kavurma, Rayner, & Karunakaran, 2017). The 
subsequent release of lipids from dying macrophages promotes the formation of a lipid or 
necrotic core in the arterial wall (Otsuka et al., 2015; Silvestre-Roig et al., 2014; I. Tabas, 
2009).  
The build-up of plaque inside the artery wall, which is predominately composed of oxidized 
lipids and calcification (Rodriguez-Palomares & Masip, 2016), causes a narrowing of the 
lumen (He, Zhang, Shi, Chen, & Gao, 2013), decreasing blood flow and increasing blood 
pressure. The necrotic core is separated from the blood by a thin fibrous cap. Over time, 
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resident macrophages may release matrix metalloproteinases degrading the fibrous cap (Kong 
et al., 2005), making the plaque prone to rupture (Gao & Long, 2008; Gupta et al., 2013). 
Plaque rupture opens the contents of the necrotic core to the blood clotting factors triggering 
thrombosis (Owens & Mackman, 2012). The thrombi can then break away from the site of 
plaque rupture and obstruct small vessels (Nakanishi & Homma, 2016). These infarcts typically 
occur in the brain or heart and often result in death (Psychogios et al., 2015). 
1.4 Health Burden of Atherosclerosis in New Zealand  
Approximately one third of mortality worldwide is attributed to cardiovascular diseases (Moran 
et al., 2014; Mozaffarian et al., 2016). In New Zealand, 33% of deaths annually are due to 
cardiovascular disease and 1 in 20 adults are currently living with the disease (National Heart 
Foundation website accessed 22 Nov 2017). A 2009 Ministry of Health report puts the 
combined cost of coronary heart disease and ischemic attacks at $621 million. This figure 
includes both the direct medical costs and the estimated loss of productivity to the economy 
(Ministry of Health, 2009). It is clear from the literature that cardiovascular disease presents a 
health, economic and social burden to New Zealand.  
Since the introduction of statins, a class of lipid lowering drugs, in the late 1980’s (Endo, 2017), 
the prevalence of cardiovascular diseases has reduced. This has coincided with a reduction in 
the number of people who smoke and exposure to second-hand smoke, a key risk factor for 
developing cardiovascular disease. Although the overall prevalence has reduced, Maori and 
Pacific Islanders remain at a higher risk of developing cardiovascular disease (Feigin et al., 
2006). There is also now significant concern about the growing effect of conditions such as 
obesity and diabetes, which are also thought to contribute to the risk of developing 
atherosclerosis (Alberti et al., 2009). Despite significant research into the underlying 
mechanisms of cardiovascular disease, it is still not well understood why some will develop 
the disease and others will not. Therefore it is important, in both the New Zealand setting and 
globally, to address the issue of diagnosis and detection using contemporary techniques such 
as imaging and biomarkers. 
1.5 Current Methods for Detection and Diagnosis 
At present detection and diagnosis of confirmed cardiovascular disease does not typically occur 
until after an initial event. Early intervention strategies are generally based on a patient’s 
modified Framingham risk score, which is determined by age, sex, smoking status, diabetic 
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status, history of cardiovascular disease, blood pressure, and lipid status (Lloyd-Jones et al., 
2000).  
1.5.1 Risk based assessment 
The Framingham Risk Assessment was based on a long term population study of the residents 
of Framingham, Massachusetts (Wilson et al., 1998). This study was fundamental to the current 
understanding of cardiovascular disease as it showed the predictive value of cholesterol 
(Natarajan et al., 2003). The initial risk assessment (1998 and 2002) was only able to predict 
the 10-year risk of coronary heart disease (CHD), but the updated 2008 model now includes 
heart failure, stroke and transient ischemic attacks (TIAs) (Pencina, D'Agostino, Larson, 
Massaro, & Vasan, 2009). The 2008 Framingham Risk Score is the current modality for 
assessing patients in New Zealand (Ministry of Health). In order to include the higher risk in 
patients of Maori and Pacific Island descent (Feigin et al., 2006; Macmahon et al., 1995), an 
extra 5% is added to these patients’ scores. The Framingham Risk Score separates people into 
categories: low risk (< 10% of CHD), intermediate risk (10-20%), and high risk (>20%). Those 
who are determined to be clinically at risk (>20%) are treated with aspirin, a beta-blocker, a 
statin and then are followed up every 6 months. Common criticisms of the Framingham Risk 
Score include that it is based on a United States only population and that it overestimates risk 
in a low-risk population and underestimates it in a high-risk population (Bove et al., 2011; 
Moss, Williams, Newby, & Nicol, 2017). Whilst risk profiling works well on a population 
level, it does not necessarily apply well at the individual level. It is quite possible for a patient 
with little to no risk factors to experience an adverse event, and conversely it is possible for 
someone with many risk factors to never develop any symptoms. In many medical fields, 
including the area of cardiovascular medicine, there is currently a move towards personalized 
medicine, where the diagnosis and treatment plan is tailored to the individual (Favalli, Serio, 
Giuliani, & Arbustini, 2017; Loscalzo, 2012). However, in order for this approach to be 
successful, the clinician needs access to accurate diagnostic information. As will be outlined in 
the following sections, the task of gaining an accurate diagnosis of cardiovascular disease either 
via non-invasive or invasive methods can be difficult. 
1.5.2 Non-invasive assessment 
There are a number of non-invasive assessment techniques available which provide clinicians 
with both functional and anatomical information relating to cardiovascular disease. Non-
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invasive assessments are not recommended as a screening tool in low risk patients due to a 
high chance of a false positive result (Aroney, 2012). In patients who are at high risk of 
cardiovascular disease or have displayed symptoms, then non-invasive assessments are the first 
option for diagnosis and treatment. Outlined here are some of the most common procedures. 
Stress electrocardiogram (ECG) 
An ECG monitors the electrical activity of the heart using electrodes. In the case of a stress 
test, this takes place while a patient is active, or can be artificially stressed using specific drugs. 
Whilst this technique is fast and relatively safe, it has a low specificity (72%) and sensitivity 
(67%) (Mohamed, 2007), and is not appropriate for all patients e.g. endurance athletes. 
Stress echocardiogram  
During a stress echocardiogram, blood pressure and heart rate are monitored while the patient 
is exercising. The procedure also involves an ultrasound of the heart to determine blood flow. 
As with any ultrasound technique, there are limitations related to user expertise in obtaining 
accurate measurements. Despite this limitation, echocardiogram has been found to have good 
prognostic and diagnostic value (Konety et al., 2016).  
Carotid artery ultrasound 
This procedure is often used to assess patients who are at risk of stroke for treatment, for 
example whether placing a stent or carrying out a removal of the plaque is appropriate (Halliday 
et al., 2004; Stein et al., 2008). The ultrasound measures blood flow and narrowing of the 
artery, which is calculated as the percentage of stenosis (Bots, Hofman, & Grobbee, 1997; M. 
P. Spencer & Reid, 1979).  
Cardiac CT 
A cardiac CT is used to detect calcium in the coronary arteries in addition to blockages (Budoff 
et al., 2006). This procedure often involves administering beta-blockers to slow the heart rate, 
and a contrast agent to improve visualization of the arteries. A calcium score is calculated based 
on the Hounsfield Units measured (Criqui et al., 2014). A score over 10 indicates coronary 
artery disease (CAD) is present, and a score over 400 indicates extensive CAD. There is some 
debate about the prognostic value of this information and how to use this information to tailor 
patient treatment is uncertain (Detrano et al., 1999; Shaw, Raggi, Schisterman, Berman, & 
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Callister, 2003; Ulzheimer & Kalender, 2003). There is a growing use of this technique to rule 
out cardiovascular disease 
Cardiac MRI 
A cardiac MRI allows clinicians to assess the anatomy and function of the heart using magnetic 
resonance (Chung, 2002; Fisher, Steinberg, & Rogers, 1987). The benefit of this over CT is 
that there is no radiation involved; however, it is much more difficult to obtain high-quality 
images using this technique, as any motion will distort the image. 
1.5.3 Invasive assessment 
Invasive assessments are typically carried out on patients showing secondary symptoms of 
cardiovascular disease (e.g. shortness of breath). Invasive assessments provide a more accurate 
diagnosis of level of disease burden and aid the correct treatment choice. However, this 
increased accuracy gained from choosing an invasive assessment over non-invasive, also 
means an increased risk of an adverse event for the patient undergoing the procedure. 
Angiogram 
An angiogram involves the threading of a catheter into the patient’s artery, where a dye is then 
injected and monitored via x-ray. The x-ray will show if any blood vessels are narrowed or 
blocked. For a long time the technique was considered the gold standard for diagnosing 
cardiovascular disease, however, with improvements in imaging modalities there may be a shift 
away from this high risk invasive technique. 
Intravascular ultrasound (IVUS) 
IVUS is similar to an angiogram in that a catheter is used, but instead of releasing a dye, the 
catheter contains an ultrasound transducer. IVUS is used to measure plaque burden and stenosis 
of the artery. 
Fractional flow reserve (FFR) 
This technique measures pressure differences across an artery caused by narrowing. To do this, 
a catheter is inserted with a specially designed transducer which is able to measure pressure, 
flow and temperature. This technique can be used to tell if a narrowing of an artery is 
functionally relevant or not. 
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Current invasive and non-invasive assessments provide anatomical and functional information 
about cardiovascular disease and aid clinicians in risk stratification. However, one particular 
area that is not covered by any of these assessments is the risk of plaque rupture, which is a 
key event in cardiovascular disease.  
1.6 Inflammation 
1.6.1 Background 
The current assessment and treatment of cardiovascular disease is heavily weighted towards 
lipid status. Since the early 1990’s, there have been indications that there may be an 
inflammatory component to atherosclerosis. The discovery of involvement of inflammatory 
cells and cytokines started a shift in thinking away from atherosclerosis simply being a 
cholesterol storage disorder. Until recently, the hypothesis that inflammation has a significant 
role in the progression of atherosclerosis was untested in humans. A review by S Antonopoulos, 
Margaritis, Lee, Channon, and Antoniades (2012) highlights some of the early evidence from 
clinical trials with statins of an anti-inflammatory effect occurring which was separate to the 
lipid-lowering mechanism. However, these trials (e.g. LIPID, JUPITER, and PRINCE) did not 
confirm that the reduction in primary end points was independent of the lipid-lowering effect 
of the statins. In 2017, the CANTOS trial came to an end. This trial, along with the CIRT trial 
which finishes in late 2018, was designed specifically to test the inflammation hypothesis. The 
study found a significant reduction in the primary end point (non-fatal myocardial infarction, 
non-fatal stroke or cardiovascular death) in patients who received a 150 mg dose of 
canakinumab every 3 months over a 48 month period compared with the placebo (Paul M 
Ridker et al., 2017). Canakinumab was specifically selected as it has no lipid-lowering 
capabilities, but instead inhibits interleukin-1β. The patients in this trial were selected for 
continuing to have high levels of inflammation as determined by high sensitivity C-reactive 
protein of 2 mg/L or greater despite receiving statins and lipid-lowering therapy. This evidence 
that targeting inflammation reduces the risk of a cardiovascular event is further evidence as to 
why diagnosis of cardiovascular disease needs to move beyond the risk factors identified in the 
Framingham Risk Score alone.   
1.6.2 Key contributors to inflammation in atherosclerosis 
From early on, it was suspected that monocyte and leukocyte recruitment contributed to the 
development of atherosclerotic plaque (Herbin et al., 2016). Whilst there is still some debate 
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as to the initiating mechanism of atherosclerosis (Stocker and Keaney Jr (2004) provide an 
eloquent overview of the oxidative modification, response-to-injury, and response-to-retention 
hypotheses), in all cases it is thought that recruitment of monocytes and T cells is a key step in 
plaque progression.  It has since been established that there are different subsets of circulating 
monocytes, classical (CD14++ CD16−), non-classical (CD14+CD16++) and intermediate 
(CD14++CD16+), which have different pro-inflammatory and anti-inflammatory properties. 
In humans, an increase in CD16+ monocytes appears to be associated with plaque vulnerability 
(Imanishi et al., 2010). A recent study with mice found that increasing circulating monocytes 
by giving a constant very low dose of LPS increased the progression of atherosclerosis by 
priming the monocytes towards an inflammatory state (Geng et al., 2016). 
More recently, resident macrophage proliferation has been found to contribute to inflammation 
and destabilize atherosclerotic plaque. Proliferation of the resident macrophages maintains the 
local macrophage population in tissue (Hashimoto et al., 2013; Jenkins et al., 2011) and in 
advanced atherosclerotic plaque (Robbins et al., 2013). In ApoE-/- mice, inhibiting macrophage 
proliferation using simvastatin suppressed atherosclerotic plaque inflammation(Tang et al., 
2015).  
It is now understood that macrophages in the plaque are not homogeneous. Macrophage 
phenotypes were initially classed into two broad categories. M1 macrophages were defined as 
macrophages with classical activation, analogous to Th1 T cells. M2 macrophages were those 
polarized towards alternative activation, or an anti-inflammatory state. It was thought that M1 
macrophages contributed to plaque progression and M2 were involved in plaque regression 
(Mantovani, Sica, & Locati, 2005). However, initial classifications were determined based on 
cell culture. Several more macrophage phenotypes have now been identified in atherosclerotic 
plaque tissue. These include M(hb), Mox, M4 among others (Chinetti-Gbaguidi, Colin, & 
Staels, 2015; Erbel et al., 2015; Kadl et al., 2010). Each has properties that define it from other 
subsets. For example, Mox macrophages are the result of exposure to oxidized phospholipids, 
and can be differentiated from others by their increased expression of heme oxygenase 1 
(Marques, Negre-Salvayre, Costa, & Canonne-Hergaux, 2016). Studies looking at the 
distribution of macrophage phenotypes with in atherosclerotic plaque have found that both M1 
and M2 markers are increasingly expressed in advanced plaque (Johnson & Newby, 2009; Ira 
Tabas, 2010), and that certain areas of the plaque such as the plaque shoulder have greater 
numbers of M1 macrophages (Stöger et al., 2012). Ira Tabas and Bornfeldt (2016) provide a 
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particularly in-depth review of changes in macrophage polarization and phenotype that occur 
during the different stages of plaque development. Interestingly, cell culture studies have found 
that it is M2 macrophages that accumulate oxLDL rather than M1, due to a higher expression 
of CD36 (Van Tits, Stienstra, Van Lent, Netea, & Stalenhoef, 2011). After accumulating 
oxLDL, the M2 cells challenged with LPS produced pro-inflammatory cytokines at levels that 
matched M1 cells.  
Efferocytosis was previously thought of as purely the removal of dead or dying cells, however, 
there is now a wider understanding of how efferocytosis, and conversely, defective 
efferocytosis affects the ongoing immune response (Elliott, Koster, & Murphy, 2017). 
Defective efferocytosis prevents the appropriate reverse cholesterol transport pathways from 
operating which encourages foam cell formation (Kojima et al., 2014). Impaired efferocytosis 
of apoptotic cells leads to secondary necrosis which results in a build-up of dead cells, which 
in atherosclerosis, go on to form the necrotic core (Thorp, 2010). In addition to the 
accumulation of dead cells, there is an increase in TNF-α and IL-6, which promote on-going 
inflammation. Apoptotic cells release a number of chemokines which attract macrophages to 
the site of inflammation. It has recently been found that nuclear receptors including PPAR-γ 
enhance transcription of phagocytosis related genes (Chinetti-Gbaguidi et al., 2011; Noelia et 
al., 2009) particularly those relating to phosphatidylserine binding receptors including CD36, 
suggesting a link between efferocytosis and immune signalling, although the mechanism of 
nuclear receptor enhancement in the presence of apoptotic cells is not understood. 
1.6.3 Macrophage based mechanisms inflammation in atherosclerosis 
Inflammation in atherosclerosis is mediated by a number of cytokines, pathways and cell 
signalling molecules. Here, three of the relevant processes are explored in more detail. A full 
account of the various processes occurring can be found in Galkina and Ley (2009).  
Signalling via interferon-γ  
Interferon-γ has been found to have a pro-atherogenic affect in mouse models via the activation 
of the JAK/STAT pathway. The JAK/STAT pathway is a signalling cascade which has been 
implicated in a variety of inflammatory pathologies. Binding of a ligand at the cell surface 
triggers the phosphorylation of various proteins in the cascade, eventually resulting in DNA 
transcription. N. Li et al. (2010) found that incubating human monocyte-like THP-1 cells with 
interferon-γ increases STAT1 phosphorylation. This effect was reliant on ERK1/2 signalling. 
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Furthermore, it was found that interferon-γ increased the uptake of acetylated or oxidized LDL, 
again an ERK1/2 dependent mechanism. ERK1/2 is a component of the MAPK/ERK pathway, 
a separate cell signalling cascade which also induces gene transcription. Typically, binding of 
epidermal growth factor (EGF) to its receptor (EGFR) at the cell surface triggers the pathway. 
Defects in this pathway are thought to contribute to uncontrolled cell growth. 
NLRP3 inflammasome 
Inflammasomes are complexes that form in the cytoplasm of macrophages in response to 
danger or pattern recognition signals (DAMPs and PAMPs). Assembly of the NLRP3 
inflammasome, which is specific for sterile (non-bacterial) inflammation results in the cleavage 
of pro-interleukin-1β via caspase-1 to the mature interleukin-1β. Interleukin-1 contributes to 
atherosclerosis through actions such as monocyte recruitment (via MCP-1) and induction of 
IL-6 secretion (Ben-Sasson et al., 2009). Loss of function studies with IL-1 have shown that 
atherogenesis is lessened in mice (Alexander et al., 2012). In humans, blocking IL-1 reduced 
CRP release after acute coronary syndrome (Crossman et al., 2008). Initially thought to be only 
activated by cholesterol crystals in atherosclerosis (Duewell et al., 2010), it is now known that 
this also is mediated by oxLDL via CD36 (Sheedy et al., 2013). Reactive oxygen species (ROS) 
including superoxide generated by NADPH oxidase are thought to contribute to the priming of 
the NLRP3 inflammasome in atherosclerosis (Martinon, 2010). 
ROS generation via NADPH oxidase 
NADPH oxidase (NOX) is an enzyme complex which facilitates the transfer of electrons, 
usually resulting in the formation of superoxide or in some cases hydrogen peroxide (Abo et 
al., 1991). NOX is a membrane bound protein which exists in various isoforms. It is usually 
composed of six subunits: Rho-GTPase, gp91phox, p22phox (NOX 1,2,3,4 only), p40phox, 
p47phox, and p67phox. Isoforms include phagocytic oxidase which can be activated by  NF-
κB (Byrne et al., 2003), NOX 1, 2, 3 and 4 which have a similar morphology to each other 
(Bedard & Krause, 2007). NOX 2 is the main isoform in phagocytic cell such as macrophages. 
NOX 3 has been found to be constitutively active in cells, whereas NOX 1 and 4 can be 
upregulated by PMA (Ueno, Takeya, Miyano, Kikuchi, & Sumimoto, 2005). NOX 5 has a 
calcium binding domain and is involved in the phosphorylation of c-abl, a kinase involved in 
cell differentiation, division, and stress response (Bánfi et al., 2004). DUOX 1 and 2 are also 
regulated by calcium binding. DUOXs contain an additional extracellular domain and produce 
hydrogen peroxide in preference to superoxide (Lambeth, Kawahara, Diebold, & Medicine, 
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2007). There are several peptide-based inhibitors of NOX (for example, GP91ds-tat) as well as 
small molecule inhibitors (e.g. VAS compounds, apocynin, GKT inhibitors, DPI) (Altenhöfer 
et al., 2015). NOX inhibitor design is now focussing on inhibiting specific isoforms, rather than 
non-selective inhibition like that achieved by apocynin and DPI. 
Superoxide is converted to other products including hypochlorous acid, hydroxyl radicals and 
hydrogen peroxide. In healthy cells, ROS remain in homeostasis due to cellular mechanisms to 
remove ROS. However, in inflammatory conditions the flux of ROS exceeds the cellular 
capability for removal and leads to the activation of a number of inflammatory pathways. The 
NF-κB pathway is one pathway which influences the transcription of a number of genes related 
to stress response. Another is the MAPK/ERK pathway detailed above. ROS also activate the 
Nrf2 pathway which promotes the translation of enzymes that remove cellular ROS such as 
glutathione synthetase and peroxiredoxin. Inhibition of NOX has been shown to reduce 
atherosclerotic lesions and vascular ROS in ApoE-/- mice (Di Marco et al., 2014). Interestingly, 
ApoE-/- overexpressing superoxide dismutase (SOD), an enzyme which dismutates superoxide 
to hydrogen peroxide, still developed lesions, whereas ApoE-/- overexpressing either catalase, 
an enzyme that converts hydrogen peroxide to water and oxygen, or both catalase and SOD, 
did not go on to develop atherosclerotic lesions.  
Hydrogen peroxide may be contributing to the lesion development through a soluble fms-like 
tyrosine kinase-1 (sFLT-1) signalling pathway (H. Li, Gu, Zhang, Lewis, & Wang, 2005). 
Hydrogen peroxide has been found to induce the expression of sFLT-1 via activation of 
apoptosis signal-regulating kinase 1 (ASK1) (Agarwal et al., 2012). sFLT-1 a protein found 
carried in the bloodstream. Under normal circumstances, sFLT-1 reduces vascularization by 
binding free vascular endothelial growth factor (VEGF). In an overabundance, it can cause 
impaired angiogenesis which leads to endothelial dysfunction, promoting lesion development. 
It is also possible that hydrogen peroxide may be participating in a Fenton reaction which could 
promote the oxidation of LDL to oxLDL (Agil, Fuller, & Jialal, 1995; Formanowicz, Radom, 
Rybarczyk, & Formanowicz, 2018; S. P. Gieseg, Crone, Flavall, & Amit, 2008). 
1.7 Biomarkers of Atherosclerosis 
As the understanding of the underlying mechanisms of atherosclerosis has improved, there has 
been significant progress towards identifying novel markers of the disease. Yet, even with the 
progress that has been achieved, no marker has yet shown enough value to be included in the 
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standard risk assessment. An ideal biomarker would be a metabolite that was robust, non-
invasive, specific, sensitive, and most importantly, clinically relevant.  
CRP is often highlighted as the most promising biomarker of atherosclerosis (Kaski et al., 
2008; Skopec et al., 2016) and certainly there is a wealth of data related to CRP. It is produced 
in the liver and at sites of inflammation. It has been shown to be an independent predictor of 
cardiovascular risk in healthy men (the MRFIT trial), and has been found when used in 
conjunction with the Framingham Risk Assessment to provide more accurate risk stratification 
(Rifai & Ridker, 2001). However, CRP has low specificity as it is also increasing during 
infection and other types of chronic inflammation. This tends to be a common drawback of any 
inflammatory biomarker. Other promising biomarkers include TNF-α (Signorelli et al., 2016), 
IL-6 (Gostner & Fuchs, 2016), MDA-LDL (Haller, Lindner, & Lammerhofer, 2015), sFLT 
(Boyaud & Inguimbert, 2011; Gruson, Hermans, Ferracin, Ahn, & Rousseau, 2016), matrix 
metalloproteinases (Halade, Jin, & Lindsey, 2013; Konstantino et al., 2009; Olson et al., 2008), 
serum myeloperoxidase (Chen, Shi, Liang, Liang, & Fu, 2011; Scharnagl et al., 2014; Wang et 
al., 2017) and PTX3 (Fornai et al., 2016; Hollan et al., 2010). It is interesting to note that 
although development of a non-invasive biomarker has been a research focus for several 
decades now, there remains a lot of work to get a biomarker to the stage of clinical acceptance.  
In conjunction with the markers above, neopterin has also been put forward as a potential 
biomarker (De Rosa et al., 2011; Firoz et al., 2015; Schnabel et al., 2010; Videm, Wiseth, 
Gunnes, Madsen, & Garred, 2007; Zhang et al., 2016; Zuo et al., 2016). To date, over 200 
clinical studies have been conducted measuring neopterin in relation to major adverse cardiac 
events (MACE) or comparing healthy populations to those with symptomatic cardiovascular 
disease. A large proportion of these studies found that neopterin had predictive value in assess 
risk of cardiovascular events. Yet despite significant evidence of the prognostic and diagnostic 
value of neopterin, there has been little movement in the past decade towards acceptance of 
neopterin as a biomarker of atherosclerosis. 
1.8 Neopterin and 7,8-Dihydroneopterin 
Neopterin is produced by human macrophages in response to immune activation. Neopterin 
production is predominately induced by interferon-γ but also to a lesser extent by IL-10, LPS 
and PHA (Christoph Huber et al., 1984). In vitro experiments have found that in macrophages 
neopterin production peaks 48 hours after stimulation (Burrowes, 2012). Neopterin production 
ranges depending on level of stimulation with reported values of 20 pmol/mL after 72 hours 
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for 2.5 x105 macrophages (Christoph Huber et al., 1984) through to 2.5 µmol/L in plaque tissue 
(Steven P Gieseg et al., 2009). In sepsis patients, it has been found that if neopterin continues 
to be produced in increasing quantities for longer than three days, there is a higher likelihood 
of patient mortality (Adamik, Kübler-Kielb, Golebiowska, Gamian, & Kübler, 2000). 
Interestingly, the biological function of neopterin is largely uncharacterized. 7,8-
Dihydroneopterin, the parent compound to neopterin, is synthesized from GTP via an enzyme 
known as GTP cyclohydrolase I (GTPCH-I) (Niederwieser et al., 1984). 
  
Figure 1.1 Chemical structures of neopterin (left) and 7,8-dihydroneopterin (right) 
Previously, this research group has shown that atherosclerotic plaque is a source of 7,8-
dihydroneopterin and neopterin in patients with symptomatic atherosclerosis (T. Janmale et al., 
2015). In most cells, 7,8-dihydroneopterin is funnelled down the folate biosynthesis pathway. 
Macrophages lack significant quantities of the enzyme 6-pyruvoyltetrahydropterin synthase 
which controls this flux into the folate pathway, so compared to other cell types macrophages 
produce an excess of 7,8-dihydroneopterin (B Widner, Enzinger, Laich, Wirleitner, & Fuchs, 
2002). Oxidation of 7,8-dihydroneopterin produces neopterin, among other compounds (e.g. 
xanthopterin) (Dantola, Thomas, Braun, Oliveros, & Lorente, 2007; B. Widner, Mayr, 
Wirleitner, & Fuchs, 2000). In the literature, this oxidation step is often ignored, and 
researchers tend to refer to neopterin as the product of GTPCH-I in macrophages. However, it 
is known from research undertaken in this laboratory and others that a substantial amount of 
the 7,8-dihydroneopterin produced by macrophages is never converted to neopterin. To say 
neopterin is a measure of immune activation in macrophages is false, neopterin is a measure of 
the combined effects of immune activation and oxidation, whereas 7,8-dihydroneopterin alone 
provides a true measure of immune activation. Despite the fact there have been a substantial 
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number of studies relating to the use of neopterin as a biomarker, not a single clinical study has 
measured 7,8-dihydroneopterin. 
7,8-Dihydroneopterin in addition to being a marker of immune activation has been found to 
have several interesting properties in in vitro cell culture studies. It has been found to have a 
protective effect against oxLDL cytotoxicity in human macrophages (Shchepetkina, Hock, 
Miller, Kennedy, & Gieseg, 2017). 7,8-dihydroneotperin has also been shown to reduce uptake 
of cholesterol and oxysterols in human macrophages pre-treated before the addition of oxLDL 
(Davies, 2015). It is thought this effect may be mediated by the downregulation of CD36, a key 
cell surface scavenger receptor for oxLDL. Whereas incubation with oxLDL increases CD36, 
7,8-dihydroneopterin has been shown to downregulate the expression of this protein. At 
present, a number of pathways are being studied to analyse how 7,8-dihydroneopterin is able 
to induce this downregulation. Initial indications are that PPAR-γ and ERK1/2 are likely to be 
involved (Yeandle, 2017). However, the specific mechanism of action on this pathway is yet 
to be resolved.  
7,8-Dihydroneopterin also acts as a chain breaking, peroxyl radical scavenging antioxidant (S. 
P. Gieseg, Reibnegger, Wachter, & Esterbauer, 1995). K. Oettl, Dikalov, Freisleben, Mlekusch, 
and Reibnegger (1997) reported that 7,8-dihydroneopterin reduced radical scavenging by 
DMPO by up to 90%. They found that the rate constants for the reaction of 7,8-
dihydroneopterin with superoxide and peroxyl radicals were 103M-1s-1 and 107M-1s-1 
respectively. Early studies in cells found that micromolar concentrations of 7,8-
dihydronopeterin were able to inhibit red blood cell lysis mediated by AAPH (a radical 
generator), hydrogen peroxide and hypochlorite (S. Gieseg, Duggan, & Gebicki, 2000). More 
recently, 7,8-dihydroneopterin has been shown to protect cells against oxLDL-mediated 
glutathione loss and GAPDH inactivation (S. P. Gieseg, Amit, Yang, Shchepetkina, & 
Katouah, 2010). Following on from this work, it has been hypothesized that 7,8-
dihydroneopterin may be scavenging superoxide radicals generated by NADPH oxidase. It is 
thought that the neopterin which is being generated by atherosclerotic plaque may be a result 
of this scavenging. 
As outlined earlier, oxidation and generation of ROS are key components driving 
inflammation. With it becoming clearer that inflammation contributes to the development and 
progression of atherosclerosis, it makes sense to try to develop biomarkers that will capture 
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specific targets such as a patient’s antioxidant capacity (7,8-dihydroneopterin), level of 
macrophage activation (total neopterin), and level of oxidative stress (neopterin). 
1.9 Imaging of Atherosclerosis 
Whilst biomarkers of inflammation would provide a quick and easy test, any inflammatory 
biomarker will always require ruling out other sources of inflammation such as infection. It is 
likely that if a biomarker is adopted it will become part of a toolbox of tests that a clinician 
has available. Part of the problem for diagnosing cardiovascular disease at present is that 
current assessments of cardiovascular disease have low sensitivity or have a relatively high 
risk of adverse effects. To address this problem, new imaging modalities are being 
investigated.  
One of these imaging modalities is spectral photon counting computed tomography (CT). 
Spectral CT is already used in a number of preclinical applications ranging from measuring 
pore size in titanium scaffolds to identifying breast cancer cells using targeted nanoparticles 
(Rajendran et al., 2014; Roeder et al., 2017). It has been identified as an innovative technique 
that may allow the diagnosis of early plaque development in the carotid artery (Galaska et al., 
2016). This technique has recently been used for vascular imaging of the head and neck in 
asymptomatic patients (Symons et al., 2017) which gave high image quality and lower noise 
with fewer artefacts than conventional single energy CT. The MARS Bioimaging group based 
at the University of Canterbury has developed a commercial preclinical spectral CT scanner 
which produces images comparable to current histological techniques (Anderson & Butler, 
2014). In addition to providing a 3D reconstruction of the scanned object, the MARS scanner 
uses a proprietary algorithm to identify and quantify up to six materials within the object. 
Depending on the material, the sensitivity is as low as 1 mg/mL. The ability of spectral CT to 
identify materials within an image means that it provides the user with significantly more 
information than traditional CT. Information is captured from each photon by a highly sensitive 
read out chip, which means the dose required is roughly 1/5th of that used in standard CT 
methods. As a sensitive, low dose non-invasive technique, spectral CT shows promise as a 
diagnostic tool, in addition to its use for preclinical studies. 
Imaging and quantification of calcification within excised plaque has previously been shown 
to be possible using MARS spectral CT. (Zainon et al., 2014; Zainon et al., 2012). As discussed 
earlier, increased calcification in the coronary arteries has been linked to a higher risk of 
adverse events. However, the level of calcification in a carotid artery is not routinely captured. 
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Understanding more about plaque morphology and calcification is essential, as this is a key 
aspect of atherosclerosis that cannot be replicated by tissue culture experiments. It is suspected 
that the morphology of the plaque tissue may influence immune activation, and therefore is 
likely to have relevance to the development of biomarkers.  
The number and distribution of inflammatory cells within plaque tissue is of particular interest 
to researchers trying to understand plaque vulnerability. Spectral CT cannot identify 
macrophages directly as the individual cells are below the spatial resolution of the scanner and 
their composition (predominately water and lipid) is the same as any cell that makes up the soft 
tissue. However, spectral CT is particularly adept at measuring materials with a high atomic 
number. These are commonly referred to as high-z  materials. These materials produce a 
distinctive spectral signal. These materials tend to be the heavier metal atoms e.g. gold. It is 
hypothesized that macrophages in plaque tissue could be identified by spectral CT using gold 
nanoparticle labelling.   
Whilst imaging of atherosclerotic plaque using spectral CT is still in its infancy, there is some 
evidence that this technique can be used to distinguish features relevant to plaque vulnerability 
(Cormode et al., 2010; Zainon et al., 2012). Key features of atherosclerotic plaques which have 
been identified as having a role in plaque vulnerability include the necrotic core, fibrous cap, 
microcalcification, and intraplaque hemorrhage. Using a non-invasive method to measure and 
monitor the features may improve detection of aspects such as silent infarction in asymptomatic 
carotid atherosclerosis (Brott et al., 1994). In addition, a better understanding of how these 
features contribute to plaque vulnerability may lead to a reduction in unnecessary carotid 
endarterectomy surgery. This surgery introduced in 1954 used to prevent strokes. At present, 
the absolute risk reduction for patients undergoing the surgery is 13.1% over 2 years for those 
with symptomatic stenosis greater than 70% (Barnett & Collaborators, 1998). Feasby and 
Barnett (2007), among others, have identified the need for better assessment tools for selection 
for this surgery.  
1.10  Summary 
Despite atherosclerosis being a leading cause of mortality, the current tools available for 
assessment and diagnosis are limited. At present, the lack of understanding of the underlying 
mechanisms of the disease has prevented the development of a sensitive yet specific biomarker 
for cardiovascular disease. Importantly however, new non-invasive imaging techniques may 
prove crucial to understanding and assessing the risks associated with plaque vulnerability. 
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Furthermore, the combination of a biomarker of inflammation and improved imaging may 
provide clinicians with the tools they need to accurately assess patient risk.  
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1.11 Research Aims and Significance 
Below are the overall objectives of the Free Radical Research Group at the University of 
Canterbury and how this thesis fits within those goals. 
Long term goal 
To identify a robust panel of biomarkers that correlate with increased risk of atherosclerosis 
and develop screening tools to assess whether patients require carotid endarterectomy surgery. 
Statistical calculations from large group studies have shown up to 65 patients need to undergo 
an endarterectomy surgery to prevent a single stroke (Barnett, 2004). Development of 
appropriate screening tools and biomarkers to identify vulnerable plaque (plaque likely to 
rupture) would prevent many unnecessary surgeries reducing the cost to the health system and 
reducing risk to the individual patient. 
Medium term goal 
Explore neopterin as a biomarker for atherosclerosis and to identify markers of vulnerable 
plaque using MARS CT. 
Neopterin is known to be elevated in patients with cardiovascular disease and has been shown 
to a predictor of adverse outcomes. If neopterin could be used as a measure of atherosclerosis 
it would provide an inexpensive assay monitoring tool. Identification of vulnerable plaque 
using non-invasive imaging modalities would allow monitoring of disease progression and the 
effectiveness of treatment. 
PhD goals  
The specific aim of this thesis is to investigate the inflammatory response of macrophages 
within excised atherosclerotic plaque and the relation of the clinical biomarker neopterin, and 
its parent compound, 7,8-dihydroneopterin, to the morphology of the plaque. 
▪ Investigate the relationship between plaque morphology and its biochemical response, 
particularly release of neopterin and 7,8-dihydroneopterin, to stimuli. 
Neopterin and 7,8-dihydroneopterin production is not consistent across the length of the 
plaque (T. Janmale et al., 2015). By exploring the material composition of the plaque (lipid, 
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calcium, water, macrophage content) we are hoping to gain a better understanding of why this 
variation occurs and what the biological significance of this might be. 
▪ To develop techniques in conjunction with others that will identify macrophages and 
regions of interest within the plaque. 
Macrophages are key target within the plaque as they are known to contribute to the oxidative 
stress by producing ROS, they take up oxLDL and form foam cells, and lately have been 
implicated in leaving micro-calcium deposits in the plaque. Identifying regions that are rich in 
active macrophages may help broaden the understanding of the disease progression. Could 
neopterin be used as a tool to assess plaque vulnerability? 
▪ To explore the role of superoxide, a reactive oxygen species produced by NADPH 
oxidase in macrophages, in the oxidation of 7,8-dihydroneopterin to neopterin. 
7,8-dihydroneopterin is known to be a strong antioxidant and radical scavenger, but its 
interactions with superoxide, a key oxidant in plaque generated by NADPH oxdiase, have not 
previously been explored.  
1.12 Thesis Outline 
A note on the format of this thesis:  
This thesis borrows some of the formatting style from a typical medical physics thesis. This 
research covered a number of research areas which had different methodologies and goals but 
ultimately all contribute to the same broader goal. For this reason, the thesis is split into a 
number of small chapters, with a general discussion tying them together.  
Chapter 2 covers the general methods used in the experimental sections of the thesis in detail, 
including the development of an HPLC assay system to measure the superoxide generated 
oxidation of 7,8-dihydroneopterin, modifications to improve the SCX based detection system 
for neopterin in plasma and cell culture samples, and advancement of the existing plaque 
culture system. 
Chapter 3 assesses the activation of macrophages within excised plaque tissue, and examines 
this in relation to plaque morphology, specifically calcium. This is the first evidence that plaque 
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morphology modulates the inflammatory response in plaque. In addition, this is the first 
evidence that macrophages are able to produce total neopterin in response to PMA. 
This chapter forms the basis for the paper “Induced macrophage activation in atherosclerotic 
plaque” which has been accepted for publication by the journal Immunobiology.  
Chapter 4 explores the formation of neopterin with superoxide to further understand the 
relationship between 7,8-dihydroneopterin and neopterin. This is the first time that it has been 
shown that neopterin is a product of the reaction between 7,8-dihydroneopterin and superoxide. 
This work is part of a paper titled “7,8-Dihydroneopterin can be oxidized to neopterin by 
superoxide: evidence from cellular, ex vivo atherosclerotic plaque, enzymatic and radiolytic 
systems” which is being drafted at present. 
Chapter 5 examines the biological significance of oxidants in plaque in relation to total 
neopterin and neopterin output. This chapter shows that modulating the oxidant levels in the 
plaque using various inhibitors and stimulants has a direct effect on the level of neopterin 
produced relative to total neopterin.  
Chapter 6 studies the relationship between plaque biomarkers, total neopterin, neopterin and 
lactate, and plasma levels of these markers. This is the first time this relationship between 
plaque biochemistry and the measurable markers has been examined. In addition, the finding 
in this chapter that plaque total neopterin is correlated to plasma lactate levels, is original. 
Chapter 7 assesses various tools associated with spectral imaging of plaques. 
Chapter 8 examines the use of functionalized and non-functionalized gold nanoparticles as a 
marker of macrophages. In addition, a protocol for identifying intraplaque hemorrhage, a key 
marker of plaque vulnerability, is developed. The identification of intraplaque hemorrhage is a 
completely novel technique for spectral CT. This chapter also addresses the improvement of 
lipid measurement in plaque. 
This chapter forms the basis for a poster was presented at the Society for Biomaterials 
conference in Atlanta, Georgia in April 2018. 
Chapter 9 summarizes the findings of this thesis and looks at the future directions of this work. 
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1.13 Major scientific findings  
1. Neopterin is generated from superoxide induced oxidation of 7,8-dihydroneopterin. The 
7,8-dihydroneopterin appears to outcompete superoxide dismutase for the superoxide 
radicals. This is significant as it suggests HOCl-mediated oxidation of 7,8-
dihydroneopterin may not be the sole source of neopterin in macrophages. 
2. Plaque total neopterin output (macrophage activation) is correlated to plasma lactate values, 
which are known to be associated with the degree of carotid atherosclerosis present, and 
inversely correlated to calcium volume. This is significant as this is a first step towards 
being able to relate macrophage activity in vulnerable tissue to plasma markers which 
would help to improve clinical assessment of atherosclerosis. 
3. Oxidant production in ex-vivo plaque tissue can be induced through the addition of either 
oxLDL or nLDL. This is significant as being able to modulate oxidants in tissue ex-vivo 
provides a complex cell system to test questions related to the progression/regression of 
atherosclerosis. 
4. MARS imaging of plaque tissue produces high quality images with excellent differentiation 
of key hallmarks of plaque vulnerability, including lipid pools within the necrotic core and 
microcalcification, which are highly consistent with visual inspection of the tissue. This is 
significant as this means MARS imaging is now at a standard where it can be used to 
accurately quantify plaque vulnerability. 
5. Intraplaque haemorrhage can be identified and differentiated from calcification in ex-vivo 
plaque tissue. This is significant as iron and calcium cannot be distinguished using 
traditional CT methods, and it provides a further tool to assess plaque vulnerability. 
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2 Methods and Materials 
2.1 Materials 
All reagents were a minimum of analytical grade. All solutions were prepared using nanopure 
water (Millipore Milli-Q, MA, USA). 
  
7,8-Dihydroneopterin Schricks Laboratory, Switzerland 
Accutase Invitrogen, Life Technologies, New Zealand 
Acetic acid Scharlau Chemie S.A., Spain 
Acetonitrile J. T. Baker, NJ, USA 
Ammonium Chloride (NH4Cl) May & Baker Ltd, Dagenham, England 
Ammonium Phosphate  Sigma-Aldrich Co. LLC, New Zealand 
Apocynin Sigma Chemical Co., MO, USA 
Ascorbic acid Sigma Chemical Co., MO, USA 
BCA protein determination kit Pierce, IL, USA 
Canola Oil Sunfield, NZ 
Chelex-100 resin Bio-Rad Laboratories, California, USA 
Cholesterol reagent Roche Diagnostics, USA 
Copper Chloride Sigma Chemical Co., MO, USA 
Dimethyl sulphoxide (DMSO) BDH Lab Supplies Ltd, Poole, England 
Dipotassium phosphate Scharlau Chemie, Italy 
Ethanol BDH Lab Supplies Ltd, Poole, England 
Ethylene-diamine-tetra-acetic acid (EDTA) Sigma-Aldrich Co. LLC, New Zealand 
Gold nanoparticles Otago School of Medicine, Christchurch, NZ 
Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) 
Bayer Healthcare Pharma. LLC, Seattle, 
USA 
Hydrochloric acid (HCl) BDH Lab Supplies, Poole, England 
Interferon-gamma (IFN-g) Sigma Chemical Co., MO, USA 
Iodine (I) BDH Lab Supplies Ltd, Poole, England 
Iodine Chloride Sigma Chemical Co., MO, USA 
Isopropanol BDH Lab Supplies Ltd, Poole, England 
Lactate kit Roche Diagnostics, USA 
Lymphoprep Axis-Shield PoC AS, Oslo, Norway 
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Methanol Merck, Darmstadt, Germany 
Neopterin Schircks Laboratory, Switzerland 
Oil Red O Sigma Chemical Co., MO, USA 
Penicillin/ Streptomycin Invitrogen, Life Technologies, New Zealand 
Phorbol-12-myristate-13-acetate Sigma Chemical Co., MO, USA 
Phosphoric acid Sigma-Aldrich Co. LLC, New Zealand 
Phytohemagglutinin Sigma Chemical Co., MO, USA 
Potassium bicarbonate (KHCO3) May & Baker Ltd, Dagenham, England 
Potassium Iodide (KI) May & Baker Ltd, Dagenham, England 
Roswell Park Memorial Institute 1640 
(RPMI 1640) 
Sigma-Aldrich Co. LLC, New Zealand 
Sodium bicarbonate (NaHCO3) May & Baker Ltd, Dagenham, England 
Sodium chloride (NaCl) BDH Lab Supplies Ltd, Poole, England 
Sodium dihydrogen orthophosphate (Na 
H2PO4) 
Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium hypochlorite (NaOCl) Clorogene Supplies, Petone, New Zealand 
Trichloroacetic acid Merck, Darmstadt, Germany 
Xanthine Sigma Chemical Co., MO, USA 
Xanthine Oxidase Sigma Chemical Co., MO, USA 
 
  




2.2 Preparation of General Solutions and Buffers 
7,8-Dihydroneopterin solution 
7,8-Dihydroneopterin was prepared fresh prior to each experiment and shielded from light. 
Generally, a 2mM stock solution was prepared by sonicating 7,8-dihydroneopterin in ice cold 
RPMI 1640 (for cell culture experiments) or in phosphate buffer. If prepared for cell culture 
the stock solution was filter-sterilised via a 0.22 um filter membrane (Satorius AG, Goettingen, 
Germany). 
HPLC Mobile Phase 
Ammonium phosphate buffer was prepared by dissolving 5.28g of ammonium phosphate in 
1900 mL of nanopure water and adjusting the pH to 2.5 with 10 M phosphoric acid. The volume 
was then adjusted to 2000 mL using nanopure water. The solution was passed through a 0.45um 
filter and sonicated to degas. The final concentration of the stock solution was 20 mM which 
was mixed online to achieve the desired concentration. 
NBT solution 
4-Nitro blue tetrazolium chloride (NBT) was prepared by dissolving 0.1832 g of NBT powder 
in 100 ml 50 mM Phosphate Buffer (described below). 
Oil Red O stock solutions 
Oil red O powder (300 mg) was dissolved in 100 mL of isopropanol. A working solution was 
prepared by diluting at 6 parts of Oil Red O stock solution to 4 parts nanopure water. The 
working solution was left to stand for 10 minutes and then filtered through a 0.45um Whitman 
filter prior to immediate use. 
A 1 M concentrated citrate solution was prepared by dissolving 1.92 g of citric acid in 10mL 
of deionized water. This was then further diluted at a 1:4 ratio in deionized water and stored at 
4 degrees Celsius. 
Phosphate Buffer for NBT and Xanthine Oxidase Assays 
A 216 mM potassium phosphate buffer of pH 7.8 was made by dissolving 4.93 g of potassium 
phosphate dibasic into 90mL of water. The pH was adjusted to 7.8 and the volume topped up 
to 100 mL.   




All cell work was conducted under sterile conditions in a Class II Laminar Flow Hood. 
 
Blood Collection 
Blood was collected from haemochromatosis patients at NZ Blood, Christchurch under ethics 
approval CTY/98/07/069 granted by the Upper South (B) Regional Ethics Committee. Blood 
for monocyte or macrophage preparation was obtained in bags with the anticoagulant citrate-
phosphate-dextrose-adenine (CPDA-1). Blood for serum preparation was obtained in 
anticoagulant-free dry bags.  
Preparation of Human Serum 
Blood in dry bags was allowed to clot overnight in the fridge. The serum was then collected 
from the bags using a cannula and syringe into 50 mL centrifuge tubes. The tubes were spun 
for 15 minutes at 500g and the supernatant was extracted. The serum was stored at -80C. 
Isolation of Monocytes and PBMCs 
Blood from an autologous bag containing an anticoagulant (CPDA-1) was centrifuged in 50 
mL tubes for 30 minutes at 1000 g, slow acceleration, slow deceleration, room temperature. 
The resulting buffy coat, a white layer of immune cells that sits between the plasma and the 
red blood cells, was transferred to new tubes (maximum 15 mL per tube). The buffy coat was 
diluted with PBS (35 mL), and lymphoprep (15 mL) was underlaid. The tubes were centrifuged 
for 30 minutes as described above. A thick band forms about the middle of the tube which is 
the PBMC layer. This was carefully collected, avoiding the red blood cells, and placed in new 
tubes. The tubes were topped up with PBS (35 mL) and spun for 15 minutes, 500 g, fast 
deceleration. The resulting cell pellet was washed a total of 3 times using PBS. After washing, 
cells were resuspended in warm RPMI-1640 (serum-free) for counting. Cells were diluted to 5 
x 106 cells/mL. In the case of PBMCs, the medium was adjusted to contain 10% human serum 
and the cells were immediately plated into 24-well plates. For monocytes and macrophages, 
the cells remained in serum-free medium and were transferred to 6 well suspension plates for 
culture in a 5% CO2 incubator for 40 hours. After 40 hours, the monocyte cells were carefully 
collected, without disturbing the platelets and T cells that had adhered to the bottom of the 
plate. The cells were pelleted by centrifuge as described above and resuspended at 5 x 106 
cells/mL in RPMI 1640 with 10% human serum. The monocytes were then plated into 24-well 
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plates. Monocytes that were being differentiated into HMDM cells were supplemented with 2 
µL/mL of GM-CSF at the time of plating. 
Cell culture 
All cells were cultured in RPMI-1640 with 10% human serum and antibiotics (pen/strep). The 
media were changed every 3 days. Monocyte and PBMC cells were used within one week of 
plating. HMDM cells were cultured for 2-3 weeks to develop a “lawn” of mature macrophages.  
BCA protein assay 
The BCA assay (Smith et al., 1985) monitors a two-step reaction of protein with copper ions 
to form a purple complex which is monitored at 562 nm. This assay was carried out following 
the manufacturer’s instructions.  Briefly, standards were prepared by diluting 2 mg/mL BSA 
into a range of concentrations (5-250 µg/mL). Protein from cell samples was diluted 1/5 to 
ensure measurements were within the linear range. It is important to note that whilst the assay 
should be used in the linear range, the standards form a curve not a straight line. This should 
be calculated using a quadratic equation to avoid error. The working reagent was prepared at 
50 parts Reagent A to 1 part Reagent B. Sample (50 µL) and the working reagent (1 mL) were 
added together to a test tube and mixed well. This solution was heated at 60C for 30 minutes. 
The tubes were cooled in ice to stop the reaction and then read at 562 nm. 
 
Plaque culture 
Freshly excised carotid plaque tissue was obtained from consenting patients undergoing 
endarterectomy at Christchurch Hospital (ethics approval CTY/01/04/036 granted by the New 
Zealand Upper South B Ethics Committee). Plaques were transported to the laboratory on ice. 
Sections were cut approximately 3 mm thick and weighed (example in Figure 2.1). These were 
cultured in individual centre-well organ culture dishes (BD Falcon, NJ, USA) in 2 mL of 
RPMI-1640 containing penicillin (100 U/mL) and streptomycin (100 g/mL), supplemented 
with 10% human serum. Human serum was prepared from whole blood and stored at −80ºC 
until required. Sectioned plaques were incubated for 24 h prior to any experimental treatment. 
The media were changed every 24 h and the media was collected for lactate measurement and 
HPLC analysis of neopterin and total neopterin. 





Figure 2.1 Example of a plaque cut into sections and placed in individual culture dishes. 
Plaque sections were in general cut to be 2-3 mm in width, however, heavy calcification such as in section 5 at 
times prevented even cutting. 
 
Lactate assay 
Media lactate concentrations were determined using an enzymatic based absorbance assay in 
the form of a commercial kit (Lactate Assay Kit from Roche Diagnostics NZ Ltd, Auckland, 
NZ) and the assay was performed following the manufacturer’s specifications.  
HPLC assay 
Neopterin, 7,8-dihydroneopterin and total neopterin concentrations were determined by 
isocratic HPLC using Phenomenex™ SCX column on a Shimadzu 20A HPLC (Flavall, Crone, 
Moore, & Gieseg, 2008). For direct measurement of 7,8-dihydroneopterin, ultraviolet and 
visible light were measured using a Photodiode Array (PDA) detector. For neopterin and total 
neopterin, a fluorescence detector was used. In supernatant or plasma samples, media proteins 
were removed by acetonitrile precipitation (Flavall et al., 2008). 7,8-dihydroneopterin is 
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difficult to detect in biological samples in its native form so it was first oxidized to neopterin 
using acidic iodide, and then measured as total neopterin. The concentration of ammonium 
phosphate was modified depending on sample type (plasma vs media) to achieve clean 
separation of peaks on the chromatograms. For media samples, separation of peaks was 
achieved at 10 mM ammonium phosphate, whereas 1 mM ammonium phosphate was 
acceptable for plasma samples. Lowering the ammonium phosphate concentration increased 
peak heights but this occurred in the same manner in both the samples and external controls.  
 In the case of the the xanthine oxidase assay, the solution was transferred directly to HPLC 
vials, and the rack temperature was increased to 25 degrees Celsius from the standard 4 degrees 
to allow the reaction to be carried out directly in the HPLC. Samples were prepared just prior 
to the relevant injection time to ensure timepoints were as accurate as possible. The samples 
were run in the absence of ACN. The 7,8-dihydroneopterin concentration was measured 
directly using absorbance detection at 254nm. The small contamination of neopterin (~3%) in 
the samples from the outset was controlled for by taking a sample at time 0 to use to measure 
the change in 7,8-dihydroneopterin and neopterin. In addition, an enzyme free sample was also 
measured to monitor the lability of 7,8-dihydroneopterin at 25 degrees Celsius. 
 
Oil Red O staining 
 
This method is based on the method described by Culling, Allison, and Barr (2014). Briefly, 
tissue sections were placed in 60% isopropanol for 10 minutes before blotting. Sections were 
then stained with fresh filtered Oil Red O for 10 minutes. The tissue was blotted again, and 
then washed with 60 % isopropanol for 2 minutes. Finally, sections were rinsed with water, 
blotted dry and then photographed. 
 
Xanthine Oxidase Superoxide Generation 
This is based on the method by Fridovich (1970). A 1.08 mM (increased from 0.108 mM in 
most methods) xanthine solution was prepared by dissolving xanthine in a small amount of 
concentrated KOH. Once the xanthine dissolved this was topped with deionized water to 90 
mL and the pH was adjusted to 7.8. The volume was then finally adjusted to 100 mL.  
A reaction buffer was created by mixing 23 mL of H2O with 25 mL of phosphate buffer. To 
this 1mL of 4 mg/mL EDTA solution was added and 50 mL of the xanthine solution described 
above. If cytochrome c was being used 1 mL of a 14.6 mg/mL (1.1 mM) cytochrome c solution 
was added at this time, otherwise this was replaced with 1 mL of water. 
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The reaction was carried out in test tubes initially using a total reaction volume of 3 mL. This 
was made up of 100 uL of diluted xanthine oxidase enzyme solution, 100 uL of diluted SOD 
enzyme solution, 100 uL of 7,8-dihydroneopterin solution (made up at a 30x final concentration 
stock solution in phosphate buffer) and was topped up to 3 mL using the reaction buffer. The 
xanthine oxidase enzyme solution was always added last to begin the reaction. 
If the reaction was being carried out in the HPLC, the test tubes would be quickly mixed, and 
1.8 mL of the reaction solution transferred to an HPLC vial, just prior to the needle injection. 
Cytochrome c Assay for Measuring Superoxide generation 
This is based on the method by McCord and Fridovich (1968). The cytochrome c assay to 
measure superoxide generation could only be carried out in the absence of 7,8-
dihydroneopterin as this reacts directly with cytochrome c. The reaction buffer was prepared 
as detailed above for the xanthine oxidase assay. Xanthine oxidase was added last to begin the 
reaction. The reaction was monitored using continuous spectroscopic detection at 550 nm. To 
assess the amount of superoxide generated, the slope of the reaction was calculated, and an 
extinction coefficient of 21.1 x 103/M/cm was used to calculate the change in cytochrome c.    
 
NBT Assay for Measuring Superoxide Generation 
The superoxide radicals were estimated by the spectrophotometric measurement at 560 nm of 
the reaction product of NBT (Beauchamp & Fridovich, 1971). The reaction mixture contained 
50 mM potassium phosphate buffer (pH 7.8), 0.5 mM xanthine, 5 mU xanthine oxidase, 100 
μM NBT, and various concentrations of 7,8-dihydroneopterin.  
Preparation of LDL  
Plasma was obtained from healthy donors under ethics approval CTY/98/07/069 granted by 
the Upper South (B) Regional Ethics Committee. LDL was isolated from donor plasma using 
a centrifugation gradient separation method as described by S. P. Gieseg and Esterbauer (1994). 
Briefly, human plasma was thawed and centrifuged at 4,700 rpm for 10 minutes at 4ºC. After 
placing in a beaker on ice, the plasma density was adjusted to 1.24 g/mL by the gradual addition 
of 11.4 g of solid potassium bromide (KBr). Next, 8 mL of 1 mg/mL EDTA (pH 7.4) was added 
to each ultracentrifugation tubes (OptiSeal™, Beckman Coulter, USA). The density adjusted 
plasma (3.8 mL per tube) was then underlain. A Beckman Near Vertical (NVTi-65) rotor was 
used to centrifuge the tubes at 60,000 rpm for 2 hours at 10ºC using slow 
acceleration/deceleration in Optima™ L-90K Preparative Ultracentrifuge (Beckman Coulter 
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Inc., Fullerton, California). Isolated LDL was washed with phosphate buffered saline (PBS) 
using an Amicon Ultra-15 membrane filter centrifugation tubes (Millipore, USA) at 3000 g, 4 
C for 30 minutes, and repeated twice. LDL concentration was adjusted to 10 mg (LDL total 
mass) per mL, which was determined using a total cholesterol assay kit (Roche Diagnostics, 
Germany), assuming the total cholesterol accounts for 31.69% of the LDL particle (MW 
2500kDa). 
Oxidation of LDL 
Oxidation of LDL was performed using the method modified from Gerry, Satchell, and Leake 
(2008). This is the standard method for producing oxLDL in this laboratory. Briefly, 
Concentrated LDL at 10 mg/mL (total mass) was mixed with 0.5 mM copper chloride and 
placed into a dialysis tube.  
The LDL-containing dialysis tubing was suspended using a microtube at one end and a 
weighted clip at the other in a large glass bottle. The bottle contained 1 L of PBS per 10 mg of 
LDL protein and copper chloride at a final concentration of 0.5 mM. The LDL was dialysed 
for 24 hours at 37ºC in an orbital shaker (Bioline, Edwards Instrument Company, Australia). 
Upon complete oxidation the solution became colourless. The oxLDL was then washed twice 
at 4ºC for two hours and finally overnight in 1 L of PBS, containing a quarter teaspoon of 
washed Chelex-100 to remove excess copper ions. OxLDL was filter-sterilised through a 0.22 
µm syringe filter and stored at 4ºC prior to use.  
 
MARS Spectral CT 
The MARS spectral scanner (V6.0 MARS Bioimaging Ltd, Christchurch, New Zealand) was 
used to image phantoms, cell samples and carotid specimens (Figure 2.2). Spectral CT operates 
in the same manner as traditional CT except that the detector measures the energy of the 
incoming photon, rather than just recording that a photon arrived. The energy of the photon 
provides information about the material that the photon travelled through before arriving at the 
detector. The data obtained from the scanner includes a reconstruction of the object with an 
image from each energy bin for each slice, and a material decomposition which uses the energy 
information to assign each voxel to a material. These material maps are then available as 
separate layers which can be viewed together or separately in 2D or 3D using the MARS vision 
software. 




Figure 2.2 The MARS small bore spectral scanner for small animal imaging 
 
Preparation of phantoms 
A phantom is a calibration tool designed to mimic the intended sample. All phantoms used in 
the MARS spectral contain at a minimum samples of lipid (canola oil) and water, as these are 
integral to the material decomposition algorithm. A number of phantoms were used for these 
studies depending on the purpose of the experiment. For plaque scans, the phantom contained, 
in addition to lipid and water, hydroxyapatite at 0, 100, 200 and 400 mg/mL. For cell work the 
phantoms contained iodine (9, 18 mg/mL) and gold (4, 8 mg/mL). Identifying intraplaque 
hemorrhage used hydroxyapatite (0, 50, 100 mg/mL) and ferric nitrate (50, 100, 200 mg/mL). 
Preparation and scanning of samples 
For scanning samples containing iodine and gold, MARS scanning was carried out using the 
“Factory Al Protocol” with 2 mm aluminium filtration. The samples were scanned using a tube 
voltage of 118 kVp, a tube current of 13 μA, and an exposure time of 300 ms per position. Four 
energy bins were used, these in the range 18 – 29.9 keV, 29.9 – 44.9 keV, 44.9-77.9 keV, and 
77.9 keV <. This energy range expresses the k-edge of iodine at approximately 33.2 keV and 
captures the increase in attenuation of gold in the higher energy band, as gold has a k-edge at 
approximately 80.7 keV. Plaques scanned for lipid, soft tissue and calcium were imaged using 
2mm Aluminium filtration with energy bands beginning at 18, 30, 40, 50 and 60 keV, tube 
voltage 118 kVP, tube current 13 μA and exposure time of 200ms per position. When 
   
41 
 
attempting to identify intraplaque haemorrhage, thresholds were set a 20, 28, 36 and 44keV 
with a tube voltage of 80kVp, a tube current of 55 μA and 100ms exposure time per position. 
Image Analysis 
Image analysis was carried using a combination of ImageJ and MARS Vision (Mars 
Bioimaging Ltd, Christchurch, New Zealand). 
Statistical Analysis 
Prism 8.0 (GraphPad Software, CA, USA) was used to analyse the data. All statistical analysis 
was carried out using Prism software (GraphPad Software Inc, USA). A repeated measures 
one-way analysis of variance (ANOVA) was performed on all plaque data, using each section 
as a replicate. A repeated measures one-way ANOVA was performed on cell culture data. 
Plaque results are from individual plaques unless stated otherwise and each plaque is from a 
separate patient. Cell culture results are mean ± SEM of three independent experiments. 
Significance is indicated as *, p<0.05; **, p<0.01; ***, p<0.001. 
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3 Macrophage activation in live excised atherosclerotic plaque  
In this chapter, I carried out two of the plaque experiments, one was conducted by Ed Marks, 
and another by Sean Cross. I carried out all cell culture experiments, and the plaque scanning 
(with some guidance from Joe Healy and Aamir Raja). I prepared the associated manuscript. 
The results from this chapter have been disseminated as a paper entitled “Induced macrophage 
activation in live excised atherosclerotic plaque”. 
3.1 Introduction 
To date, most research into the role of neopterin in inflammatory conditions has made use of 
isolated cultures of macrophages or peripheral blood mononuclear cells (PBMC), however, this 
approach does not allow for the investigation of the more complex interactions between array 
of cell types (smooth muscle cells, macrophages, monocytes, T cells) and cytokines within the 
plaque tissue (Hsu, Lim, Tintut, & Demer, 2016; Wolf, Zirlik, & Ley, 2015). In this chapter, 
this disadvantage of mono layer cultures is overcome by activating resident macrophages in 
live carotid plaque tissue samples from carotid endarterectomy patients.  
Three different known macrophage stimulants were used to active plaque in this chapter, 
interferon-γ, PMA and PHA and compared activation within the plaque tissue with traditional 
monolayer cultures in the presence and absence of T cells. Interferon-γ directly induces the 
production of 7,8-dihydroneopterin in macrophages via the enzyme GTP cyclohydrolase I 
(GTPCH-I), while PMA and PHA are known to activate T cells, which produce interferon-γ in 
response (CF, 1986; Gostner et al., 2015; C. Huber et al., 1984; A. Lindsay et al., 2015). PMA 
and PHA are capable of indirectly increasing 7,8-dihydroneopterin. As 7,8-dihydroneopterin 
and its oxidation product neopterin are of low molecular weight, they easily diffuse out of the 
plaque into the blood stream or tissue culture media and can be measured as serum markers of 
macrophage activity and oxidation (S. P. Gieseg et al., 2008). 
Typically, in clinical settings only serum neopterin levels are analysed. In this study, both 
neopterin and 7,8-dihydroneopterin are measured. Neopterin can be measured directly and 7,8-
dihydroneopterin indirectly by oxidizing to neopterin. In a sample that has undergone this 
laboratory oxidation, the measured value is referred to as ‘total neopterin’ as the value given 
contains both the laboratory oxidized 7,8-dihydroneopterin and any biologically produced 
neopterin (A. Lindsay, Janmale, Draper, & Gieseg, 2014; A. Lindsay, Othman, Prebble, 
Davies, & Gieseg, 2016). The concentration of 7,8-dihydroneopterin alone can be inferred by 
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subtracting the known neopterin value which was measured in the non-oxidized sample. The 
advantage to analysing both total neopterin and neopterin is that the amount of oxidation (as 
neopterin) and the level of macrophage activation (as total neopterin) occurring in the tissue is 
measured.  
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3.2 Methods in brief 
This chapter examines the inflammatory and oxidative state of plaques from the carotid arteries 
of four individual patients. The plaques were prepared and cultured as described in Chapter 2.  
Neopterin levels in the media were determined by isocratic HPLC using Phenomenex™ SCX 
column on a Shimadzu 20A HPLC with fluorescence detection of the eluting neopterin as 
previously described. Media proteins were removed by acetonitrile precipitation. Due to the 
non-fluorescent nature of 7,8-dihydroneopterin, this was first oxidized to neopterin using acidic 
iodide, and then measured as total neopterin.  
Media lactate concentrations were determined using a lactate assay as described in Chapter 2. 
Primary cultures of human PBMC (a mixture of lymphocytes and monocytes) and HMDM 
cells were isolated from fresh whole blood donated under ethics approval CTY/98/07/069 and 
cultured as described in Chapter 2.  
Fourteen plaque sections from two plaques were scanned using a MARS spectral scanner 
(MARS Bioimaging Ltd, New Zealand) using a 2mm Aluminium filter at 30, 40, 50 and 60 
keV and material decomposition carried out using MARS Vision software (Butler et al.; Zainon 
et al.) Image J was used for additional image analysis. 
All statistical analysis was carried out using Prism software (GraphPad Software Inc, USA). A 
repeated measures one-way analysis of variance (ANOVA) was performed on all plaque data, 
using each section as a replicate. A repeated measures one-way ANOVA was performed on 
cell culture data. Plaque results are from individual plaques unless stated otherwise and each 
plaque is from a separate patient. Cell culture results are mean ± SEM of three independent 
experiments. Significance is indicated as *, p<0.05; **, p<0.01; ***, p<0.001. 
  




3.3.1 7,8-Dihydroneopterin and neopterin formation in unstimulated plaque 
Unstimulated plaque in tissue culture is viable and produces both 7,8-dihydroneopterin 
(measured as total neopterin) and neopterin. The plaque was obtained from a 49-year-old male 
ex-smoker who presented with a stroke, retinal ischaemia, and familial hypercholesterolaemia 
and cut into sections before being cultured. The mean total neopterin produced by the plaque 
between 48 and 72 h was 0.34 ± 0.08 nmol/g and the mean neopterin was 0.23±0.05 nmol/g. 
The incubation of unstimulated plaque for 72 h resulted in a significant decrease (-0.27 nmol/g, 
p = 0.027) in total neopterin at 48 h, but then no further change (Figure 3.1a). Mean neopterin 
did not significantly decrease (-0.05 nmol/g, p = 0.012) until 72 hours (b). Neither mean 
neopterin nor total neopterin increased at any point, which is consistent with the plaque being 
unstimulated.  
 































































































Figure 3.1 Production of total neopterin and neopterin in media from an unstimulated plaque.  
The plaque was retrieved from a 49-year-old male ex-smoker who presented with a stroke, retinal ischaemia, 
and familial hypercholesterolaemia. Ultrasound of the artery determined 60−69% stenosis. The plaque was 
incubated in RPMI-1640, supplemented with 10% human serum for a total of 72 h (N=1). (a) shows the total 
neopterin produced, as measured by HPLC at each media change. (b) shows the neopterin for the same time 
periods. Plaque total neopterin and neopterin concentrations for each section are given in nmol/g of plaque. (c) 
and (d) compare the mean and range of plaque total neopterin and neopterin at each time point. A repeated 
measures one-way ANOVA was conducted. Significance is indicated as compared to the previous 24 h period: 
*** indicates p<0.05. 
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3.3.2 Direct activation of plaque macrophages by interferon-γ in cultured plaque  
Interferon-γ, generated in vitro by T helper-1-type (Th-1) cells, is a key stimulator of the 
macrophage inflammatory response (C. Huber et al., 1984). A single addition of interferon-γ 
(500 U/mL) to a plaque obtained from an 82-year-old male non-smoker who presented with a 
transient ischaemic attack and right upper limb weakness caused a sustained rise in total 
neopterin and neopterin (Figure 3.2 a and b, also Figure 3.3). The initial levels of total neopterin 
before the addition of the interferon-γ ranged from 0.48 nmol/g to 4.28 nmol/g, suggesting this 
patient had higher levels of baseline inflammation in their plaque tissue, compared to the plaque 
analysed in , which ranged from 0.28 nmol/g to 1.03 nmol/g. The neopterin was less than 0.44 
nmol/g for all 8 sections prior to interferon-γ addition. For all sections, there was a significant 
rise in both the mean total neopterin following interferon-γ addition, which increased by 4.89 
nmol/g (p = 0.003) and neopterin (2.82 nmol/g p = 0.037) over the 72 h. The magnitude of rise 
was different for each section, with some sections responding slowly to the interferon-γ 
stimulation (, sections 5–7). This demonstrates that along the length of the plaque there are 
marked differences in inflammatory activity as well as differing levels of oxidative stress. The 
high levels of lactate released from the plaques confirmed that the plaques remained 
metabolically active during the entire incubation. The lactate levels ranged from 121.7 
μmol/g/24 h to 318.4 μmol/g/24 h. 



























































Figure 3.2 Media total neopterin and neopterin from plaque stimulated with 500 U/mL of interferon- γ. 
Interferon-γ stimulation of the plaque or cells occurred in a single dose after an initial 24 h of media with 10% 
human serum. Subsequent media changes at 48 h and 72 h contained RPMI-1640 with 10% human serum only. 
(a) and (b) show the total neopterin and neopterin measured in the interferon-γ treated plaque (N=1) obtained 
from an 82-year-old male non-smoker who presented with a transient ischaemic attack and right upper limb 
weakness; 80–95% stenosis of the artery was determined by ultrasound. The plaque tissue exhibited moderate 
levels of calcification. Repeated measures one-way ANOVA was carried out. Significance is indicated as 
compared to the previous 24 h period: ** indicates p<0.01; ***, p<0.001. 
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Figure 3.3 Production of total neopterin and neopterin in media from plaque, macrophages, and PBMC 
culture stimulated with 500 U/mL of interferon- γ. 
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Interferon-γ stimulation of the plaque or cells occurred in a single dose after 24 h. Subsequent media changes 
contained RPMI-1640 with 10% human serum only. (a) and (b) show the total neopterin and neopterin measured 
in the interferon-γ treated plaque (N=1) obtained from an 82-year-old male non-smoker who presented with a 
transient ischaemic attack and right upper limb weakness; 80–95% stenosis of the artery was determined by 
ultrasound. The plaque tissue exhibited moderate levels of calcification. Unrelated human HMDM and PBMCs 
were analysed. Total neopterin and neopterin were also measured in a HMDM culture (c) and (d), and in a 
PBMC culture (e) and (f) (N=3). Error bars represent SEM. Repeated measures one-way ANOVAs were carried 
out on each dataset. Significance is indicated as compared to the previous 24 h period: ** indicates p<0.01; ***, 
p<0.001. 
3.3.3 Direct activation of macrophages by interferon-γ in cell culture 
To better understand the dynamic behaviour of neopterin-releasing cells within the plaque, we 
examined cultured HMDM and PBMC prepared from donated blood supplied by the blood 
bank. The interferon-γ activation of the HMDM cells produced a significant 29-fold increase 
in total neopterin (p = 0.004) after 24 h (Figure 3.3c). The level remained around 200 nmol/g 
cell protein for the whole 72 h period. However, there was no significant neopterin formation 
until 48 h after adding interferon-γ (Figure 3.3d). The level of neopterin then decreased in the 
following 24 h, indicating a decrease in oxidant production. Interferon-γ stimulation of the 
PBMC caused a total neopterin rise that was larger than that seen with HMDM (Figure 3.3e). 
In contrast, the neopterin rose immediately and stayed elevated for the whole 72 h of incubation 
which was like that seen in the plaque stimulated with interferon-γ. 
3.3.4 Indirect stimulation of macrophages in cultured plaque with PMA 
Both PHA and PMA stimulation of T cells has been shown to cause the release of interferon-γ 
which is capable of inducing macrophages to produce 7,8-dihydroneopterin (C. Huber et al., 
1984). A plaque obtained from a 65-year-old male non-smoker who was suffering from 
dysphasia and amaurosis fugax was sectioned (shown in Figure 2.1), and after a 24 h washout 
period was stimulated with PMA. In the first three sections (1−3) of the plaque there was a 
substantial rise in total neopterin within 24 h, and the level continued to rise in the following 
24 h period (Figure 3.5a). Sections 4, 7, and 8 only showed a rise after the second dose of PMA. 
However, the overall mean change in total neopterin across the plaque was not significant due 
to the wide variation between sections (3.06 ± 1.54 nmol/g, p = 0.073). The level of oxidation 
in the plaque measured by neopterin was low compared to the output of total neopterin (Figure 
3.5b c.f. Figure 3.5 a). The rise in mean neopterin over 72 hours (4.78 ± 1.99 nmol/g) was 
significant (p = 0.037).  
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3.3.5 Stimulation of macrophages and PBMCs in cell culture with PMA 
With HMDM cells, total neopterin significantly increased with the addition of PMA after both 
24 and 48 h of stimulation (Figure 3.5c). The PMA was given twice as it is likely to take longer 
than 24 hours to reach maximal activation if the process is being driven from a gene 
transcription level. The PMA was removed for the last 24 h incubation and replaced with 
interferon-γ to test whether stimulation had been successful, which generated a small but 
significant increase. The same treatment with PBMC showed a similar trend of increasing total 
neopterin by the PMA, but twice the level seen with the interferon-γ. The presence of the T 
cells appears to have greatly enhanced the generation of 7,8-dihydroneopterin from the 
monocytes. 
The time course of 7,8-dihydroneopterin oxidation to neopterin with PMA-stimulated HMDM 
cells was very like that seen with interferon-γ, with an initial delay of 24 h in the rise of 
neopterin levels (Figure 3.5d). With PBMC, the presence of the PMA has abolished the delay 
in the oxidation of 7,8-dihydroneopterin, starting strongly after 24 h, but with a small decrease 
in the following 24 h (Figure 3.5f). The replacement of the PMA with interferon-γ in the 
HMDM cells showed a decrease in oxidation or neopterin formation of 34%, but with PBMC 
the decrease was not significant. 






























































Figure 3.4 Media total neopterin and neopterin from plaque stimulated with 5 µM PMA. 
The plaque (a) and (b) and cells were treated with PMA for 2 d following an initial media-only day (N=1). The 
plaque was obtained from a 65-year-old male non-smoker who was suffering from dysphasia and amaurosis 
fugax. Stenosis of the artery was reported as 80–99%.  In the HMDM (c) and (d) and PBMC (e) and (f) 
experiments (N=3), 500 U/mL of interferon-γ was added on the final day. Error bars represent SEM. 
Significance is indicated as compare d to the previous 24 h period: * indicates p<0.05; **, p<0.01; ***, 
p<0.001. 
 




Figure 3.5 Production of total neopterin and neopterin in media from plaque, macrophages, and PBMC 
culture stimulated with 5 µM PMA. 
The plaque (a) and (b) and cells were treated with PMA for 2 d following an initial media-only day (N=1). The 
plaque was obtained from a 65-year-old male non-smoker who was suffering from dysphasia and amaurosis 
fugax. Stenosis of the artery was reported as 80–99%.  In the HMDM (c) and (d) and PBMC (e) and (f) 
experiments (N=3), 500 U/mL of interferon-γ was added on the final day. Error bars represent SEM. 
Significance is indicated as compare d to the previous 24 h period: * indicates p<0.05; **, p<0.01; ***, 
p<0.001. 
   
52 
 
3.3.6 Indirect stimulation of plaque with PHA 
Addition of PHA a plaque obtained from a 77-year-old male non-smoker who was suffering 
from dysarthria and TIAs caused an increase in both mean total neopterin (5.28 nmol/g, p < 
0.0001) and neopterin (2.95 nmol/g, p < 0.0001) by 72 hours (Figure 3.7a and b). The addition 
of interferon-γ for the final 24 hours resulted in a further rise in both mean total neopterin (1.3 
nmol/g, p < 0.0001) and neopterin (1.0 nmol/g, p < 0.0001).  
3.3.7 Indirect stimulation of macrophages and PBMCs in cell culture with PHA 
In tissue culture, addition of PHA to HMDM cells produced a significant increase in mean total 
neopterin at 72 hours (162.8 nmol/g, p < 0.0001) and a further rise with the introduction of 
interferon-γ (92.85 nmol/g, p = 0.0021), like that seen in the plaque (Figure 3.7c). Neopterin 
also rose significantly in the first 72 hours (130.1 nmol/g, p < 0.0001), however, unlike the 
plaque, neopterin fell upon stimulation with interferon-γ (-73.71 nmol/g, p < 0.0001) (Figure 
3.7d). In PBMCs both total neopterin and neopterin increased significantly by 72 hours (20.86 
nmol/g, p < 0.0001 and 11.73 nmol/g, p = 0.005 respectively) (Figure 3.7e and f). Addition of 
interferon-γ caused a significant rise in total neopterin (31.74 nmol/g, p < 0.0001) but not in 
neopterin.    
The increase in total neopterin in both PBMC and some sections of the plaque tissue is 
suggestive of an interaction between T cells and macrophages within atherosclerotic plaque.  











































































Figure 3.6 Production of total neopterin and neopterin in media from plaque, macrophages, and PBMC 
culture stimulated with 50 ng/mL PHA. 
The plaque (a) and (b) was treated with PHA for 2 d following an initial media-only day, 500 U/mL of 
interferon-γ was added on the final day (N=1). The plaque was obtained from a 77-year-old male non-smoker 
who was suffering from dysarthria and TIAs. Stenosis of the artery was reported as 80–95%. Significance is 
indicated as compared to the previous 24 h period: * indicates p<0.05; **, p<0.01; ***, p<0.001. 





Figure 3.7 Production of total neopterin and neopterin in media from plaque, macrophages, and PBMC 
culture stimulated with 50 ng/mL PHA. 
The plaque (a) and (b) was treated with PHA for 2 d following an initial media-only day, 500 U/mL of 
interferon-γ was added on the final day (N=1). The plaque was obtained from a 77-year-old male non-smoker 
who was suffering from dysarthria and TIAs. Stenosis of the artery was reported as 80–95%.  In the HMDM (c) 
and (d) and PBMC (e) and (f) experiments (N=3), cells were treated with PHA for 2 d following an initial 
   
54 
 
media-only day and 500 U/mL of interferon-γ was added on the final day. Error bars represent SEM. 
Significance is indicated as compared to the previous 24 h period: * indicates p<0.05; **, p<0.01; ***, p<0.001. 
3.3.8 Plaque calcium quantification by spectral imaging 
Examination of plaque tissue segments shows a variety of structural features (Figure 2.1). It 
was hypothesised that the measured output of total neopterin may vary from section to section 
due to the morphology of the tissue and the level of calcification. Because of the nature of the 
tissue after several days of culture it was not possible to use traditional histology. Instead, to 
quantify the level of calcification, sections were imaged, and calcium levels quantified by 
MARS imaging.  
Calcium content was inversely related to post-PMA treatment total neopterin values (R 2= 
0.91) (a). Plaque sections with vastly differing weights (e.g. 0.166 g vs 0.082 g) but with very 
similar volumes of calcium (46 mm3 vs 49 mm3) were activated to the same extent (4.2 nmol/g 
and 3.8 nmol/g total neopterin). Figure 3.8 b to e are material decomposition images of section 
5 from the plaque in photographed in Figure 2.1 (and analysed in a). These images taken at 
different planes through the plaque section, show many spotty calcium deposits and some lipid-
rich areas. In comparison, section 7 from the same plaque, which had moderate levels of total 
neopterin production, is predominantly composed of lipid-rich tissue (f). 




Figure 3.8 MARS imaging of plaque tissue. 
Relationship between total neopterin production in plaque tissue and the volume of calcium present in each 
section using 14 sections from two PMA-treated plaques, prior to and after stimulation (N=2). R2 for the non-
linear line of best fit was 0.76 for unstimulated plaque and 0.91 for stimulated. (b) – (g) Three-dimensional 
reconstructions of MARS spectral CT slices using material decomposition for water, lipid, and calcium. 
Sections 5 (b) – (e) and 7 (f) – (g) of the PMA-treated plaque were selected for examining morphological 
differences. Tissue samples were retrieved after being cultured and imaged using the MARS spectral scanner. In 
this slice-through view, (b) – (e) are images from plaque section 5, which are progressing away from the viewer 
moving along the Z-axis. White arrowheads show examples of calcification; lipid is in yellow. A green 
arrowhead indicates the polypropylene sample tube, which gives a lipid-like reading. (f) A view of the whole of 
section 7. (g) A cut-through image midway through section 7. 




Here it has been shown that macrophages in live plaque tissues can be activated indirectly, 
possibly via de novo synthesis of interferon-γ by Th-1 cells or directly through the addition of 
exogenous interferon-γ. Comparisons to mono-layer tissue culture of either HMDMs or 
PBMCs demonstrate the effect of the complexity of plaque tissue on its biochemical profile. 
Live plaque tissue was more likely to respond immediately to stimuli than cells in culture, 
possibly due to differences in gene expression in the plaque tissue or the milieu of cells 
available. 
Interferon-γ stimulation of excised live plaque induced the activation of macrophages 
confirmed by a rise in total neopterin. This was accompanied by an increase in oxidant 
generation, which was measured as a rise in neopterin. As in previous work, the response of 
each section of plaque tissue is highly variable and not related to its location along the length 
of the plaque (T. Janmale et al., 2015). The macrophage activation was sustained even after the 
removal of interferon-γ from the media. This phenomenon is consistent with other research that 
indicates interferon-γ induces the expression of the enzyme GTPCH-I (Gesierich, Niroomand, 
& Tiefenbacher, 2003), which controls the rate limiting step in the production of 7,8-
dihydroneopterin. The results confirm that atherosclerotic plaque is a source of neopterin, 
particularly when macrophages are activated. Other studies have previously found that 
neopterin is increased after events such as stroke (Emsley et al., 2007; Lin et al., 2012) which 
is associated with macrophage activation (Chiba & Umegaki, 2013). Elevated serum neopterin 
is also a predictor of major adverse coronary events (Avanzas, Arroyo-Espliguero, Quiles, Roy, 
& Kaski, 2005). Generation of neopterin from 7,8-dihydroneopterin is evidence of an increase 
in oxidative stress in the plaque tissue. This is likely due to interferon-γ causing an increase the 
expression of gp91phox and p47phox which form the active NOX complex, generating 
superoxide (Ellison et al., 2015). 
The activation of HMDMs by PMA and PHA was somewhat surprising as the generation of 
7,8-dihydroneopterin and neopterin by HMDM cells alone has not been previously reported. 
PMA is known to activate the NOX complex via protein kinase C activation (Matthews et al., 
2016). Total neopterin in plaque tissue treated with PMA rose significantly over 72 h. Initial 
indications suggest that this is due to de novo synthesis of interferon-γ by T cells within the 
plaque. It was surprising to find that PMA could cause a significant increase in the production 
of 7,8-dihydroneopterin in a macrophage-only culture in the absence of interferon-γ . In vivo 
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labelling studies have shown that although interferon-γ controls the expression of GTPCH-I, 
the activity of the enzyme is under post-translational control through phosphorylation 
(Hesslinger, Kremmer, Hultner, Ueffing, & Ziegler, 1998). PMA has been shown to cause 
hyperphosphorylation of GTPCH-I which induces a substantial rise in enzyme activity 
(Hesslinger et al., 1998). 
These results suggest that both de novo synthesis of interferon-γ and phosphorylation of 
GTPCH-I may be occurring in the PMA treated plaque tissue. Oxidant production as measured 
by neopterin was much higher in the monolayer cultures (PBMC and HMDM) compared to the 
PMA-treated plaque tissue. Neopterin generation in the monolayer cultures was expected due 
to the PMA-induced activation of NOX. In the plaque, most of the 7,8-dihydroneopterin 
remained unoxidized suggesting that the treatment with PMA had elevated the antioxidant 7,8-
dihydroneopterin such that it greatly exceeded any oxidant generation, or that the level of 
oxidant generation in the plaque was much lower than in tissue culture.  
There is an inverse association between the amount of calcification and the macrophage-
derived production of 7,8-dihydroneopterin and neopterin in advanced atherosclerotic plaque. 
This finding suggests that plaque tissue with large volumes of calcium contributes less to the 
inflammatory burden than tissue with little calcification. From these results it is not possible to 
distinguish whether the increase in macrophage activation in sections containing smaller 
volumes of calcium is due to a change in macrophage phenotype related to the presence of 
microcalcifications or if there is an exclusion of macrophages in highly calcified tissue which 
lowers the immune activation.  
3.5 Conclusion 
Macrophages present in ex-vivo carotid plaque samples can be stimulated either directly or 
indirectly via T cells. Macrophage behaviour in live plaque samples varies along the length of 
the plaque. Cell culture experiments, therefore, have limited use in modelling the inflammatory 
response within atherosclerotic plaque. In addition, it has been found that the 
microenvironment of the plaque is associated with differences in macrophage activation, again 
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4 Relationship between 7,8-dihydroneopterin and neopterin in the presence of 
superoxide  
 
I was the sole contributor to this chapter. 
 
4.1 Introduction 
Neopterin is known to be elevated in a wide range of inflammatory conditions including 
sepsis, cardiovascular disease and HIV. In these diseases, neopterin has been shown to 
strongly correlate with negative outcomes (Baydar et al., 2009; Pihlstrøm et al., 2014; 
Wirleitner, Schroecksnadel, Winkler, & Fuchs, 2005). One potential source of neopterin is 
from HOCl mediated oxidation of 7,8-dihydroneopterin (B. Widner et al., 2000), which is 
thought to occur through MPO catalyzed conversion of hydrogen peroxide to HOCl in cells 
(Hampton, Kettle, & Winterbourn, 1998). In reaction mixtures, it has been found that HOCl 
can oxidize 7,8-dihydroneopterin to neopterin with between 50-80% stoichiometric 
efficiency (B. Widner et al., 2000), (unpublished data) and this may explain why there is 
such a dramatic increase in serum neopterin in bacterial inflammatory conditions (140-150 
nM cf. 5 ± 2 nM in healthy individuals) (Behnes et al., 2008; Tatzber et al., 1991). 
However, in cardiovascular disease, MPO is less likely to be contributing significantly to 
the generation of neopterin. This is primarily due to the main source of MPO being 
neutrophils (Shukla & Walsh, 2015), whereas macrophages appear to be the primary 
inflammatory cell involved in the pathogenesis of cardiovascular disease (see Chapter 1). As 
identified in the previous chapter, patients with symptomatic cardiovascular disease exhibit 
a small, compared to bacterial infection, but nevertheless measurable increase in neopterin 
over healthy patients. With HOCl being an unlikely explanation for the neopterin generated 
by atherosclerotic plaque, this chapter examines the role of superoxide, one of the main 
oxidants generated in macrophages (Johnston, Godzik, & Cohn, 1978), as a potential source 
of neopterin in non-bacterial inflammatory conditions, often referred to as sterile 
inflammation.  
Superoxide is a promising candidate for two reasons. First, several other candidates have 
been explored previously including hydrogen peroxide and hydroxyl radicals. All oxygen 
based reactions with 7,8-dihydroneopterin to date have primarily caused a loss of the side 
chain forming 7,8-dihydroxanthopterin, only HOCl has resulted in oxidation of 7,8-
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dihydroneopterin without cleavage of the side chain (Suckling et al., 2008). Secondly, in 
inflammatory conditions, such as atherosclerosis, there is an increase in NOX activity (Niu 
et al., 2010) and therefore an increase in superoxide, as well as other related oxidants. There 
is evidence from earlier research that part of the reason 7,8-dihydroneopterin offers 
protection against oxLDL mediated cell death is that it reduces the oxidant burden in the cell 
(S. P. Gieseg et al., 2010), as 7,8-dihydroneopterin has been shown to reduce DHE 
fluorescence, a measure of superoxide generation, in cells treated with oxLDL (Katouah, 
Chen, Othman, & Gieseg, 2015; Shchepetkina et al., 2017). However, it is unknown if 7,8-
dihydroneopterin is acting directly as an antioxidant, or if this reduction in superoxide is 
through another pathway controlled by 7,8-dihydroneopterin. 
The aim of this chapter is to investigate whether superoxide is a potential source of neopterin. 
Understanding the mechanisms of 7,8-dihydroneopterin oxidation and neopterin formation 
may improve the utility of neopterin as a biomarker of inflammation and oxidative stress. 
4.1.1 Measuring neopterin formation by superoxide in a xanthine oxidase system 
Fridovich (1970) first established the xanthine oxidase reaction system which generates 
superoxide through the enzymatic hydroxylation of xanthine to uric acid. This system has 
been chosen for use in this chapter over alternatives, which include superoxide salts and 
solid state reactions (Hayyan, Hashim, & AlNashef, 2016). These alternatives would require 
stop flow UV-Vis absorbance measurements and would likely compromise the ability to 
quantify neopterin via HPLC. The xanthine oxidase enzyme system is well established, and 
therefore there are known and expected values for how the assay will perform.  
Whilst the xanthine oxidase system is the most appropriate for the following experiments, it 
does have some constraints. One drawback of this system is that neopterin inhibits the 
enzyme once it reaches above 10 µM (Wede, Altindag, Widner, Wachter, & Fuchs, 1998) 
and 7,8-dihydroneopterin over 100 µM. High concentrations of neopterin prevent the 
formation of uric acid so it is thought that neopterin may compete with xanthine for the 
molybdenum active site. Experiments have been carried out with an excess of xanthine 
substrate to try to prevent competition occurring in the enzyme active site. In addition, to 
avoid the inhibitory effects of neopterin most experiments have been carried out at 10 µM 
of 7,8-dihydroneopterin. This low concentration makes detection slightly more difficult. 
Fortunately, HPLC is fairly sensitive with 7,8-dihydroneopterin being accurately detected 
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down to ~2 µM and neopterin down to ~10 nM. However, this low concentration of 7,8-
dihydroneopterin does prevent the ability to monitor the reaction directly via UV-Vis or 
fluorescence. 
A second consideration is that there is some debate about whether xanthine oxidase is 
producing purely superoxide, or whether some is hydrogen peroxide (Kelley et al., 2010). In 
addition, hydrogen peroxide will be produced by the dismutation of superoxide. Superoxide 
production by xanthine oxidase is typically measured via the cytochrome c assay where Fe3+ 
is reduced to Fe2+, however, in the presence of hydrogen peroxide there may be a back 
reaction, where the hydrogen peroxide oxidizes the Fe2+  (Vandewalle & Petersen, 1987). 
The reaction of hydrogen peroxide with 7,8-dihydroneopterin is known to be very slow and 
unlikely to occur in the timeframes of the majority of the experiments detailed here 
(Maghzal, 1999). Catalase, an enzyme that catalyses the dismutation of hydrogen peroxide 
to water and oxygen, has been used in specific experiments in this chapter to investigate the 
role of superoxide alone.  Due to the presence of hydrogen peroxide, there is the possibility 
that the cytochrome c assay is under reading the rate of superoxide production, as the back 
reaction with hydrogen peroxide masks the superoxide reduction. 
 
 Xanthine oxidase catalysed reactions of xanthine with oxygen and the resulting products. 
Finally, one further consideration is that this reaction is generally monitored by cytochrome 
c reduction as mentioned above. However, 7,8-dihydroneopterin will cause the direct 
reduction of cytochrome c. To overcome this, an NBT assay is used when 7,8-
dihydroneopterin is present in the reaction mixture. This is a colorimetric assay based on 
two superoxide radicals converting one tetrazolium salt to a formazan dye. This has the 
advantage that there is no possible back reaction, however NBT has been shown to be 
slightly less competitive for superoxide than cytochrome c (Auclair, Torres, & Hakim, 
1978).  
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The aim of this chapter is to measure the production of neopterin in the presence of xanthine 
oxidase generated superoxide using the reactions detailed below. It is already known that 
superoxide reacts with 7,8-dihydroneopterin at a rate constant of 103 M-1 S-1, a second order 
reaction. This was established using a spin trapping study by K. Oettl et al. (1997). However, 
measurement of the products of this reaction by HPLC has not previously been attempted. 
 
Diagram of known reactions occurring in the xanthine oxidase system and the 
proposed oxidation of 7,8-dihydroneopterin. 
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4.2 Methods in brief 
All xanthine oxidase experiments were carried out in a pH 7.8 potassium phosphate buffer, to 
limit the production of hydroperoxyl radicals (Halliwell & Gutteridge, 1999), containing 500 
µM of xanthine (see Chapter 2) at 25ºC shielded from light. All solutions were chelexed prior 
to use to prevent Fenton reactions occurring. 7,8-dihydroneopterin was diluted from a stock 
solution directly into the xanthine/potassium phosphate buffer to achieve a final concentration 
of 10 µM for most experiments, or a suitable dilution achieve the desired final concentration 
up to a maximum of 130 µM. Concentrations above this could not be achieved due to the need 
to balance components in the reaction mixture, and the solubility of 7,8-dihydroneopterin.   
Enzyme solutions of xanthine oxidase (0.05 U/mL), superoxide dismutase (up to 1000 U/mL) 
and catalase (up to 1000 U/mL) were prepared fresh in ice cold water. One unit of xanthine 
oxidase will convert 1 µmole of xanthine to uric acid per minute at pH 7.8 and 25 ºC. 
Superoxide dismutase catalyzes the dismutation of superoxide into molecular oxygen and 
hydrogen peroxide.  
2𝑂2
  ∙− ∙ + 2𝐻+  →  𝑂2  +  𝐻2𝑂2 
One unit of superoxide dismutase will reduce the rate of cytochrome c reduction by 50% in the 
presence of 5 mU (or 1.67 mU/mL) xanthine oxidase. Catalase catalyses the decomposition of 
hydrogen peroxide to molecular oxygen and water at a rate of 1 µmole of hydrogen peroxide 
per minute pH 7.0 and 25℃. 
2𝐻2𝑂2  →  𝑂2  + 2𝐻2𝑂    
Enzyme solutions were diluted as necessary, and always added as a 100 µL aliquot (each) as 
the final addition. Total reaction volume for all experiments was 3 mL. 
Reactions were monitored by the cytochrome c assay (see Chapter 2) or NBT assay (see 
Chapter 2). Measurement of 7,8-dihydroneopterin and neopterin concentrations were carried 
out via absorbance and fluorescence HPLC using the SCX detection method as described in 
detail in Chapter 2. 
  




4.3.1 Superoxide induced loss of 7,8-dihydroneopterin and generation of neopterin 
To test whether 7,8-dihydroneopterin was oxidised by superoxide, increasing initial 
concentrations of 7,8-dihydroneopterin were incubated with 1.67 mU/mL of xanthine 
oxidase for 60 minutes. This amount of xanthine oxidase will generate a theoretical 200 µM 
of superoxide. Figure 4.1 shows neopterin is a product of the reaction between superoxide 
and 7,8-dihydroneopterin. The amount of 7,8-dihydroneopterin lost or neopterin gained is 
relatively linear until 50 µM 7,8-dihydroneopterin, with approximately 50% of the initial 
7,8-dihydroneopterin remaining after 60 minutes. The asymptote for neopterin production is 
at 25 µM for 200 µM of assumed superoxide generated. However, this asymptote is not 
reached until an initial concentration of 1200 µM 7,8-dihydroneopterin.  
The reaction efficiency appears to shift as the concentration of 7,8-dihydroneopterin 
increases. Figure 4.1a shows that the absolute amount of 7,8-dihydroneopterin lost during 
the 60 minute incubation with xanthine oxidase continued to increase as the initial 
concentration of 7,8-dihydroneopterin increased. However, the highest proportion of 
neopterin gain occurs at the lowest initial concentrations of 7,8-dihydroneopterin. At 10 µM 
of 7,8-dihydroneopterin starting concentration, 1 neopterin is produced for every 2.2 7,8-
dihydroneopterin molecules lost, whereas at 130 µM, 1 neopterin is being produced for every 
3.15 7,8-dihydroneopterin molecules lost. 
 
  




Figure 4.1 Loss of 7,8-dihydroneopterin and gain of neopterin at different initial concentrations of 7,8-
dihydroneopterin after 60 minutes of incubation with 1.67 mU/mL xanthine oxidase. 
The change in 7,8-dihydroneopterin concentration was measured by absorbance at 254nm using the SCX 
method on HPLC (a). Neopterin was simultaneously measured using fluorescence detection at ex 353 and em 
438 (b). The black line is the fitting of a hyperbolic curve to all data points, whereas the red dotted line indicates 
the initial straight line trend through the first 4 data points. This graph shows results from a single experiment.  
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4.3.2 Measurement of 7,8-dihydroneopterin superoxide scavenging ability 
It is known that neopterin and 7,8-dihydroneopterin have the ability to inhibit the xanthine 
oxidase enzyme. To test how much inhibition is occurring in this modified xanthine oxidase 
system where xanthine oxidase is at a concentration of 1.67 mU/mL, an NBT assay was 
carried out at increasing concentrations of 7,8-dihydroneopterin (Figure 4.2). The 
measurement of superoxide production by the NBT assay shows that low concentrations of 
7,8-dihydroneopterin reduce the amount of superoxide being scavenged by the NBT, 
however, the higher concentrations of 50 µM and 100 µM of 7,8-dihydroneopterin have little 
to no effect on the amount of superoxide being scavenged. One unit of SOD resulted in an 
approximately 50% reduction in NBT formation as expected, given that definition of a unit 
of SOD is the amount of enzyme that will reduce xanthine oxidase formation  by half. 
Finally, there is no evidence of inhibition of the enzyme at higher 7,8-dihydroneopterin 
concentrations which may be due to the increased substrate availability in this modified set 
up.  




Figure 4.2 NBT assay of superoxide production with increasing concentrations of 7,8-dihydroneopterin in 
the presence of 1.67 mU of xanthine oxidase. 
Absorbance of NBT-diformazan product formation with superoxide was measured at 550 nm over a total of 2500 
seconds (a) with various concentrations of 7,8-dihydroneopterin. A close up of the first 300 seconds is displayed 
in (b). This graph shows results from a single experiment. 
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Measurement of superoxide production by either cytochrome c assay or NBT assay indicated 
a lower than theoretical rate of superoxide generation (Table 4.1). The cytochrome c assay and 
NBT assay are generally in agreement with each other; with the cytochrome c assay reading 
slightly lower than the NBT assay (100.2 µM per hour vs 124.5 µM per hour, respectively). 
 
Table 4.1 Theoretical and measured values for superoxide production using 1.67 mU/mL of xanthine 
oxidase 
Units Theoretical  
(2 µmoles of superoxide 
from 1 µmole of uric 





µmoles per minute 0.01 0.005 0.006 
µM per hour 200.0 100.2 124.5 
 
7,8-dihydroneopterin (10 µM) was incubated with increasing amounts of xanthine oxidase 
enzyme to measure the effect of variable rates of superoxide generation on the efficiency of 
the oxidation of 7,8-dihydroneopterin to neopterin. 7,8-dihydroneopterin was incubated with 
0.03 mU/mL – 1.67 mU/mL of xanthine oxidase for 60 minutes (Figure 4.3). The amount of 
superoxide generated during the 60 minutes is ~112 µM (average of the values measured by 
cytochrome c and NBT assays) at 1.67 mU/mL. For 0.3 mU/mL, 0.17 mU/mL, 0.067 
mU/mL and 0.03 mU/mL, the respective superoxide generation is 22.4 µM, 11.2 µM, 4.5 
µM and 2.2 µM. The rate of superoxide generation is 1.87 µM min-1 at 1.67 mU/mL of 
xanthine oxidase.  
  












































Figure 4.3 Effect of increasing concentrations of xanthine oxidase enzyme on loss of 7,8-dihydroneopterin 
and gain of neopterin. 
7,8-dihydroneopterin (10 µM) was incubated with various concentrations of xanthine oxidase enzyme for 60 
minutes. The change in 7,8-dihydroneopterin concentration was measured by absorbance at 254nm using the 
SCX method on HPLC (a). Neopterin was simultaneously measured using fluorescence detection at ex 353 and 
em 438 (b). Data is mean ± SEM (n=3). 
  




The rate of 7,8-dihydroneopterin loss at 1.67 mU/mL of xanthine oxidase is 0.074 µM min-
1 and the rate of neopterin gain is 0.031 µM min-1. Clearly the rate of superoxide generation 
is much higher than the rate of 7,8-dihydroneopterin loss or NP gain, yet in Figure 4.2 10 
µM of 7,8-dihydroneopterin results in a 28% reduction of the superoxide output.  
A time course of the reaction between superoxide and 7,8-dihydroneopterin at increasing 
rates of superoxide production shows that 7,8-dihydroneopterin is not completely oxidized 
by 300 minutes. The remaining 7,8-dihydroneopterin was measured at time 0 and every 30 
minutes subsequently for up to 300 minutes (Figure 4.4a). Neopterin gain was assessed at 
the same intervals (Figure 4.4b). The total superoxide generation over the 300 minute time 
course was 112 µM at 0.3 mU/mL of xanthine oxidase, and 56 µM, 22.4 µM and 11.2 µM 
for 0.17 mU/mL, 0.067 mU/mL and 0.03 mU/mL , respectively. The rate of superoxide 
generation is 0.37 µM min-1 at 0.3 mU/mL of xanthine oxidase. The final concentration of 
7,8-dihydroneopterin at the end of the time course in the presence of 0.03 mU/mL of 
xanthine oxidase was 8.34 µM compared to 0.81 µM with 0.3 mU/mL of xanthine oxidase. 
At 0.03 mU/mL of xanthine oxidase just 0.59 µM of neopterin was generated over the time 
course, compared with 3.7 µM of neopterin when 0.3 mU/mL of xanthine oxidase was 
present. This experiment showed that superoxide is a source of neopterin as increasing the 
superoxide generation increased the corresponding production of neopterin. As could be 
expected in a two-electron oxidation, neopterin generation is not a 1:1 ratio to 7,8-
dihydroneopterin loss, however, the roughly 1:3 (neopterin gain: 7,8-dihydroneopterin loss) 
ratio at the highest concentration of enzyme is unusual. Interestingly, the loss of 7,8-
dihydroneopterin did not correspond to the theoretical rate of superoxide generation. This 
will be explored more fully in subsequent experiments. Figure 4.2 and Figure 4.4 confirm 
that modifying either the concentration of 7,8-dihydroneopterin or the concentration of 
superoxide will change the rate of reaction, as expected with a second order reaction. 
  





Figure 4.4 Loss of 7,8-dihydroneopterin and gain of neopterin over time in the presence of increasing 
concentrations of xanthine oxidase enzyme. 
7,8-dihydroneopterin (10 µM) was incubated with various concentrations of xanthine oxidase enzyme for 300 
minutes. The change in 7,8-dihydroneopterin concentration was measured by absorbance at 254nm using the 
SCX method on HPLC (a). Neopterin was simultaneously measured using fluorescence detection at ex 353 and 
em 438 (b). Data is mean ± SEM (n=3).  
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4.3.3 Competition between 7,8-dihydroneopterin and superoxide dismutase 
Including SOD in the reaction mixture prevented the formation of neopterin and the 





































Figure 4.5). By 1.67 U/mL of SOD only a very small amount of neopterin (0.06 µM) is 
produced, and by 3.3 U/mL of SOD almost all 7,8-dihydroneopterin loss is abated. This 
confirms that the production of neopterin is occurring via superoxide, and that hydrogen 
peroxide generated by xanthine oxidase is not directly contributing to the formation of 
neopterin.  
  








































Figure 4.5 Effect of increasing concentrations of SOD on loss of 7,8-dihydroneopterin and gain of 
neopterin in the presence of 1.67 mU/mL of xanthine oxidase for 60 minutes. 
7,8-dihydroneopterin (10 µM) was incubated with various concentrations of SOD enzyme for 60 minutes. The 
change in 7,8-dihydroneopterin concentration was measured by absorbance at 254nm using the SCX method on 
HPLC (a). Neopterin was simultaneously measured using fluorescence detection at ex 353 and em 438 (b). This 
graph shows results from a single experiment.  
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To test whether SOD was having any direct effect on 7,8-dihydroneopterin, 10 µM of 7,8-
dihydroneopterin was incubated for 30 minutes with 0.3 U/mL of SOD and 1.67 mU/mL of 
xanthine oxidase in the presence or absence of xanthine (Figure 4.6). As expected, adding 
SOD in the absence of the enzyme substrate, xanthine, had no effect on the concentration of 
either 7,8-dihydroneopterin or neopterin. In contrast, adding SOD in the presence of xanthine 
significantly (p = 0.03) decreased the amount of neopterin formed, and prevented the loss of 
7,8-dihydroneopterin (p = 0.0019). This figure also confirms that there is no direct reaction 
between xanthine oxidase and 7,8-dihydroneopterin in the absence of the substrate. 
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Figure 4.6 Effect of SOD on loss of 7,8-dihydroneopterin and gain of neopterin in the presence or absence 
of the enzyme substrate with 1.67 mU/mL of xanthine oxidase for 30 minutes. 
7,8-dihydroneopterin (10 µM) was incubated with 0.3 U/mL of SOD enzyme for 30 minutes in the presence or 
absence of xanthine. The change in 7,8-dihydroneopterin concentration was measured by absorbance at 254nm 
using the SCX method on HPLC (a). Neopterin was simultaneously measured using fluorescence detection at ex 
353 and em 438 (b).  
   
75 
 
4.3.4 Initial reactions of 7,8-dihydroneopterin with superoxide 
The following two experiments were carried out at 15 minutes to capture the initial reactions 
to isolate the main mechanism of neopterin formation from 7,8-dihydroneopterin by 
superoxide. The first experiment uses a low concentration of 7,8-dihydroneopterin (10 µM) in 
the presence of excess of catalase (CAT) and SOD (Figure 4.7). The second experiment was 
conducted in the same manner but at 100 µM of 7,8-dihydroneopterin (Figure 4.8). In Figure 
4.7, the addition of SOD completely abolishes any loss of 7,8-dihydroneopterin and results a 
very small amount of neopterin. Somewhat surprisingly, catalase causes a substantial reduction 
in 7,8-dihydroneopterin well over and above that caused by the presence of xanthine oxidase 
alone. The addition of both catalase and SOD together abolishes the protective effect of SOD, 
but the loss of 7,8-dihydroneopterin is reduced in comparison to catalase alone. The changes 
in neopterin were small and not statistically significant. 
  





Figure 4.7 Effect of 33 U/mL of CAT and 100 U of SOD on 10 µM of 7,8-dihydroneopterin in the presence 
of 1.67 mU/mL of xanthine oxidase for 15 minutes. 
7,8-dihydroneopterin (10 µM) was incubated with 33 U/mL of catalase (CAT) or 33 U/mL of SOD enzyme for 
15 minutes in addition to 1.67 mU/mL of xanthine oxidase. The change in 7,8-dihydroneopterin concentration 
was measured by absorbance at 254nm using the SCX method on HPLC (a). Neopterin was simultaneously 
measured using fluorescence detection at ex 353 and em 438 (b). Data is mean ± SEM (n=2). A two-way 
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In Figure 4.8, 100 µM 7,8-dihydroneopterin is outcompeting both catalase and SOD for the 
xanthine oxidase-generated superoxide. Here in the presence of 7,8-dihydroneopterin alone, 
generating 28 µM of superoxide results in the loss of 22 µM of 7,8-dihydroneopterin, and an 
accompanying gain of 11 µM of neopterin (50% of 7,8-dihydroneopterin lost). The loss of 7,8-
dihydroneopterin in the presence of catalase that was seen in Figure 4.7 has been abolished at 
100 µM 7,8-dihydroneopterin. Instead, as in the case of 7,8-dihydroneopterin alone, ~22 µM 
of 7,8-dihydroneopterin has been oxidized. As also seen in the previous figure, catalase is the 
most effective at preventing the formation of neopterin, whereas SOD is the most effective at 
preventing the loss of 7,8-dihydroneopterin. There is a gain of 5.7 µM of neopterin, which is 
approximately half of the neopterin gain seen in the 7,8-dihydroneopterin alone condition, 
although this was not found to be a statistically significant difference. The addition of SOD 
results in a loss of 11 µM of 7,8-dihydroneopterin, half that occurred in the 7,8-
dihydroneopterin alone treatment, and a gain of 8.5 µM of neopterin. The neopterin gain is 
reduced by 23% compared to the 7,8-dihydroneopterin alone treatment but a 1.5-fold increase 
compared to 7,8-dihydroneopterin with catalase. The presence of both catalase and SOD again 
lead to the loss of 7,8-dihydroneopterin (11 µM). The neopterin gain of 6.5 µM is like that 
produced when incubated with SOD.  
  











































































Figure 4.8 Effect of 33 U/mL of CAT and 33 U/mL of SOD on 100 µM of 7,8-dihydroneopterin in the 
presence of 1.67 mU/mL of xanthine oxidase for 15 minutes. 
7,8-dihydroneopterin (100 µM) was incubated with 33 U/mL of CAT or 33 U/mL of SOD enzyme in addition to 
1.67 mU/mL of xanthine oxidase for 15 minutes. The change in 7,8-dihydroneopterin concentration was 
measured by absorbance at 254nm using the SCX method on HPLC (a). Neopterin was simultaneously 
measured using fluorescence detection at ex 353 and em 438 (b). Data is mean ± SEM (n=2). A two-way 
ANOVA was carried out. Signficance indicated as * is p<0.05. 
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4.3.5 Potential other products of the reaction between superoxide and 7,8-dihydroneopterin 
There is a distinct difference between the amount of 7,8-dihydroneopterin consumed by the 
reaction with superoxide and the amount of neopterin that results. The HPLC chromatograms 
were examined closely to identify any possible other products. There was no evidence of 
dihydroxanthopterin or xanthopterin formation, which would be expected to produce 
distinctive peaks between 4.3 and 5 minutes (Figure 4.9a) in the fluorescence chromatogram 
(ex. 353nm, em. 438 nm). The peaks visible at 3.8 and 4.1 minutes are likely to be xanthine 
and uric acid. Neopterin can be seen clearly at 5.4 minutes (blue line = 100 nM neopterin 
standard). The peak at 7.0 minutes is 7,8-dihydroneopterin. Figure 4.9b is a close up of Figure 
4.9a. The black line represents 10 µM of 7,8-dihydroneopterin at t=0, the pink line is 25 µM 
of 7,8-dihydroneopterin at t=0. Although this is noted as time 0, there was an unavoidable delay 
of almost two minutes prior to the needle acquiring the sample. At both 10 and 25 µM of 7,8-
dihydroneopterin, there are distinctive peaks at 5.2 and 5.7 minutes which both sit underneath 
the 100 nM of neopterin standard (pH 6). After 60 minutes incubation with xanthine oxidase, 
both peaks have increased in height, but the peak at 5.2 minutes has increased substantially 
more than the peak at 5.7 minutes (Figure 4.9c). Figure 4.9d is a close up of 10 µM of 7,8-
dihydroneopterin at t=0 (pink) and t=60 (black) showing the gain in peak height at 5.2 and 5.7 
minutes and the corresponding decrease of the peak at 7.0 minutes. Examining the absorbance 
of the compounds at t=0 (brown, 25 µM 7,8-dihydroneopterin; blue 10 µM 7,8-
dihydroneopterin) and t=60 (pink, 25 µM 7,8-dihydroneopterin; black, 10 µM 7,8-
dihydroneopterin) using the PDA set to 254 nm, identified a distinctive drop in 7,8-
dihydroneopterin concentration at 6.8 minutes (Figure 4.9e). There are two non-resolved peaks 
that form at 5.1 and 5.3 minutes in the t=60 samples that appear to correspond to the 5.2 minute 
fluorescence peak. There is no absorbance peak that corresponds to the 5.7 minute fluorescence 
peak.  
To see if the unidentified peak at 5.7 minutes had any biological relevance, media from a plaque 
sample was analysed. Figure 4.9f is the fluorescence chromatogram of media from an 
unstimulated plaque. The black line represents the media injected which has a pH of 7.4, the 
pink line represents media which has been acidified to pH 6. Interestingly, at pH 6, the 
neopterin peak at 5.2 minutes is much more distinct, and a there is a peak that occurs at 5.7 
minutes. 
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Figure 4.9 Chromatograms of 7,8-dihydroneopterin and neopterin detection via SCX method. 
(a) Fluorescence chromatogram of injected standard of 100 nM neopterin (blue line), overlaid with the 
chromatograms from 10 µM of 7,8-dihydroneopterin (black) and 25 µM of 7,8-dihydroneopterin (pink) at time 
0. (b) Close up of the fluorescence chromatogram described in (a). (c) Fluorescence chromatogram of injected 
standard of 100 nM neopterin (blue line), overlaid with the chromatograms from 10 µM of 7,8-dihydroneopterin 
(black) and 25 µM of 7,8-dihydroneopterin (pink) at time 60 minutes. (d) Fluorescence chromatogram of 10 µM 
of 7,8-dihydroneopterin at time 0 (pink) and time 60 minutes (black). (e) Absorbance chromatogram of 10 µM 
of 7,8-dihydroneopterin and 25 µM of 7,8-dihydroneopterin at time 0 (blue and brown respectively) and time 60 
minutes (black and pink, respectively). (f) Fluorescence chromatogram of plaque media at pH 7.4 (black) and 
pH 6.0 (pink). The results displayed here are from a single experiment. 
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The results from this chapter show that the oxidation of 7,8-dihydroneopterin to neopterin is 
not a straightforward reaction. In Figure 4.10, a potential mechanism is proposed, however, 
further study is required to confirm this proposed scheme.  Using the information that has been 
gleaned from these experiments, it is possible to begin to form a hypothesis about the reactions 
occurring. The first piece of information is that superoxide will react with 7,8-
dihydroneopterin. Secondly, SOD protects against 7,8-dihydroneopterin loss but at high 
concentrations 7,8-dihydroneopterin will still scavenge superoxide in the presence of SOD. 
Thirdly, introducing catalase at high concentrations of 7,8-dihydroneopterin has no effect on 
superoxide scavenging but lowers the amount of neopterin formed. In reaction 1a, a molecule 
of superoxide reacts with 7,8-dihydroneopterin to form a deprotonated and charged species and 
a hydroperoxyl radical (similar to the reactions in Nanni Jr, Stallings, and Sawyer (1980)). The 
resulting hydroperoxyl radical can participate in several different reactions outlined in 1a, b 
and c. In reaction 2, the deprotonated and charged species from reaction 1 reacts with a 
hydroperoxyl radical (generated from reaction 1b), which forms neopterin and hydrogen 
peroxide. Reaction 2a shows that there are multiple other possible products if the deprotonated 
and charged species reacts with an alternative oxidant or radical species. 
  





Figure 4.10 Hypothesised reaction mechanisms of 7,8-dihydroneopterin with superoxide. 
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As 100 µM of 7,8-dihydroneopterin is able to outcompete 33 U/mL of SOD, which is known 
to react with superoxide at a rate constant of 2 x 109, there is the possibility that the rate of 
reaction between 7,8-dihydroneopterin and superoxide may actually be faster than the rate 
constant of 103 M-1 S-1 that K. Oettl et al. (1997) have established, resulting in a deprotonated-
7,8-dihydroneopterin (reaction 1). The additional peak that appears in the HPLC 
chromatograms adds support to this theory that a relatively stable charged intermediate may be 
being generated. The rate that K. Oettl et al. (1997) measured may in fact not have been the 
initial reaction with 7,8-dihydroneopterin which effectively regenerates superoxide (reaction 
1a) but a subsequent and slower reaction, for example a reaction of superoxide with the product 
of reaction 1 (see reaction 2a). This concept is further supported by finding that the presence 
of catalase in conjunction with SOD removes the protective effect of SOD against 7,8-
dihydroneopterin loss. This is likely to occur through the removal of hydroperoxyl radicals 
from the system caused by a shift in the reactant/product balance in reaction 1c. This in turn 
could impact the protonated/deprotonated 7,8-dihydroneopterin equilibrium (reaction 1) 
increasing the favourability of the deprotonated product. Hence, the effect of SOD is likely 
occurring at a later step in the oxidation process than initially thought, i.e. mitigating the effects 
of reaction 1b, which may decrease the favourability of reaction 2, the step which forms 
neopterin. As this mechanism is seeking to establish how neopterin formation occurs, the 
effects of other oxidants e.g. superoxide, at reaction 2 have not been considered, although these 
are likely to produce alternative products. This may explain the discrepancy between 7,8-
dihydroneopterin loss and neopterin gain. 
The NBT experiment provided some surprising results, where low concentrations of 7,8-
dihydroneopterin reduced the formation of NBT via superoxide but higher concentrations did 
not. It is known from Figure 4.1 that 7,8-dihydroneopterin is being oxidized to neopterin in the 
presence of xanthine oxidase generated superoxide at all concentrations. NBT reacts with 
superoxide at a rate constant of 1 x 104 M/s. If the initial reaction of superoxide with 7,8-
dihydroneopterin is faster than this, then it may not be the initial reaction that is being 
monitored here. Since the reaction is likely to be a two-step mechanism, and superoxide or a 
superoxide derivative may be involved in both steps of the reaction, it is possible the NBT 
assay is only capturing the second or rate-limiting step of the reaction. At high concentrations 
of 7,8-dihydroneopterin, the second step could be less favourable due to the abundance of 7,8-
dihydroneopterin, meaning any available superoxide is more likely to react with the NBT. At 
low concentrations of 7,8-dihydroneopterin, the second step may be more favourable, and this 
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is likely to be the step that removes superoxide from the system. As the NBT reading for 
superoxide produced is almost identical in the absence of 7,8-dihydroneopterin and in the 
presence of 50 µM and 100 µM, this would suggest the initial reaction of 7,8-dihydroneopterin 
with superoxide is not consuming the superoxide. This would be possible if a proton was 
abstracted from 7,8-dihydroneopterin in the first reaction forming a hydroperoxyl radical, as 
the pH of the solution would favour that species reforming superoxide almost instantaneously. 
Karl Oettl, Greilberger, and Reibnegger (2000) showed that 7,8-dihydroneopterin does not 
react directly with NBT at concentrations as high as 500 µM.  Wede et al. (1998) found that 
7,8-dihydroneopterin diminished the production of uric acid up to 40% at 200 µM of 7,8-
dihydroneopterin, however, at the same concentration the measured reduction in NBT was only 
20%. When they measured the remaining pterins after incubation with NBT, they found no 
change in the concentration of 7,8-dihydroneopterin. It seems plausible that NBT may be 
outcompeting the deprotonated-7,8-dihydroneopterin for the hydroperoxyl generated 
superoxide radicals. In the absence of NBT, 7,8-dihydroneopterin loss does not correlate well 
to the superoxide production which suggests that 7,8-dihydroneopterin may, cycling between 
protonated and deprotonated species, with only some 7,8-dihydroneopterin committed to 
further oxidation reactions.  
In the first proposed reaction superoxide is acting as an oxidizing agent, generating a 
deprotonated form of 7,8-dihydroneopterin and releasing a hydroperoxyl radical. The 
hydroperoxyl radical is much more reactive than superoxide. The hydroperoxyl radical will 
react with itself to form hydrogen peroxide (reaction 1c) and oxygen or with superoxide to 
form oxygen and a hydroperoxyl anion (reaction 1b) (Nanni Jr et al., 1980). The hydroperoxyl 
radical is in equilibrium with superoxide but at pH 7.8 the equilibrium is heavily in favour of 
superoxide (reaction 1a) (Augusto & Miyamoto, 2011). It is proposed that neopterin is formed 
through the reaction of the deprotonated species with a hydroperoxyl anion. In addition to 
neopterin, this reaction produces hydrogen peroxide. With neopterin formation only occurring 
in the second step of the reaction, it is no surprise that there is variation in the percentage 
conversion of 7,8-dihydroneopterin to neopterin. In the case of low superoxide (Figure 4.4, 
0.03 mU/mL xanthine oxidase) to 7,8-dihydroneopterin, it appears that reaction 1 
predominates. However, as the amount of superoxide increases, the balance shifts further in 
favour of reaction 2, probably due to an increased likelihood of reaction 1b occurring. 
Experiments in the presence of catalase showed that removing hydrogen peroxide had a 
detrimental effect on neopterin generation yet caused a marked decrease in 7,8-
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dihydroneopterin concentration. Potentially, removing hydrogen peroxide from the system 
prevents the deprotonated-7,8-dihydroneopterin from regenerating 7,8-dihydroneopterin, in 
addition to preventing the forward reaction towards neopterin by increasing hydroperoxyl-
hydroperoxyl reactions as discussed earlier. 
Finally, whilst following the loss of 7,8-dihydroneopterin and gain of neopterin via HPLC is 
cost effective and easy, it is worth noting that the SCX method is not particularly sensitive for 
7,8-dihydroxanthopterin or xanthopterin, so it is not possible to rule out the potential formation 
of low (sub 10 µM) amounts of these products (possibly generated through reaction 2a). Given 
the identification of an alternative, but unquantified peak at 5.7 minutes, which also appears to 
have relevance to biological samples, it seems the logical next step would be to monitor this 
reaction using mass spectrometry. Furthermore, the results with the SCX method, which uses 
hydrogen-bonding, suggests that the method is much more susceptible to variations in sample 
pH than initially thought, which strengthens the case for either controlling pH or using a 
method that is not susceptible.    
4.5 Conclusion 
From the data presented here, superoxide appears to be necessary for the generation of 
neopterin in this system but appears to not be the sole oxidant involved. It appears that the 
balance of neopterin to other products can be modified by the ratio of various oxidants 
available. It is possible that 7,8-dihydroneopterin may react with multiple molecules of 
superoxide. The reaction of 7,8-dihydroneopterin with superoxide may generate a 
deprotonated, charged form, which may be of relevance in biological systems. These reactions 
may be less favourable in a system that contains other oxidants. Future work is required to 
confirm the mechanism of oxidation. 
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5 Effect of oxidant modulation on 7,8-dihydroneopterin and neopterin 
generation in biological systems 
5 
5.1 Introduction 
NOX is a potential source of superoxide in the plaque (Judkins et al., 2009). In this chapter, 
experiments were conducted with apocynin, a common inhibitor of p47phox containing NOXs 
(Stolk, Hiltermann, Dijkman, & Verhoeven, 1994). The p47phox subunit is crucial to the 
activation of NOX through its phosphorylation and subsequent binding to the p22phox domain 
(Takeya et al., 2003). Interestingly, apocynin is thought to only act as a competitive inhibitor 
of p47phox binding in NOX when it is in the dimerized form (Ismail, Scapozza, Ruegg, & 
Dorchies, 2014). The formation of the dimer is via a myeloperoxidase (MPO)-mediated 
oxidation (Ximenes, Kanegae, Rissato, & Galhiane, 2007). It has also been suggested that the 
radical form of apocynin generated by MPO may damage thiol groups on the NOX, and prevent 
NOX activation in that manner (Heumüller et al., 2008). In the absence of MPO, apocynin has 
been found to act as an antioxidant, although the mechanism of this is not well understood 
(Kanegae, da Fonseca, Brunetti, de Oliveira Silva, & Ximenes, 2007). There has been some 
suggestion that the antioxidant activity of apocynin in cells is not direct, but rather is via 
regulation of Nrf2 which is involved in the synthesis of GSH and peroxiredoxin (Lim et al., 
2014). 
 
Figure 5.1 Apocynin and diapocynin molecules 
In order to be confident that any effect seen with apocynin was due to reduction in NOX 
activity, it was necessary to investigate MPO activity in the plaque tissue. As mentioned earlier, 
MPO, in addition to oxidizing apocynin, has a role in producing hypochlorite from hydrogen 
peroxide. If MPO was present in plaque tissue, it would be expected that neopterin could be 
produced from the reaction between hypochlorite and 7,8-dihydroneopterin. If this is the case, 
by blocking MPO in plaque tissue, it would be expected that total neopterin would increase 
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and neopterin would decrease. At the same time, inhibiting MPO could prevent cellular 
hydrogen peroxide from becoming hypochlorite, increasing the intracellular hydrogen peroxide 
levels. If the mechanism of 7,8-dihydroneopterin loss and neopterin formation presented in the 
previous chapter is correct, then it would be expected that an increase in hydrogen peroxide 
would favour total neopterin regeneration. To test the effect of MPO in the plaque, 4-
aminobenzoic acid hydrazide (ABAH) was used as an inhibitor. ABAH irreversibly inactivates 
MPO (Kettle, Gedye, Hampton, & Winterbourn, 1995; Malle, Furtmüller, Sattler, & Obinger, 
2007). This inactivation thought to occur through the oxidation of MPO by ABAH to a radical 
form. If the radical form interacts with hydrogen peroxide then irreversible inactivation occurs, 
but in the presence of oxygen, enzyme turnover occurs (Kettle, Gedye, & Winterbourn, 1997).  
Finally, to directly confirm the effect of removing superoxide, a plaque was incubated with 
PEG-SOD, a pegylated form of the enzyme superoxide dismutase, which is membrane-
permeable (Pannirselvam, Verma, Anderson, & Triggle, 2002). This was the first experiment 
to attempt to use intra-plaque controls, which meant the treatment was only added to every 
second section of plaque. The theory being that the sections either side of the treatment section 
would help to assess how the tissue may have behaved if the treatment had not been added. 
Next, the effect of increasing cellular oxidants on 7,8-dihydroneopterin and neopterin 
production in plaque was tested using the addition of oxLDL. OxLDL was chosen for use in 
these experiments for two reasons. One, it is known to increase intracellular oxidant production 
including superoxide (Stielow et al., 2006), and two, for its biological relevance to the 
development of atherosclerosis (Pirillo, Norata, & Catapano, 2013). In this series of 
experiments, several hypotheses were tested. Firstly, was there an effect of oxLDL on 7,8-
dihydroneopterin and neopterin in PMA-stimulated cells. Secondly, was this effect specific to 
the oxidized form, as opposed to native LDL. Finally, was oxLDL toxic to the cells in the 
plaque? In addition, an experiment with HMDM cells was used to test whether the extracellular 
response to oxLDL reflects was is occurring intracellularly. Understanding how the balance of 
oxidants in plaque tissue modulates 7,8-dihydroneopterin and neopterin release is a crucial step 
in improving the usefulness of 7,8-dihydroneopterin and neopterin as biomarkers of advanced 
cardiovascular disease.  
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5.2 Methods in brief 
Plaques were obtained fresh from Christchurch Hospital and cut into sections and cultured as 
described in Chapter 2. Total neopterin and neopterin were measured by HPLC as described in 
Chapter 2. Lactate measurements were conducted by a colorimetric assay as described in 
Chapter 2. 
HMDM cells were cultured in accordance with the method described in Chapter 2. The cells 
were incubated with oxLDL (2 mg/mL), and/or 50 U/mL of PEG-SOD in the presence or 
absence of 200 µM 7,8-dihydroneopterin for 24 hours. At the end of the 24 hours, the media 
was removed for analysis. To the remaining cells, 200µL of ice-cold PBS was added and then 
the cells were scrapped from the plate surface using a pipette tip. The resulting liquid was 
frozen to ensure cell lysis prior to analysis. Intracellular and extracellular total neopterin and 
neopterin were measured by HPLC as described in Chapter 2. Protein concentrations were 
determined using the BCA assay in Chapter 2. 
  





5.3.1 Reducing superoxide production by inhibiting NADPH oxidase in plaque 
A plaque was collected from the right internal carotid artery of a 73-year-old, non-smoking, 
diabetic female who had experienced a TIA with leg weakness (Figure 5.2). The patient had a 
blood pressure of 150/65 and weighed 86.2 kg. Assessment of the carotid artery by ultrasound 
showed stenosis of 80-85%. Treating PMA stimulated plaque sections with apocynin increased 
the total neopterin to 1993 ± 1277 pmol/g on average (p=0.0079, paired t-test) (compared to 
1040 ± 771 pmol/g in the PMA only treatment) as shown in  a & b, but did not change the 
neopterin production compared to the previous day (385 ± 277 pmol/g vs. 400 ± 289 pmol/g; 
n.s.). Earlier experiments with PMA suggest that typically both total neopterin and neopterin 
continue to increase with ongoing stimulation of cells; however, plaque tissue is variable in its 
response to stimuli. It is not possible to know for certain whether the ablation of neopterin 
generation is directly due to the addition of the apocynin.  
In  Figure 5.2c & d, the plaque from the left internal carotid artery of a 64 year old, recent ex-
smoker, non-diabetic male who suffered from a stroke resulting in facial droop and slurred 
speech was cultured with apocynin prior to the addition of PMA. Blood pressure, weight and 
stenosis of the artery were not recorded on the patient information form. When apocynin was 
added before stimulating the plaque, there was an increase in basal total neopterin (210 ± 87 
pmol/g vs 118 ± 49 pmol/g (media only); p=0.03), which was unexpected. As the plaque was 
unstimulated in this case, it is likely that this effect is due to the addition of the apocynin. 
Interestingly, there was little to no change in neopterin (27 ± 10 pmol/g vs. 27 ± 25 pmol/g 
(media only); n.s.). However, upon stimulation with PMA there was a marked increase in 
neopterin production (110 ± 62 pmol/g vs 27 ± 10 pmol/g; p=0.01). It is not possible to tell 
from these results whether apocynin is competitively binding to p47phox and therefore 
preventing NOX activation or acting as an antioxidant. 
A separate plaque was obtained from the left carotid artery of an 83 year old male who 
experienced TIAs and weakness in their right hand (Figure 5.3). Stenosis was measured as 50-
69%.  Figure 5.3a shows that incubation with apocynin alone resulted in the immediate increase 
in total neopterin (1801 ± 815 pmol/g vs. 671 ± 522 pmol/g (media only); p=0.0007). In most 
sections, there was only a slight increase in neopterin (213 ± 189 pmol/g vs. 142 ± 83 pmol/g 
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(media only); n.s.)  accompanying the rise in total neopterin (Figure 5.3b). Incubation of 
apocynin in conjunction with interferon-gamma continued the increase in total neopterin 
(average increase 936 ± 306 pmol/g; p=0.0002), however, this time there was an accompanying 
increase in neopterin (190 ± 87 pmol/g; p=0.0012). Finally, incubation with interferon-gamma 
alone caused a further increase in both total neopterin (1332 ± 498 pmol/g; p=0.0004) and 
neopterin (330 ± 146 pmol/g; p=0.001). Apocynin is unable to abolish the interferon-gamma 
induced production of neopterin, however, the ratio of total neopterin to neopterin appears 
unexpectedly high.  
 




Figure 5.2 Effect of 100 µM of apocynin before or after stimulation using 5µM of PMA on total neopterin 
and neopterin production in plaque.  
(a) and (b) show the total neopterin and neopterin measured in a plaque from a 73-year-old, non-smoking, 
diabetic female. The plaque was cultured with PMA after the initial media only day and then with PMA and 
apocynin. This work was carried out by Sean Cross. (c) and (d) show the total neopterin and neopterin measured 
in a plaque from a 64-year-old, non-diabetic, recent ex-smoker male. The plaque was cultured with apocynin 
after the initial media only day and then with PMA. 
































































Figure 5.3 Effect of 100 µM of apocynin (a and b) before IFN-γ (500 U/mL) stimulation on total neopterin 
and neopterin production in plaque. 
 (a) and (b) show the total neopterin and neopterin measured in a plaque from a 64-year-old, non-diabetic, recent 
ex-smoking male. The plaque was cultured with apocynin after the initial media only day and then with 
apocynin and IFN-γ. On the final day, the plaque was cultured with IFN-γ alone. 




5.3.2 Experiments with interferon-gamma and ABAH 
An experiment with interferon-gamma alone found that after two days of interferon-gamma 
stimulation, there were between 2-3 pmol/g of total neopterin per 1 pmol/g of neopterin 
(Figure 5.4). This plaque from the bifurcation of the right common and internal carotid artery 
had been obtained from a 56 year old diabetic, non smoking male who weighed 107 kg. The 
patient had experienced amaurosis fugax (blindness) in both eyes. Stenosis of the artery was 
reported as 80-90%.  
A plaque from the left internal carotid artery was obtained from a 64 year old, non-smoking, 
non-diabetic male (Figure 5.5). The patient experienced TIAs and sensory loss in their right 
arm. Stenosis of the artery was recorded as 50-69%. Attempting to inhibit myeloperoxidase 
activity using ABAH had no effect on total neopterin (96 ± 61 pmol/g vs. 118 ± 48 pmol/g 
(media only); n.s.) or neopterin (59 ± 22 pmol/g vs. 83 ± 51 pmol/g (media only); n.s.) in 
the absence of stimulants ( a & b). Co-incubation of ABAH and interferon-gamma resulted 
in an increase in both total neopterin (319 ± 109 pmol/g vs. 96 ± 61 pmol/g (ABAH only); 
p=0.0007) and neopterin (184 ± 91 pmol/g vs. 59 ± 22 pmol/g (ABAH only); p=0.01). 
Further stimulation with interferon-gamma alone caused an increase in total neopterin in all 
sections (average increase 139 ± 69 pmol/g; p=0.0018), and neopterin in sections 3, 5, 6, and 
7 (average increase for all sections 87 ± 82 pmol/g; p=0.0312). ABAH does not appear to 
have an effect on plaque with neither a gain of total neopterin or the ability to prevent the 
formation of neopterin.  




Figure 5.4 Effect of IFN-γ (500 U/mL) stimulation on total neopterin and neopterin production in plaque. 
(a) and (b) show the total neopterin and neopterin measured in the media from a plaque obtained  from a 56-










Figure 5.5 Effect of 1 mM of ABAH (a and b) before IFN-γ (500 U/mL) stimulation on total neopterin and 
neopterin production in plaque. 
(a) and (b) show the total neopterin and neopterin measured in the media of a plaque obtained from a 73-year-
old, non-smoking, diabetic female. The plaque was cultured with ABAH after the initial media only day and 
then with ABAH and IFN-γ. On the final day, the plaque was cultured with IFN-γ alone.  
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5.3.3 Removing superoxide in plaque culture directly using PEG-SOD 
The previous experiments with ABAH and apocynin do not conclusively implicate 
superoxide in the formation of neopterin. Therefore, it was thought to test removing the 
superoxide directly using PEG-SOD (Figure 5.6). The plaque from the right internal carotid 
artery of a 69-year-old female, both a smoker and diabetic, was obtained. The patient had 
had a stroke in their right frontal lobe. Stenosis of the artery was described as 50-69%. PMA 
was added to the plaque tissue for two days to reach the maximal level of macrophage 
stimulation, and then on the final day, either PMA was added (in sections 1, 3, 5, and 7) as 
a control or PMA and PEG-SOD (sections 2, 4, 6, 8) to test the effect of removing 
superoxide. PMA stimulation increased total neopterin in all sections at 48 hours (1368 ± 
1054 pmol/g) and in 7 out of 8 sections at 72 hours (3562 ± 2328 pmol/g). Interestingly, 
from the lactate data it can be seen that peak glycolysis occurs at 72 hours coinciding with 
peak total neopterin production (Figure 5.6 e & f). At 96 hours, PEG-SOD treated section 2 
showed a sustained increase in total neopterin, whereas sections 4, 6, and 8 showed a slight 
decrease (mean increase 225 ± 2277 pmol/g; n.s. c.f. PMA only). Sections 1 and 3 
experienced a dramatic decrease in total neopterin, whereas 5 and 7 had a slight increase 
(mean decrease 79 ± 138 pmol/g; n.s. c.f. PEG-SOD). From b it can be observed that pattern 
of total neopterin across the sections of the plaque does not appear to change with the 
addition of PEG-SOD. Neopterin increased in 7 sections at 48 hours, and in 5 sections at 72 
hours. At 96 hours there was a decrease in neopterin across all sections, regardless of whether 
PEG-SOD was added or not.  
 




Figure 5.6 Effect of 5µM of PMA and PEG-SOD (50 U/mL) on total neopterin (a and b), neopterin (c and 
d) and lactate (e and f) production in plaque. 
(a) shows the total neopterin measured in in the media from a plaque obtained from a 69-year-old, smoking, 
diabetic female graphed according to each section, whereas (b) displays the same data per day. The plaque was 
cultured with PMA for two days after the initial media only day and then with PMA and PEG-SOD. (c) and (d) 
show the neopterin measured from the same plaque. (e) and (f) show the measured lactate levels. 
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5.3.4 Increasing the oxidant production in plaque by adding oxidized LDL 
Adding oxLDL to plaque culture after stimulating with PMA caused an increase in neopterin 
output (Figure 5.7). The plaque from the right internal carotid artery was obtained from an 81-
year-old non-smoking, non-diabetic male. The patient had experienced a stroke and had 
previously had a plaque from their left internal carotid artery removed in 2005. Stenosis of the 
artery was reported as 50-69%. In the absence of oxLDL, sections 1, 3, 7 experienced an 
increase in total neopterin compared to the previous day. In section 5, however, total neopterin 
decreased substantially from the previous day. The overall effect was no statistically significant 
change in total neopterin. In sections treated with oxLDL the results were also mixed, 2 of the 
sections (2, 8) had an increase in total neopterin, whereas sections 4 and 6 had a decrease. In 
the case of neopterin, all sections treated with oxLDL showed an increase, and  d shows that 
these sections are clearly producing more neopterin than the neighbouring sections, however, 
on the average difference in neopterin of 149 pmol/g between sections with oxLDL and without 
oxLDL is not significant. Combining sections showed there was no significant difference 
between those treated with and without oxLDL (Figure 5.8). OxLDL had no obvious effect on 
lactate production. 
A second experiment was conducted using native LDL (n-LDL) as the control instead of PBS. 
Sections were incubated with either nLDL (sections 1, 3, 5, 7) or oxLDL (2, 4, 6, 8) for two 
days (Figure 5.9). This plaque from the left carotid artery of an 85-year-old, non-diabetic male 
had been obtained. The patient had experienced a TIA and the stenosis of the artery was 
reported as 70-80%. Lactate was assessed to see if oxLDL influenced plaque metabolism. In 
sections incubated with nLDL, total neopterin increased at 48 hours (307 ± 92 pmol/g vs. 156 
± 81 pmol/g (media only); p=0.017). At 72 hours, total neopterin decreased in section 1, 
remained relatively constant in section 7, and increased in sections 3 and 5. OxLDL treatment 
resulted in an increase in total neopterin in all sections at 48 hours (mean = 423 ± 187 pmol/g) 
and in section 2 at 72 hours. Sections 4 and 6 experienced a slight decrease in total neopterin 
at 72 hours. Treatment with oxLDL caused a continual increase in neopterin in all plaque 
sections (mean values: 35 ± 19 pmol/g, 24 h.; 203 ± 99 pmol/g, 48 h; 233 ± 131 pmol/g, 72 h). 
Sections 4 and 6 both seem to produce much more neopterin than the surrounding sections. 
OxLDL treatment appeared to have no effect on lactate levels (figure 5.7). In contrast, nLDL 
treatment increased neopterin at 48 hours (96 ± 31 pmol/g vs. 31 ± 8 pmol/g; n.s.), although 
this was not statistically significant, but the effect at 72 hours was more variable (mean 103 ± 
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84 pmol/g). Intriguingly, sections treated with nLDL experienced a large decrease in lactate 
production at 72 hours, which did not occur in the oxLDL treatment.  




Figure 5.7 Effect of 5µM of PMA and OxLDL (2 mg/mL) on total neopterin (a and b), neopterin (c and d) 
and lactate (e and f) production in plaque. 
(a) shows the total neopterin measured in the media from a plaque obtained from an 81-year-old, non-smoking, 
non-diabetic male graphed according to each section, whereas (b) displays the same data per day. The plaque 
was cultured with PMA for two days after the initial media only day and then with either PMA alone or PMA 
and oxLDL. (c) and (d) show the neopterin measured from the same plaque. (e) and (f) show the measured 
lactate levels. 
































































Figure 5.8 Combined plaque sections after incubation with  5µM of PMA with or without OxLDL (2 
mg/mL) on neopterin (a) and total neopterin (b) 
shows the total neopterin measured in the media from a plaque obtained from an 81-year-old, non-smoking, 
non-diabetic male. Data is mean with SD. An unpaired t-test was carried out on each dataset (n=4). There was 
no statistical difference between the presence or absence of oxLDL for either neopterin (p=0.0795) or total 
neopterin (p=0.3296). 
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Figure 5.9 Effect of OxLDL (2 mg/mL) and nLDL (2 mg/mL) on total neopterin (a), neopterin (b) and 
lactate (c) production in plaque. 
(a) shows the total neopterin measured in the media from a plaque obtained from an 81-year-old, non-smoking, 
non-diabetic male. The plaque was cultured with either nLDL or oxLDL for two days after the initial media only 
day (b) shows the neopterin measured from the same plaque. (c) shows the measured lactate levels. 
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5.3.5 Increasing and inhibiting oxidants in macrophages  
In HMDM cells with no exogenous 7,8-dihydroneopterin, the experiment took place over 12 
hours, to prevent major cell loss because of oxLDL toxicity. Treatment with oxLDL caused a 
small but non-significant rise in intracellular total neopterin (Figure 5.10). Co-incubation of 
oxLDL with PEG-SOD resulted in 91.5 pmol/mg protein of total neopterin. OxLDL and PEG-
SOD with oxLDL both resulted in a decrease in intracellular neopterin compared to a cell only 
control (10 pmol/mg and 8.8 pmol/mg respectively, c.f. 14.8 pmol/g for the control). However, 
the extracellular results were the opposite. OxLDL alone and oxLDL with PEG-SOD decreased 
total neopterin compared to the control (84 pmol/g and 53 pmol/g respectively, c.f. 150 pmol/g 
for the control) and increased neopterin (11 pmol/g and 16 pmol/g respectively, c.f. 8.9 pmol/g 
for the control). When the intra- and extracellular results are combined, in the absence of 
exogenous 7,8-dihydroneopterin, oxLDL decreased total neopterin, whether PEG-SOD is 
present or not, but there is little to no effect on neopterin. PEG-SOD appears to influence the 
location of the total neopterin and neopterin, increasing intracellular total neopterin and 
extracellular neopterin. 
In HMDM cells with exogenous 7,8-dihydroneopterin, the experiment was carried out at 24 
hours to better match the plaque experiments. OxLDL toxicity is unlikely to be an issue in the 
presence of exogenous 7,8-dihydroneopterin which is known to protect against cell death. 
Photographs of the cells show no evidence of cell death (Figure 5.12). The addition of PEG-
SOD without oxLDL significantly (p=0.01) increased intracellular total neopterin by 3090 
pmol/g (Figure 5.11). PEG-SOD in the presence of oxLDL ablated the decrease in total 
neopterin that occurred in the oxLDL only treatment. OxLDL caused a small decrease (70 
pmol/g) in neopterin, however, this was not statistically significant. HMDMs treated with 
oxLDL had significantly less extracellular total neopterin compared to the control (p<0.0001), 
whereas the introduction of PEG-SOD in the absence of oxLDL cause a significant rise in total 
neopterin (35.70 nmol/g) compared to the control. As occurred in the intracellular results, PEG-
SOD in conjunction with oxLDL ablated the decrease in total neopterin that occurred within 
the oxLDL only treatment. Finally, treatment with oxLDL in the presence or absence of PEG-
SOD had no effect on neopterin, however, treatment with PEG-SOD alone significantly 
decreased extracellular neopterin. PEG-SOD appears to be better at protecting cells from 
extracellular 7,8-dihydroneopterin loss in the presence of exogenous 7,8-dihydroneopterin. 




Figure 5.10 Effect of 2mg/mL of oxLDL and 50 U/mL of PEG-SOD on intracellular and extracellular 
total neopterin and neopterin on HMDM cells in the absence of exogenous 7,8-dihydroneopterin. 
HMDM cells with either PBS, 2 mg/mL of oxLDL, 2 mg/mL of oxLDL with 50 U/mL of PEG-SOD or 50 
U/mL of PEG-SOD alone for 12 hours (n=3). Intracellular total neopterin and neopterin were measured in a 
HMDM culture (a) and (b), and extracellular total neopterin and neopterin (c) and (d). (e) and (f) represent the 
combined intracellular and extracellular values. Error bars represent SEM. A one-way ANOVA was performed, 
and there was no statistically significant difference between any of the data. 








Figure 5.11 Effect of 2 mg/mL of oxLDL and 50 U/mL of PEG-SOD on intracellular and extracellular 
total neopterin and neopterin on HMDM cells in the presence of exogenous 7,8-dihydroneopterin (200 
µM). 
HMDM cells were incubated in 200 µM of 7,8-dihydroneopterin for two hours prior to the addition of either 
PBS, 2 mg/mL of oxLDL, 2 mg/mL of oxLDL with 50 U/mL of PEG-SOD or 50 U/mL of PEG-SOD alone for 
24 hours (n=3). Intracellular total neopterin and neopterin were measured in a HMDM culture (a) and (b), and 
extracellular total neopterin and neopterin (c) and (d). Error bars represent SEM. Significance is indicated as 
compared to the 7,8-dihydroneopterin only control: * indicates p<0.05; **, p<0.01; ***, p<0.001. 





Figure 5.12 Light microscopy of HMDM cells after 24 hours culture. a) represents HMDMs that were 










The effect of ABAH on plaque appears to be muted. One might suggest that it is not possible 
to know whether the ABAH molecule inhibited MPO, as there was no change in measured total 
neopterin or neopterin. Comparing the ABAH molecule to apocynin (Figure 5.13) or PMA, 
which have both been found to act upon plaque, there is no immediate reason to believe that 
this molecule would not be taken up by the plaque. This plaque responded to the introduction 
of IFN-γ, so it is unlikely there is anything relating specifically to this plaque that would prevent 
uptake from occurring, although it is recommended that for future experiments as secondary 
marker is used to confirm uptake of the target molecule. Furthermore, the use of ABAH to 
inhibit MPO is well characterized in cell culture experiments (Kettle et al., 1995). A possible 
reason for the limited effect is significant amounts of MPO are not present in plaque at this 
advanced stage. Sugiyama et al. (2001) identified some MPO-positive macrophages in ruptured 
plaque (~118 per 100x field of view). However, it was clear not all macrophages in the plaque 
were producing MPO. In addition, they found little evidence of MPO-positive neutrophils. This 
suggests that the processes occurring in plaque are likely quite separate to the rapid neopterin 










Figure 5.13 Chemical structures of PMA and ABAH 
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As the results indicate that MPO may not be particularly active in the plaque, then it is possible 
that apocynin may be having an antioxidant effect in the plaque culture experiments rather than 
directly inhibiting NOX. This hypothesis could be confirmed through direct measurement of 
MPO in the plaque. This may explain why the effect on total neopterin is much larger than the 
effect on neopterin. It may also explain why removing apocynin from the media produced an 
immediate increase neopterin. A comparison to other known antioxidant in plaque culture 
would be useful to further understand this effect. Whilst the experiments with apocynin do not 
give a clear answer on the involvement of NOX in the generation of superoxide in plaque, they 
do show that adding 100 µM apocynin is not enough to prevent neopterin formation. 
The effect of PEG-SOD and oxLDL in HMDMs seems to be at complete odds with the plaque 
data. Excess 7,8-dihydroneopterin in plaque culture was generated using PMA but was likely 
to be lower than the 200 µM 7,8-dihydroneopterin added to HMDM culture. PMA also has the 
effect of generating superoxide, but PEG-SOD in plaque did not seem to have any major effect 
on total neopterin or neopterin, so potentially PMA is not generating a large number of 
oxidants. This is backed up by the evidence that generally in plaque tissue treated with PMA 
the amount of total neopterin being generated is 5-7x higher than the amount of neopterin being 
produced. The PEG-SOD was carried out in a high responder plaque, whereas the oxLDL 
experiment was carried out in a low-responder plaque.  
It seems from this work that is very easy to increase 7,8-dihydroneopterin or neopterin 
production in plaque tissue but shutting down this process is a much more difficult task. If 
anything, these results appear to suggest that the cells in plaque tissue are responding correctly. 
The cells identify a threat or increase in oxidants, there is a burst of antioxidant activity, and 
then there is a slow down once the threat has been dealt with. Perhaps, but incubating the plaque 
tissue with such high levels of stimulants to ensure a response, it is mimicking a situation of 
bacterial threat. It would be interesting to experiment with constant low doses of oxidants to 
measure the response in a situation that is likely to be more similar to the slower progression 
of atherosclerosis. Particularly of note from these experiments and those in Chapter 4, is that 
the plaque clearly has the capability to produce significant quantities of both 7,8-
dihydroneopterin and neopterin, however, it is very rare that they do on the media only day. 
This seems to suggest that the plaques, although they are vulnerable, and have often recently 
ruptured, are not in an activated state.  
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5.4.1 Plaque Culture 
Plaque culture provides an effective system to test how the plaque tissue truly behaves but this 
has several aspects that are not possible to control. These begin at the patient level, with a wide 
age range, patients on a mixture of different drug treatments, and different patient histories 
(smoker, diabetic). It is not possible to know how these variables impact the result that is seen 
in the tissue. If enough plaques could be collected it may be possible to do a multi-factorial 
statistical assessment to find which changes at the patient level have a significant impact on 
biomarkers. At present, with just receiving plaques from a single hospital that services a 
population of less than 500,000 it is too difficult to obtain enough numbers to conduct this kind 
of study. However, the ability to do large scale testing is further limited by time constraints. 
Each plaque culture and analysis takes a minimum of a week. For the meantime that limits the 
research to studies where relative changes in biomarkers are assessed as opposed to absolute 
biomarker levels. Despite these limitations, these experiments are beneficial in the context that 
many of these questions have never been explored in plaque tissue previously.  
At the experimental level there are also several factors at play. It is not possible to cut the 
sections to be the same size, as even if the sections are sliced at the same width, they vary in 
diameter and thickness. This will always result in variations in surface to volume ratio. Again, 
it is unknown whether this difference in tissue size has implications for the results. Typically, 
treatments are added at a standard dose without considering the size or weight of the tissue. It 
is possible some of the differences in the response of the tissue may be due to some pieces 
receiving a dose of 20 µM per gram and others receiving 8 µM per gram. This issue becomes 
fraught when considering that the weight of the piece of tissue may be greatly affected by the 
volume of calcium present. Ideally, one would know the cellular (or non-calcified) composition 
of the tissue before beginning the experiment, however, with the time required to process the 
material decomposition of the MARS image, this is not currently feasible. However, it is likely 
with improvements to the system, this should be feasible soon. Fortunately, this is not such an 
issue for considering how typical drug treatments impact plaque inflammation status, which 
would normally be delivered as a bolus in vivo, for example, understanding the effects of 
statins. For this reason, this is probably the best avenue to exploit with the plaque culture system 
going forward.  
The method employed here has been to carry out a single experiment per donated plaque. This 
limits the ability to carry out statistical analysis as even though the plaque is cut into 7 or 8 
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sections, the n value per experiment is 1. But with the very limited supply of plaques available, 
carrying out the same experiment across multiple plaques would greatly limit the number of 
questions that could be investigated. Proposed here is a new method, which would overcome 
some of these issues. This new method has been developed based on the results from the plaque 
experiments in this thesis. This would involve using two sections from each plaque to conduct 
an experiment, one from the outer edge, and one from the inner part, as the experiments in this 
thesis have shown that these two areas behave differently. In an 8 section plaque experiment 1 
would be conducted on sections 1 and 5, experiment 2 on sections 2 and 6 and so on. This 
would allow four experiments per plaque. These same experiments would then be repeated 
across five separate plaques. That would provide four experiments with n=5 and a total of 10 
data points each, which should be enough to carry out statistical analyses. This should reduce 
variation, as  showed that plaque segments from similar parts of the plaque behave more 
similarly to each other than those from different regions within a single plaque. 
There is difficulty in modifying just a single variable at a time due to temporal effects. The 
experiment with a single dose of interferon gamma showed the prolonged effect the stimulation 
had even the interferon gamma was removed from the media. This continued effect is most 
likely due to modifications at the DNA and RNA level, which from time of stimulation can 
take 24-48 hours to reach their peak. This becomes difficult if you are adding a different 
treatment each day and trying to isolate the effect of that treatment. The experiment with PMA 
+ PEG-SOD showed this. If all segments had had PEG-SOD added on the final day, the 
decrease in neopterin and total neopterin would have been thought to be due to the addition of 
the PEG-SOD, but the control cells which only had PMA showed a decrease was also naturally 
occurring. The reason for stimulating the plaques was two –fold: one, to produce a signal that 
is high enough to be easily assayed by HPLC and two, to mimic an active plaque amid 
inflammation. However, the amount of stimulus added is probably excessive compared to what 
would be normally found, and it may be better to investigate plaque behaviour without artificial 
stimulation. This would make the HPLC assay more difficult as the changes in neopterin would 
be much subtler, but this could be overcome by spiking the samples with a known concentration 
of neopterin to give greater clarity to the peaks. If the plaque has not been pre-stimulated, then 
it is possible to be confident that the effect measured is due to the stimulus added. To assess, 
combinations of effects, its best to carry these out in separate experiments. For example, a 
single experiment with oxLDL, and then a second experiment testing the effect of oxLDL with 
7,8-dihydroneopterin. These two experiments would be carried out as described earlier so the 
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only difference would be that they were using different sections from plaques, but the data 
points would be made up by the same patients, which should eliminate plaque to plaque 
variation. 
5.5 Conclusion 
Oxidant production in excised plaque tissue can be modulated through the addition of 
exogenous stimulants. This provides a system to test the response of plaques to other 
compounds such as statins or other medications patients may be receiving to learn how this 
affects the oxidative biomarkers that are measured in clinical settings. 
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6  Plaque baseline production of 7,8-dihydroneopterin and neopterin: 
correlation to plasma markers 
 
In this chapter, I collected, cultured and carried out the analysis for 11 of the plaques. 5 plaques 
were prepared by Sean Cross. All data interpretation in the chapter is my own.  
 
6.1 Introduction 
Neopterin has shown promise as an inflammatory biomarker for cardiovascular disease. 
However, the relationship of neopterin and 7,8-dihydroneopterin as measured in the plasma 
compared to its production in excised plaque tissue has not previously been explored. In fact, 
there is no evidence from the literature of a plasma biomarker being compared to its production 
in a live tissue counterpart. It is hypothesized that plaque tissue is a major source of plasma 
neopterin and 7,8-dihydroneopterin in vivo (Adachi et al., 2007; S. P. Gieseg et al., 2008). As 
mentioned previously, due to its small size, neopterin diffuses out of tissue into the plasma. 
Neopterin is cleared fairly rapidly from the plasma into the urine via glomerular filtration 
(Werner et al., 1987), but it is less clear whether 7,8-dihydroneopterin is cleared as effectively 
as neopterin. At present, there is a lack of studies investigating plasma 7,8-dihydroneopterin 
levels. The aim of this chapter is to investigate whether there is a relationship between plasma 
total neopterin, 7,8-dihydroneopterin or neopterin and their plaque counterparts. This likely 
depends on whether the excised piece of tissue is representative of the level of inflammation 
occurring in the patient’s cardiovascular system as a whole. Due to the small nature of this 
study, correlations have been carried out on an unadjusted dataset. It is recognized that factors 
such as age and sex are known to affect patient neopterin levels (M. E. Spencer et al., 2010), 
but given that this work is exploring the relationship between matched plasma and tissue 
samples, these factors are unlikely to have a major effect. In addition, the correlation of blood 
lactate with the inflammatory markers is also considered. Lactate was already being monitored 
in the plaque media as a method for obtaining glycolytic activity, plasma (or blood) lactate has 
previously been identified as being increased during carotid atherosclerosis (Shantha et al., 
2013). Blood lactate has also been hypothesized as a marker of oxidative capacity (Mongraw-
Chaffin et al., 2012). 
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6.2 Methods in brief 
This chapter examines the baseline plaque production of neopterin and total neopterin (and by 
subtraction, 7,8-dihydroneopterin). All readings were taken from the supernatant from the 
second day of culture, after an initial wash out day. The plaques at this stage were only 
incubated with human serum containing media. No stimulants were added. The plasma samples 
that were analysed were obtained just prior to surgery. Neopterin and total neopterin levels in 
the media and plasma were determined HPLC as previously described.  
In this chapter, total neopterin and neopterin values are standardized by the plaque section 
weight. Correlations are carried out using the average value i.e. total neopterin or neopterin 
output per plaque (standardized per gram) divided by the number of sections. This analysis was 
limited to plaques that were suitable for tissue culture (n = 16). Plaques examined were 112, 
113, 114, 116, 119, 120, 122, 123, 126, 127, 129, 131, 134, 135, 137, 138 – refer to Appendix 
B. Not all plaques had a blood sample supplied by the surgeon. Four plaques without plasma 
samples have been excluded from the correlation (n=12). One plaque was not correctly 
assessed for lactate and has been excluded (n=11). 
Media lactate concentrations were determined using a lactate assay as described in Chapter 2. 
  




6.3.1 Variation in whole plaque and plaque section weight 
The number of sections produced by each plaque is limited by the length of the excised 
specimen. Only one plaque produced less than five sections (Table 6.1). Five plaques produced 
seven sections and ten plaques that produced eight sections. The average section weights are 
similar but there is a wide standard deviation, particularly for sections 2 and 3. Although the 
procedure aimed to produce sections of a consistent width, this was not always possible due to 
areas of dense calcification that caused the scalpel blade to deflect. Even if the width was 
consistent, it was not possible to control the tissue diameter or volume (level of stenosis) within 
or between plaques. Plaque total weight ranged between 0.4 g and 1.4 g with most plaques 
weighing between 0.7 and 0.9 g (Figure 6.1). Tissue thickness and the amount of calcification 
present likely contributed to this variation.  
Table 6.1 Average weight per plaque section from all cultured plaques. 
Each plaque was sectioned into pieces of approximately 2mm width. This resulted in between 4 and 8 plaque 
sections depending on the length of the piece of tissue. Individual tissue culture plates were weighed. The plaque 
section was then placed into the plate and reweighed. The plate weight was then subtracted to find the section 
weight. 
 
Section Average Weight (g) SD N 
1 0.085 0.055 16 
2 0.089 0.095 16 
3 0.090 0.087 16 
4 0.092 0.045 16 
5 0.093 0.056 15 
6 0.095 0.045 15 
7 0.101 0.038 15 
8 0.103 0.044 10 
 




Figure 6.1 Mean and Standard Deviation of Total Plaque Weight from Cultured Plaques. 
Plaques were weighed whole prior to sectioning, immediately after arrival in the laboratory. 
6.3.2 Variation in total neopterin and neopterin in media and plasma between individuals 
The average total neopterin output in plaque was most variable in sections 1, 2, 3, 8 (Figure 6.2). 
Total neopterin values had a much wider range than neopterin (0 – 7800 pmol/g vs 0 – 1100 
pmol/g respectively). Neopterin showed a relatively similar amount of variation across all 
sections, with mean neopterin values close to 250 pmol/g for all sections. A comparison of the 
total plaque output of total neopterin compared to neopterin clearly demonstrates this 
difference in variation between the two (Figure 6.3). The graph of total plaque output suggests 
that some patients have a much higher antioxidant capacity being generated by their plaques 
than others, as evidenced by the difference between the total neopterin and neopterin values. 
Interestingly, by comparison plasma does not show such a clear difference with neopterin and 
total neopterin values varying by roughly similar ranges (15- 45 nM for total neopterin and 8 
– 30 nM for neopterin) (Figure 6.4). The next section examines the relationship between plaque 
antioxidant capacity and plasma antioxidant capacity.  




Figure 6.2 Mean and Standard Deviation of Baseline Total Neopterin and Neopterin produced in all 
cultured plaque sections. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. The media from the 
cultured plaque sections were assayed for neopterin and total neopterin using the SCX HPLC method. A one-way 
ANOVA was performed. There was no statistical difference in total neopterin or neopterin production between 
sections. 
































Figure 6.3 Mean and Standard Deviation of Baseline Neopterin and Total Neopterin produced in all 
cultured plaques. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. The media from the 
cultured plaque sections were assayed for neopterin and total neopterin using the SCX HPLC method. Neopterin 
and total neopterin values from the sections of each plaque were summed together. A paired t-test was performed 
(n=12). There was no statistical difference between total neopterin and neopterin production (p=0.068). 
 
























Figure 6.4 Mean and Standard Deviation of Neopterin and Total Neopterin in patient plasma samples. 
Patient plasma samples were obtained immediately prior to surgery. The plasma was separated from the red blood 
cells by centrifugation. The plasma samples were assayed for neopterin and total neopterin using the SCX HPLC 
method. A paired t-test was performed (n=12). There was a statistical between neopterin and total neopterin in the 
plasma samples (p=0.0157).   
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6.3.3 Relationship between neopterin, 7,8-dihydroneopterin and total neopterin 
The table below (Table 6.2) shows the relationship between total neopterin, neopterin and 7,8-
dihydroneopterin values in the plasma of carotid endarterectomy patients. The table has been 
arranged according to their 7,8-dihydroneopterin concentration. Quartiles were determined 
from the patient data. The 1st quartile is labelled low; however, this term low means relative 
to the other patients as opposed to healthy controls. The lowest neopterin value measured in 
this cohort was 8.42 nM (maximum; 28.3 nM) whereas the reported healthy range for neopterin 
is 5-7 nM (Tatzber et al., 1991). Patients with low 7,8-dihydroneopterin (less than 2.3 nM) 
exhibited high or very high neopterin levels, with only one patient with low levels of total 
neopterin. This suggests this group is experiencing increased oxidative stress. Patients with 
high or very high 7,8-dihydroneopterin levels had variable neopterin and total neopterin levels. 
This suggests that high 7,8-dihydroneopterin levels are not purely due to high inflammation or 
low oxidation but rather a complex interplay between the two. As this study was open to all 
patients undergoing endarterectomy surgery at Christchurch Hospital, this is a cross-sectional 
group. The information about the patient’s co-morbidities and percent stenosis have been 
recorded in the table below but there are not enough data points in each category to assess any 
relationship between % stenosis, disease severity or co-morbidities and 7,8-dihydroneopterin 
values.  
Not all patients with plasma samples had their plaques cultured, and conversely, not all patients 
with cultured plaques had plasma samples available.  contains the values from all the plaques 
that were cultured. Patients without values in this table either did not have blood samples 
supplied or the sample was stored in a way that prevented accurate neopterin/total neopterin 
analysis. Of note is that the group that had the highest levels of plasma 7,8-dihydroneopterin 
are the same group that show the lowest plaque levels of 7,8-dihydroneopterin. This is a 
relationship that is worth investigating further. Here we have only examined the plaque output. 
The relationship between total neopterin and 7,8-dihydroneopterin appears to be much more 
straightforward in plaque culture, for example, low total neopterin typically results in low 7,8-
dihydroneopterin. Patients with very high total neopterin typically also had very high levels of 
7,8-dihydroneopterin and neopterin. It is not yet understood how total neopterin and neopterin 
levels in the plaque tissue impact the patients’ health outcomes.  
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Table 6.2 Patient data arranged by plasma 7,8-dihydroneopterin level 
1st quartile = low; 2nd and 3rd quartiles = high, 4th quartile = v.high  
# Age Event Smoker Diabetic Weight % Stenosis Sex Total Neopterin Neopterin 78NP 
1 81 stroke 
  
82 50-69 M High V.High Low 
2 70 TIA no yes 
 
50-69 M High High Low 
3 83 TIA 
   
50-69 M High V.High Low 
4 89 weakness 
 
no  60-70 M Low High Low 
 
5 83 TIA no no  50-69 M Low High High  
6 75 TIA no yes  <50 M High  V.High  High  
7 79 TIA    50-69 M V.High  High  High  
8 65 dysphasia ex no 70 80-99 M High  High  High  
9 64 stroke recent ex    M Low Low High  
10 64 TIA no no 65 50-69 M Low Low High  
           
11 68 TIA no no 93  M High  High  V.High  
12 75 Stroke no no 60 60 F V.High  High  V.High  
13 81 stroke no no  50-69 M V.High  Low V.High  
14 56 Amaurosis no yes 107 80-90 M V.High  Low V.High 
 
 
Table 6.3 Patient data arranged by plaque 7,8-dihydroneopterin level 
 
       
     
Plaque 
 
# Age Event  Smoker Diabetic Weight % Stenosis Sex Total Neopterin Neopterin 78NP 
11 68 TIA no no 93   M Low Low Low 
10 64 TIA no no 65 50-69 M Low High Low 
13 81 stroke no no   50-69 M Low Low Low 
12 75 Stroke no no 60 60 F Low High Low 
 
6 75 TIA no yes 
 
<50 M High High High 
 73 TIA 
 
yes 86 80-85 F High High High 
3 83 TIA       50-69 M High High High 
14 56 Amaurosis no yes 107 80-90 M High Low High 
5 83 TIA no no   50-69 M V.High V.High High 
9 64 stroke recen
t ex 
     M Low Low High 
 85 TIA   yes   70-80 M Low Low High 
 
 69 Stroke yes yes 
 
50-69 F High High V.High 
 82 TIA no     80-95 M V.High V.High V.High 
2 70 TIA no yes 
 
50-69 M V.High V.High V.High 
8 65 dysphasia ex no 70 80-99 M V.High V.High V.High 
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6.3.4 Correlation between plasma and plaque values of neopterin, total neopterin, and 7,8-
dihydroneopterin 
Where both plasma and plaque data were available, the relationship between the plasma 
biomarkers and those released into the tissue culture media were assessed. The were no 
significant correlations between average plaque neopterin and plasma neopterin, plaque total 
neopterin and plasma total neopterin, and plaque 7,8-dihydroneopterin and plasma 7,8-
dihydroneopterin. The relationship of plaque total neopterin to plasma total neopterin was 
completely random (r=-0.09). Plasma neopterin to plaque neopterin had the strongest 
correlation of r=-0.40, but the residuals (the distance between the line of best fit and the data 
points) are large. The data suggests that there is no relationship between total neopterin in 
plaque and plasma, but it may worth exploring the relationship between plaque and plasma 
neopterin with a larger dataset where adjustments for age, sex and co-morbidities are possible. 
The correlation between plasma total neopterin and plaque neopterin is very close to 0 (r= -
0.08, n.s.), but this is somewhat expected, as it would have been unlikely for plasma total 
neopterin to have a bearing on plaque neopterin that is being measured ex vivo. It is not possible 
to rule out that there would be a relationship between these two values in vivo, where there is 
more chance of an interplay between plasma and plaque. There was a very slight correlation 
(r=-0.22) between plasma neopterin and plaque total neopterin but again the small sample size 
makes generating meaningful statistics difficult.  
Intracellular plaque values have not been assessed as these plaques were used for further 
experimentation in the subsequent days after the baseline assessment was carried out. 




Figure 6.5 Correlation of (a) plaque neopterin to plasma neopterin, (b) plaque total neopterin to plasma 
total neopterin, and (c) plaque 7,8-dihydroneopterin to plasma 7,8-dihydroneopterin. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. Patient plasma 
samples were obtained immediately prior to surgery. The plasma was separated from the red blood cells by 
centrifugation. The plasma samples and cultured media were assayed for neopterin and total neopterin using the 
SCX HPLC method. A Pearson correlation was performed, and a regression line applied to the dataset. 





Figure 6.6 Correlation of (a) plaque total neopterin to plasma neopterin and (b) plaque neopterin to 
plasma total neopterin. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. Patient plasma 
samples were obtained immediately prior to surgery. The plasma was separated from the red blood cells by 
centrifugation. The plasma samples and cultured media were assayed for neopterin and total neopterin using the 
SCX HPLC method. A Pearson correlation was performed, and a regression line applied to the dataset. 
 
6.3.5 Correlation of blood and plaque lactate values to plaque total neopterin and neopterin 
values 
Blood lactate has previously been identified as being positively correlated with carotid 
atherosclerosis (Shantha et al., 2013). A normal blood lactate value is between 0.5 and 1.0 mM 
(Mongraw-Chaffin et al., 2012). Blood lactate, measured in the plasma, increased with plaque 
total neopterin (Figure 6.7). The Pearson correlation coefficient for this was 0.62, which was 
significant. Neither the relationship of blood lactate to neopterin nor 7,8-dihydroneopterin were 
significant, although both had a positive association. There was no correlation between plaque 
lactate and blood lactate (Figure 6.8). There was also no relationship between the amount of 
neopterin or total neopterin generated by a plaque and the amount of lactate generated by the 
plaque (Figure 6.9). 




Figure 6.7 Correlation of blood lactate to plaque total neopterin (a), neopterin (b) and 7,8-
dihydroneopterin (c).  
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. Patient plasma 
samples were obtained immediately prior to surgery. The plasma was separated from the red blood cells by 
centrifugation. Lactate was measured in the plasma samples using a colorimetric lactate assay kit and cultured 
media were assayed for neopterin and total neopterin using the SCX HPLC method. A Pearson correlation was 
performed and a regression line applied to the dataset. 





Figure 6.8 Correlation of Blood Lactate to Plaque Lactate. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. Patient plasma 
samples were obtained immediately prior to surgery. The plasma was separated from the red blood cells by 
centrifugation. Lactate was measured in the plasma and plaque media samples using a colorimetric lactate assay 




Figure 6.9 Correlation of plaque lactate to plaque (a) total neopterin and (b) neopterin. 
The plaques were incubated in RPMI-1640, supplemented with 10% human serum for 24 h. Patient plasma 
samples were obtained immediately prior to surgery. The plasma was separated from the red blood cells by 
centrifugation. Lactate was measured in the plaque media samples using a colorimetric lactate assay kit and the 
plasma samples were assayed for neopterin and total neopterin using the SCX HPLC method. A Pearson 
correlation was performed and a regression line applied to the dataset. 
 
  




Total neopterin, neopterin and 7,8-dihydroneopterin values obtained from plaque culture do 
not appear to be correlated with their plasma counterparts from the results presented here. The 
initial study here comparing the levels of plaque neopterin and total neopterin to the plasma 
biomarkers shows some promising trends, however, the study is impeded by the small sample 
size. It was difficult to determine if there are any outliers in the dataset, so all points available 
are contributing to the dataset. 
It was interesting to find that high 7,8-dihydroneopterin levels in plasma were often not 
reflected in the plaque tissue. This raises some questions about whether 7,8-dihydroneopterin 
is intended to act as an antioxidant at source or whether it is generated elsewhere and enters 
the plasma to be transported to appropriate locations around the body. The literature is 
surprisingly silent on the in vivo role of 7,8-dihydroneopterin (S. P. Gieseg et al., 2008; S. P. 
Gieseg et al., 1995). Entering the plasma would allow 7,8-dihydroneopterin to counter sudden 
oxidative bursts which individual cells may be too slow to react to. It is known that upregulating 
7,8-dihydroneopterin from the gene level takes 24-48 hours to reach a maximum level of output 
(Burrowes, 2012). Previous work carried out in this laboratory has shown that 7,8-
dihydroneopterin is taken up into the cell via ENT/CNT transport (Tejraj Janmale, 2013), yet 
cells making 7,8-dihydroneopterin seem to leak significant amounts to the extracellular space, 
an interesting and largely unexplored dynamic, which may have physiological relevance.  
Total neopterin in plaque was found to be correlated with blood lactate levels. Blood lactate is 
associated with mitochondrial dysfunction (Yeo et al., 2008), and in particular endothelial cell 
dysfunction and has previously been found to be associated with carotid atherosclerosis 
(Mongraw-Chaffin et al., 2012; Shantha et al., 2013). It is unknown whether there is any link 
between blood lactate and total neopterin, or whether they are separately upregulated in carotid 
atherosclerosis. It may be worth exploring whether there is any association between 
macrophage activation and endothelial dysfunction.  
This work confirms previous results found in this laboratory that the levels of neopterin and 
total neopterin vary through the different regions of the plaque (Tejraj Janmale, 2013; T. 
Janmale et al., 2015) and that there is a large amount of variation amongst individuals. 
Obtaining healthy controls for live plaque tissue for comparison is largely not possible due to 
the fact healthy tissue is generally not removed from patients. However, the ends of the plaque 
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tissue tend to appear less diseased than the central regions, which may explain why the ends 
tends to show higher levels of cellular activation. Interestingly, histological studies have found 
that cellular density increases in the shoulder and cap regions of the plaque, but where 
macrophages make up 46% of the shoulder region, they only contribute 1.6% to the cap 
(Docherty, Carswell, Friel, & Mercer, 2018).  
6.5 Conclusion 
 
Whilst the results here do not show a correlation between plaque and plasma values except in 
the case of total neopterin and blood lactate, there may be a relationship between some of these 
values. Obtaining further data points would allow a multivariate analysis to look at the impact 
of sources of variation, e.g. co morbidities, on this relationship. There is significant value to 
being able to draw conclusions about a patient’s plaque or their cardiovascular system from 
their plasma levels of biomarkers, so it is certainly worth continuing to explore this further as 
samples become available. 
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7 Developing imaging procedures for assessing plaque vulnerability 
The research was carried out in collaboration with Harshil Gulati (summer student), and Emily 
Searle (MSc candidate), as part of a summer studentship funded by Callaghan Innovation. For 
this body of work, I contributed to the design of the experiments and carried out all manual 
preparation of the plaque samples including the photography. I conducted the scanning and 
material decomposition of the  plaques in Fig 7.3 and assisted Harshil with the plaque in 7.14, 
Emily conducted the scanning and material decomposition of the remain plaques. I prepared 
the chemical and blood phantoms. The scanning and material decomposition was carried out 
by Emily. Raj Panta provided technical assistance for modifying the scanner calibration. All 
interpretation of the results here is my own. 
The work in this chapter relating to section 7.8.3 is being published as 
a conference proceeding in the Journal of Instrumentation. 
 
7.1 Introduction 
Plaque vulnerability, the breakdown of structural integrity in the plaque resulting in thrombus 
formation (Hansson, Libby, & Tabas, 2015), is the key to whether a patient is at risk of an 
adverse event. Yet, these small changes in the structure of the plaque are incredibly difficult to 
study or assess in humans due to the quality of information achieved using current imaging 
techniques. As early as 2012, the MARS scanner has been shown to be able to non-invasively 
identify components that are thought to contribute to the destabilization of plaque (Zainon et 
al., 2012). The research conducted here investigates optimizing MARS scanning to identify 
components of the plaque that have been identified in the literature as being related to plaque 
vulnerability, including calcium and lipid. It continues to build on the previous work using the 
improved hardware, detection and material decomposition algorithms and by investigating the 
identification of intraplaque haemorrhage using ferric nitrate. The MARS project brings 
together a range of disciplines, ranging from medical physics to software development, and is 
constantly evolving. Many of the research projects currently being conducted to are contributed 
to by numerous people in the team. These ongoing developments include a concerted effort to 
improve the quality and performance of the system. In the time since the initial research was 
conducted and even over the course of this thesis, the system was upgraded from single chip to 
a 3-chip camera. This dramatically reduced the time need to scan a sample, from around an 
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hour per sample, to now around 10 minutes. Other improvements to the scanner have reduced 
the time required for reconstruction and analysis. The small animal scanner is now at a level of 
development where relatively high throughput can be achieved. One of the aims of this work 
is to demonstrate that MARS spectral scanning has reached a level of quality and stability 
where it is now possible to design larger sample size studies to investigate plaque morphology. 
7.1.1 Principles of spectral CT for quantitative material assessment 
Traditional CT uses energy integrating detectors to measure the intensity of photons passing 
through an object. The denser the material, the fewer the photons that reach the detector. This 
ignores the fact that each incoming photon has its own energy. The energy of the photon gives 
information about the material in the object. Photon counting detectors such as Medipix3, used 
by the MARS scanner, measure the energy of each arriving photon, and then allocate that 
photon to an energy bin. These energy bins or thresholds are flexible and user-defined. By 
measuring reference materials, characteristic curves for known materials can be generated. 
These are used to quantitatively assess materials in an unknown sample using a process called 
material decomposition. It is only possible to separate materials if there is a substantial enough 
difference between the characteristic curves of the materials. For example, separating glucose 
from fructose would be impossible, but separating gold from iodine is quite feasible. 
7.1.2 Separating iron from calcium in spectral CT 
Traditional CT is not typically used to discriminate iron as its attenuation profile too like other 
materials (Figure 7.1). Separating the iron and calcium signal with spectral CT is challenging, 
as whilst spectral CT is capable of distinguishing and quantifying multiple materials at once, 
this becomes problematic if the spectral signals are not distinct. As can be seen from Figure 
7.2 below, the k-edges, which give high-z materials their distinctive spectral signal, in iron and 
calcium are relatively close to one another, and sit outside of the diagnostic energy range. 
Whilst this is challenging, parameters on the scanner such as the energy bins and the choice of 
material concentrations in the calibration phantom can be modified. This work builds on 
previous calibration and protocol testing looking at improving the separation of the two 
materials. The aim here is to show that iron and calcium separation can be achieved in a 
biological sample containing haemorrhage. 




Figure 7.1 Image of a thrombus taken by traditional CT. Image reproduced from Roshal (2016). Permission 
has been sought from the publisher. 
 
Figure 7.2 Spectral signal and k-edge of calcium and iron. Images reproduced from Hubbell and Seltzer 
(1995). Permission has been sought from the publisher. 
 
7.2 Methods in brief 
7.2.1 MARS spectral scanning protocols 
Phantoms were designed as described in Chapter 2. Plaque imaging for lipid, water and calcium 
was conducted using 2mm Aluminium filtration with energy bands beginning at 18, 30, 40, 50 
and 60 keV, tube voltage 118 kVp, tube current 13 μA and exposure time of 200ms. When 
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assessing iron content as well, thresholds were set at 20, 28, 36 and 44 keV, with a tube voltage 
of 80 kVp, a tube current of 55 μA and 100ms exposure time. For the plaque with haemorrhage, 
2mm Al filtration was used with a tube voltage of 120 kVp, tube current of 36 μA. Energy 
thresholds were set at 18, 29, 45, and 75 keV. Exposure time was 100 ms with 720 projections 
captured. 
7.2.2 Method developed for calculating plaque volume by using ImageJ 
Total plaque volume provides interesting insight into the size of the plaque sample relative to 
its weight. This provides information about the density of the tissue, and a tool by which to 
compare between plaque samples. For example, to investigate whether plaque volume 
increases with age or percent stenosis. To obtain total plaque volume the area containing all 
materials excluding the sample tube were measured. This was carried out by cropping out the 
sample tube and using the image thresholding technique in ImageJ as follows: 
Reconstructed energy images were opened in ImageJ. The cropping tool was used to select the 
area inside the tube, and then selecting to delete everything outside of the highlighted area. The 
stack was converted to a hyperstack and the dimensionality reduced to ensure only one energy 
image from each slice was used. The threshold was then adjusted to make sure the highlighted 
area included all regions of the plaque. The analyse particles tool was then used to measure the 
resulting thresholded areas. The area of each slice was multiplied by the slice thickness to 
achieve a volume. The volumes from each slice were added together to get the total plaque 
volume.  
7.2.3 Calculating plaque calcium volume by using ImageJ 
The calcium volume was calculated in much the same way but instead of using the energy 
reconstruction, the material decomposition files were used. The material decomposition images 
from the hydroxyapatite channel were loaded into image J. As these were material 
decomposition there was no need to reduce dimensionality as there was only one image per 
slice. The thresholding tool was used making sure that all the calcium, no matter what density, 
was selected to ensure microcalcifications were captured. The analyse particles tool was then 
used as described above and the volume calculation was performed.  
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7.3 Results and Discussion 
7.3.1 Identification of calcium as a marker of plaque vulnerability 
In Chapter 3, it was found that volume of calcium was inversely related to the amount of plaque 
activation. MARS spectral CT is able to identify both dense calcification (Figure 7.3, top) and 
microcalcification (Figure 7.3, bottom). Section 5 has calcification evenly dispersed 
throughout the section, whereas section 4 has one area of dense calcification on the surface of 
the tissue, and then very fine microcalcification throughout the rest of the tissue. Interestingly 
these two sections were immediately adjacent to one another in a single plaque specimen. It is 
possible that the calcification in section 5 was so dense that scalpel blade essentially skimmed 
the outside of it, resulting in these two very different sections. 
 
 
Figure 7.3 MARS images of plaque sections 5 (top) and 4 (bottom) of plaque 120 displaying two different 
types of calcification from within a single plaque. 
Red represents soft tissue (water), calcium is in white, and lipid is in beige. Images on the left include all 
material channels. Images on the right highlight just the calcium channel. The colour scheme is the same for the 
top and bottom images. The plaque section in the top image contains more lipid than the section in the bottom 
which is predominately soft tissue and calcium.   
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Examining a small number of plaque specimens showed wide variation (2.8% - 29%) in the 
percentage of the plaque made up of calcium deposition (Table 7.1 ). Calcium score is not 
traditionally measured in carotid arteries, but this information may be of relevance for 
clinicians. 
Table 7.1 Plaque volume and total volume of calcification in a selection of plaques 
Plaque Number  82 115 118 136 
Ages (yrs.) 75 81 73 82 
% stenosis 60-69 50-69 severe critical narrowing  75 
Plaque volume (mm3) 1379.36 987.52 762.76 1223.51 
Total Assigned Calcium Volume(mm3) 
 38.07 63.14 219.61 147.15 
Calcium as % of total volume 2.8% 6.4% 29% 12% 
7.3.2 Investigation of inconsistent plaque lipid values in material decomposition 
Each MARS scanner comes with factory designed protocols in which the parameters have been 
set to provide the best results for an experimental sample. The plaque protocol was designed 
with the goal of accurately separating lipid, calcium and soft tissue. This protocol had been 
used successfully for over a year to generate material decomposition of plaque tissue. Figure 
7.4 to Figure 7.7 were the first examples of receiving an unexpected result using this well-
established scanning protocol. Plaques previously scanned using the protocol produced a 
distribution of lipid, soft tissue and calcium consistent with literature descriptions of plaque 
morphology and composition (as demonstrated in Figure 7.3). The plaques in Figure 7.4 to 
Figure 7.7 are notable in the lack of lipid signal present. In addition to the lack of lipid signal, 
the images appear to lack the complexity that previous images contained. For example, whilst 
calcium has been identified, there seems to be no evidence of microcalcification. In all the 
images, soft tissue seems to be the dominant material, but even within this, the density appears 
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Figure 7.4 Photograph (left) and MARS image (right) of Plaque 82.  




Figure 7.5 Photograph (left) and MARS image (right) of Plaque 115 
This plaque was obtained left internal carotid artery of an 81-year-old male who had suffered from a stroke and 
hypertension. Stenosis was recorded as 50-69%.  
 





Figure 7.6 Photograph (centre) and MARS image (left and right) of Plaque 118. 
The plaque was obtained from the right internal carotid artery of a 73-year-old diabetic male who had a TIA and 






Figure 7.7 Photograph (first and third image) and MARS image (second and fourth image) of Plaque 136. 
The plaque was obtained the left internal carotid artery of an 82-year-old male who had suffered a stroke. 
Stenosis was recorded as 75%. 
 
The first assessment of the situation was that the MARS images appeared to lack definition 
compared to previous plaque scans. It was also noted that the datasets appeared to contain 
almost no lipid. After establishing that this was not due to the colour scheme selected but due 
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to an inherent issue in the data set several hypotheses for what could have caused the problem 
were formulated. Firstly, it was thought that perhaps the plaques chosen may have been of a 
more fibrous phenotype. It seemed relatively unlikely that five separate plaques selected at 
random would all display this phenotype. To assess this, plaques were stained with oil red O 
to rule out the issue being a lack of lipid in the plaque material itself (Figure 7.8 and Figure 
7.9). This seemed unlikely to be the case but was relatively easy to test. The areas of gruel in 
two separate plaques both stained with the oil red O as well as areas around the edge of the 
tissue showing that lipid is present in the plaque samples. This suggests that there was a 
problem with the material decomposition computation or the scanner itself. 
 
 
Figure 7.8 Photograph of Plaque 82 unstained (left) or stained with oil red o (right) 
  






Figure 7.9 Photograph of Plaque 136 stained with oil red o (left) or unstained (right) 
Secondly, it was noted that these scans were carried out after the installation of a new 3 sensor 
camera on the scanner. It was thought that a material decomposition calibration of the scanner 
was not performed at the time the camera was changed over (1 chip upgraded to 3 chips). A 
recalibration of the scanner was performed, which improved the automatic reconstruction of 
scans to some extent, but is unlikely to explain the lack of lipid in the material decomposition 
images above as the MARS images shown in Figure 7.4 to Figure 7.7 were produced using a 
manual calibration using values that were obtained from a phantom performed at the same time 
as the scan. It was noted that linear attenuation values between scans can be variable, which is 
why it is recommend that a phantom be scanned along with the samples of interest. 
Thirdly, it was noted that extremely low levels of calcium had been identified in nearly all 
voxels. It was thought that perhaps microcalcification was preventing the lipid signal from 
being seen due to the partitioning in the material decomposition algorithm. A plan was made 
to test this by swapping the values for lipid and water, so that voxels made up of lipid and 
calcium could possibly be identified. However, before this could be implemented it was noted 
that there were inconsistencies in the phantom used to produce the plaque images. Given that 
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micro calcification had never had such a dramatic impact on lipid values previously, it was 
decided that examining the phantom MD in more detail would be a better direction to pursue.   
A closer examination of the phantom used for the material decomposition for these plaques 
found that the material decomposition was not correctly identifying the materials (Table 7.2). 
Lipid is identifying as 60% water, and only 34% lipid, a large misclassification. Water was 
identifying correctly with no misclassification of lipid or hydroxyapatite (calcium) present. 
However, hydroxyapatite was not classifying correctly. The measured concentration was at 
most half the expected value (200 mg/ml in the 400 mg/mL sample). The 400 mg/ml 
hydroxyapatite sample recorded 3.37 g/mL of water, which is not physically possible. In 
examining the phantom, it was noted that the lipid vial was placed in the centre which is not 
recommended due to the possibility of increased beam hardening in the middle of the phantom. 
This may have contributed to the poor resolution of water from lipid. In addition, the water vial 
was next to the highest concentration of hydroxyapatite, which is also likely to cause beam 
hardening. It is recommended that for each protocol a range of normal linear attenuation and 
material decomposition values are established, so that errors can quickly be identified, and the 
source of the error can be tracked down. It would be worthwhile to quantify the effect of 
phantom layout on linear attenuation values to establish whether the placement of vials is 
having a detrimental impact on the material decomposition.  
Table 7.2 Measurements from the phantom used to calibrate the MD for the previous images. 
Water Content (g/mL) Lipid Content (g/mL) Hydroxyapatite Content (g/mL) 
Water 1.03 Water 0.01 Water 0.00 
Lipid  0.61 Lipid  0.34 Lipid  0.00 
Ha00  1.10 Ha00  0.00 Ha00  0.00 
Ha50  1.21 Ha50  0.00 Ha50  0.03 
Ha100  1.31 Ha100  0.00 Ha100  0.06 
Ha200 1.51 Ha200 0.00 Ha200 0.11 
Ha400 3.37 Ha400 0.00 Ha400 0.21 
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7.3.3 Imaging intraplaque haemorrhage  
Intraplaque haemorrhage is associated with plaque vulnerability (Michel, Virmani, Arbustini, 
& Pasterkamp, 2011). Whilst conducting the plaque culture experiments described in chapter 
4 it was noted that neovascularization and haemorrhage were relatively common features 
(Figure 7.10). However, these plaques did not always survive the four days in culture intact 
(Figure 7.10) which meant they could not be scanned later. From experience, it was known that 
plaques that had a darker discolouration on the exterior tended to contain areas of intraplaque 
haemorrhage. Whilst it would also be interesting to investigate neovascularization, plaque 
haemorrhage was selected as the first target due to the higher likelihood of being able to identify 
it using spectral imaging. At present, neovascularization sits just below the resolution the 
MARS spectral scanner. It was unknown whether it would be possible to separate calcium from 
iron, as they are relatively close to each other on the periodic table (Fe 26, Ca 20), and it was 
uncertain if the k-edge of iron and calcium would sit in different energy bins. Ferric nitrate was 
chosen to represent iron due to its similarity to the form of iron likely to be found in vivo. An 
initial test carried out by Ms Searle showed that using ferric nitrate phantoms, iron should be 
identified within blood clots. 
 
  






Figure 7.10 Evidence of neovascularization and intraplaque haemorrhage in plaque sections 
 
 
Figure 7.11 Plaque 158 with suspected intraplaque haemorrhage 
 
 
Figure 7.12 Ferric Nitrate signal in blood clots 
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Given the issues that had occurred previously with quantification of materials in the phantom, 
the misidentification and quantification of the calibration phantom for this scan was carefully 
assessed. Figure 7.13 shows the measured concentration of ferric nitrate against the given 
concentration. At all concentrations ferric nitrate is measured as less than the actual 
concentration. This is mainly due to the overlap between calcium and ferric nitrate which is 
not unexpected. Interestingly, the values for ferric nitrate are much higher in the plaque (in the 
order of g/mL rather than mg) than we are using for the phantom. It may be possible to increase 
the concentrations of ferric nitrate to improve the separation between ferric nitrate and calcium. 
It is much easier to modify the ferric nitrate values as these are solutions are prepared in the 








Figure 7.13 Misidentification of materials 
  




The plaque selected for this experiment was obtained from the right internal carotid artery of a 
74-year-old male smoker who weighed 62 kg (Figure 7.14). The patient had suffered a stroke 
in his retina. The patient had a blood pressure of 154/70. An ultrasound had identified the 
stenosis to be 70%. The cut that can be seen in the photo of the plaque is caused by the 
procedure used to remove it. The plaque measures 32 mm in length and 14 mm in width. A 
bifurcation is clearly identifiable. In the cut images, the bifurcation sits at the rear the right-
hand segment. There is a distinctive discoloration under the tissue in the central region of the 
plaque. Tissue at the extremities of the plaque seems relatively smooth and healthy. This plaque 
contains a typical necrotic core. Areas of dark brown discolouration within the necrotic core 
can be seen, as well as voids and areas of yellow deposits, most likely lipid. The fibrous cap 
containing the necrotic core can be seen at the outer edges. This layer has eroded in the centre 
of the necrotic region. On the right hand cut section, there is an area of what appears to be 
ulceration in centre of the necrotic core.  
 
  







Figure 7.14 Photographs of Plaque 158, back view, front view, sagittal slice view. 
The plaque was obtained from the right internal carotid artery of a 74-year-old male smoker weighing 62 kg. 
The patient had suffered a retinal stroke. Ultrasound identified the stenosis at 70%. The top image shows the 
front and back of the specimen prior to it being cut open. The bottom image is after a single cut was performed 
through the length of the plaque. The open plaque reveals a gruelly mass consistent with an advanced plaque. 
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Analysis of the plaque using MARS spectral scanning found the discoloration to be caused by 
deposits of a material that identified as ferric nitrate like, which is most likely to be intraplaque 
haemorrhage (Figure 7.15). Further analysis of the plaque shows regions of dense calcification 
as well as distinct microcalcification. A closer examination of the bifurcation shows an area of 




Figure 7.15 3D visualisation of plaque 158 from MARS Vision of the whole plaque (left), magic lens to 
show intraplaque haemorrhage (centre, blue), and with photo of the interior of the bifurcation overlain 
(right).  
Red represents the soft tissue, beige represents lipid, white represents calcium and blue represents iron. The 
image on the left is a 3D mesh, showing just the materials present on the surface of the tissue. The image in the 
centre has a circular magic lens applied which will reveal only iron, all other materials are stripped away.  
 
A close up of the area associated with the intraplaque haemorrhage within the bifurcation 
reveals an area where the fibrous cap appears to have failed and a portion of the necrotic core 
appears to have eroded (Figure 7.16). Given that this patient suffered a stroke in their retina, it 
is likely that this is the source of the stroke. Interestingly, the area where the fibrous cap appears 
to have eroded is mostly identifying as calcification, while the area where there is ulceration is 
coated in lipid. The areas closest to the eroded cap appear to contain lipid deposits as well as 
several distinct areas of intraplaque haemorrhage. Further examination using the magic lens 
tool which strips away all layers except the one that has been selected shows that there are 
spotty iron deposits throughout the region potentially associated with the rupture. This may 
explain the distinctive red coloration in the tissue. Sequential axial slices show remnants of the 
lipid rich area that has most likely ruptured.  






Figure 7.16 MARS image of plaque bifurcation (a), photograph of plaque bifurcation (b), close up of 
MARS image of plaque bifurcation (c) and with magic lens for iron (d). 
Orange-red represents soft tissue, beige is lipid, white is calcium, and iron is in dark red-maroon. The blue box 
in (a) and (b) highlights the area of ulceration. Black dashed line in (c) indicates area of thin fibrous cap erosion. 
The area of normal fibrous cap below it can be seen as containing lipid. 
a b 
c d 
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Examining just prior to the ulceration, it can be seen that some of the lipid core remains (Figure 
7.17a, yellow arrow). There is evidence of surface disruption surrounding the ulceration. An 
area directly to the left of the lipid core contains iron deposits as indicated by the red arrow. To 
the right is an area where calcification (white arrow) has reached the surface of the tissue. There 
is lipid coating the bottom of the ulceration. The ulceration is roughly 2mm in diameter. 95% 
of ruptured fibrous caps are less than 65 µM thick possibly composed of foam cells (Burke et 
al., 1997). Figure 7.17 b and c appear to be consistent with this measurement as the remaining 
cap is close to a single voxel (90 µM) in thickness. These images show a high degree of 
complexity in the distribution of lipid, soft tissue, calcium and iron. This shows that the issues 
of material identification in section 7.3.2 associated with the scans in Figure 7.4 - Figure 7.7 
have been resolved by using better constructed phantoms for calibration. 
Figure 7.17 Axial slices (a-d) showing the progression of an ulceration in plaque 158 in four separate slices. 
Orange-red represents soft tissue, beige is lipid (yellow arrow), white is calcium (white arrow), and iron is in dark 
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Figure 7.18 shows the benefit of being able to examine the entire plaque tissue. Current 
histology techniques would have meant that areas of interest need to be preselected through the 
choice of where to slice the plaque with the potential to miss crucial or interesting results. The 
number of histological slices that can be produced per sample is generally limited due to 
practicality reasons. Here it is easy to identify the distribution of the materials of interest, e.g. 
iron, across the entire sample. In this sample, the intraplaque haemorrhage is co-localized with 
areas of denser calcification. While there is a small possibility this is due to misidentification 
of materials, this finding is consistent with histological studies on excised carotid plaque 
specimens (Bini et al., 1999).   
Figure 7.18a also contains multiple air pockets in the tissue, which possibly indicate areas of 
previous ulceration and remodelling. Again, these air pockets would be very difficult to 
visualise using histology due to the methods used to prepare samples. Many methods end up 
washing away some of the principal components such as microcalcifications or cholesterol 
crystals, which means it would be difficult to identify whether a void had truly been a void in 
the tissue or was just an artefact from the histology procedure. Figure 7.18 b (black arrow) 
indicates another ulceration, which can be identified in the photographs (again indicated by a 
black arrow in Figure 7.19) as well as in the 3D model. As this ulceration is on the part of the 
plaque that leads to the brain, it is possible that this patient may have had a silent infarction, 
which is known to occur in up to 15% of patients with high grade stenosis (Brott et al., 1994). 
In Figure 7.18 b and c, tissue with a healthy appearance gives a strong lipid signal on both the 
interior and exterior walls but as the tissue becomes more diseased the lipid signal on the tissue 
surface disappears. This suggests that with further analysis of the distribution and thickness of 
lipid on the plaque surface, it should be possible to create a tool to analyse the surface for areas 
of disruption and weakness which contribute to plaque vulnerability. 
 




Figure 7.18 Axial, coronal and sagittal slices from plaque 158. 
Orange-red represents soft tissue, beige is lipid, white is calcium, and iron is in dark red-maroon as identified in 
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To further characterize this plaque, it was sliced open horizontally. Figure 7.19 and Figure 7.20 
compare photographic images of the plaque to an example from an axial slice of the 3D 
rendered MARS image. The dashed arrows on Figure 7.19 indicates where the axial slice was 
taken from. The red circles identify areas of increased iron deposits, and the yellow circle, lipid. 
The solid black line identifies an area of ulceration which was discussed previously. In figure 
7.20, calcium is in white, lipid in yellow, iron is dark red and soft tissue is in orange.  
 
  





Figure 7.19 Photograph of Plaque 158 cut in half. 
Red circles indicate areas of potential iron deposits and yellow for lipid. The solid arrow indicates an area of 







Figure 7.20 Axial 3D MARS image of plaque 158. 
Orange-red represents soft tissue, beige is lipid, white is calcium, and iron is in dark red-maroon. Red circles 
indicate areas of potential iron deposits and yellow for lipid. The dashed white line represents the horizontal cut 
in the plaque 




Overall, there is excellent alignment between the photographic evidence and the MARS 
material image. This shows that MARS imaging is now at a stage where it can produce high 
quality, material decomposition images with good alignment to expected results. With high 
level images such as these it is now possible to start exploring ways to quantify plaque 
vulnerability across a range of subjects, using some of the methods suggested here such as 
plaque surface disruption, quantification of the amount of haemorrhage or microcalcification. 
It may be possible to move from the current cross-sectional approach to a more targeted 
approach analysing, for example, the differences in plaques based on the age of the patient. 
This could initially be conducted from the catalogue of frozen plaques that are currently stored. 
In addition, it may be worth also obtaining frozen plaque samples from other hospitals to 
increase the sample size for each grouping.  
By resolving the issue around lipid detection and introducing detection of intraplaque 
haemorrhage, MARS imaging of vulnerable plaque is now sufficiently advanced to begin use 
as a quantitative tool. It is now possible to successfully obtain the distribution and concentration 
of microcalcification across the plaque, and there is initial evidence supporting the ability to 
detect ulceration and disturbances in the fibrous cap. Furthermore, a technique for identifying 
intraplaque haemorrhage has been successfully tested in blood clots and plaque tissue.   
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8 Imaging of nanoparticle probes targeting macrophages 
The research was carried out in collaboration with Emily Searle (MSc candidate) and Dr Aamir 
Raja (Research Fellow, University of Otago), as part of a short project funded by a Grant-In-
Aid from the Heart Foundation of New Zealand. For this body of work, I contributed to the 
design of the experiments and prepared the labelled LDL. I conducted all aspects relating to 
cell culture. Emily conducted the scanning and material decomposition of the samples. All 
interpretation of the results here is my own. 
The work in this chapter was presented as a poster at the Society for Biomaterials meeting, 
Atlanta, GA, USA, 2018.    
8.1 Introduction 
For the last 30 years, iodine has been the primary contrast agent for imaging with CT (Riederer 
& Mistretta, 1977). Recently, it has been shown that two contrast agents (iodine and 
gadolinium) can be detected simultaneously using dual energy CT (Badea, Holbrook, Clark, & 
Ghaghada, 2018). However, spectral CT introduces the ability to capture the k-edge of multiple 
materials simultaneously (Moghiseh et al., 2016). This has opened the development of new 
contrast agents for CT. One of the most utilized of these new contrast agents has been gold 
nanoparticles due to their flexibility for attachment of antibodies, sensitivity of detection, and 
ease of use (Cormode et al., 2010; Hainfeld, Slatkin, Focella, & Smilowitz, 2006; Haller et al., 
2015; Park, Pramanick, Kim, Lee, & Kim, 2017).  
Here, the uptake of non-functionalized gold nanoparticles in HMDM cells has been explored 
in the presence and absence of human serum. In addition, functionalized nanoparticles were 
produced by using contrast agent, either iodine or gold nanoparticles, attached to a natural 
nanoparticle, LDL. Using LDL would be significantly more cost effective than antibody 
targeting. The advantage to using gold in the nanoparticle form is the ability to attach many 
more atoms of gold than if it were in an ionic form (Liu, Atwater, Wang, & Huo, 2007).  
To test the in vitro uptake of labelled LDL a monocyte-like cell culture line, U937, which can 
be differentiated into macrophage-like cells has been used. Monocytes and macrophages have 
been identified as a key target, as these cells are involved in the very first stages of the 
development of the atherosclerotic lesion (Biessen & Wouters, 2017). Monocytes and 
macrophages take up LDL, which has become oxidised in the intima, via the scavenger receptor 
CD36 (Ceolotto et al., 2017; Chistiakov, Bobryshev, & Orekhov, 2016; Shchepetkina et al., 
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2017). This process is uncontrolled and eventually the cells become full of toxic oxLDL and 
become necrotic, causing the formation of the necrotic core (Bekkering et al., 2014; Boshuizen 
et al., 2016).  
The work in this chapter was focused on the methodology around producing contrast-enhanced 
LDL and is the first step towards a wider aim of developing spectral imaging techniques in 
conjunction with nanoparticle contrast agents that may allow atherosclerosis to be diagnosed 
at an early stage, where intervention will be much more effective. 
8.2 Methods in brief 
Plasma was obtained from healthy donors under ethics approval CTY/98/07/069 granted by 
the Upper South (B) Regional Ethics Committee. LDL was isolated from donor plasma using 
a centrifugation gradient separation method as described by Gieseg and Esterbauer (1994) as 
described in detail in Chapter 2. Isolated LDL was washed with phosphate buffered saline 
(PBS) using an Amicon Ultra-15 membrane filter centrifugation tubes (Millipore, USA) at 
3000 g, 4ºC for 30 minutes, and repeated twice. LDL concentration was adjusted to 10 mg 
(LDL total mass) per mL, which was determined using a total cholesterol assay kit (Roche 
Diagnostics, Germany), assuming the total cholesterol accounts for 31.69% of the LDL particle 
(MW 2500kDa). 
Iodinated LDL (I-LDL) was prepared by gently mixing 500 µL of 20 mM ICl in 2M NaCl with 
1 mL of 10 mg/mL LDL. This solution was washed using the ultra-membrane filter tubes as 
described above. Native LDL (n-LDL) was prepared in the same manner except with the 
addition of 500 µL of PBS rather than ICl. Gold nanoparticle labelled LDL (Au-LDL) was 
prepared by mixing 500 µL of 0.5 mg/mL AuNPs with 1 mL of 10 mg/mL LDL (method 
modified from Handley, Arbeeny, and Chien (1981)). All solutions were filter sterilized 
through a 0.22 um filter prior to use in cell culture. Precipitation of LDL was initially carried 
out using 50% Trichloroacetic acid (TCA)/50% H2O. Upon scanning the pellets, the native 
LDL pellet registered as containing as much iodine as the I-LDL 




Figure 8.1 Iodine measurement by spectral CT of pellets of n-LDL and I-LDL. The iodine concentration 
was measured by selecting five regions of interest each of the same size within the pellet. Error bars are SD. 
As the signal was consistent in both the pellet and the liquid region above the pellet which 
contained TCA, it was suspected that the misidentification was being caused by the TCA, 
possibly due to the high chlorine content. For subsequent experiments precipitated LDL was 
obtained by adding 500 µL of acetonitrile (ACN) to 500 µL of LDL (native, iodinated or Au-
labelled) in 1.7 mL Eppendorf tubes and vortexing for 30 seconds. Precipitates were then 
centrifuged at 15,000 RPM for 10 minutes at 4ºC to form pellets. The ACN supernatant was 
then removed and the pellets were carefully removed from the Eppendorf tubes and placed into 
PCR tubes for MARS spectral scanning. ACN precipitated pellets did not result in the 
misidentification of iodine. 
 
Figure 8.2 ACN precipitated pellets of I-LDL, Au-LDL and n-LDL (left to right) 
 
For cell experiments, U937 cells were cultured in RPMI-1640 media containing 5% FBS. 
U937s were plated into 12 well plates (Nunc, Thermo Fisher Scientific, NZ Ltd) and 
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(PMA). Cells were then treated with n-LDL, Au-LDL and I-LDL at a final concentration of 2 
mg/mL for 24 hours. The supernatant was then removed and the U937 cells were lifted from 
the plate using 200uL of Accutase which was incubated at room temperature for 15 minutes. 
The resulting liquid was transferred to PCR tubes and the cells were pelleted by centrifugation 
(1500 RPM, 5 minutes 20ºC).   
The MARS Spectral scanner (V 6.0) was used to image the tubes containing the samples of 
LDL (native, iodinated, and Au-labelled). For the initial analysis, the sample holder contained 
the liquid and precipitated LDL samples, in both their native form (control) and iodinated (I-
LDL). In addition, samples of water, lipid, 9 mg/mL iodine and 18 mg/ml iodine were present, 
which are necessary for the calibration of the scan and analysis of results. In the same manner 
for the subsequent scan, the sample holder included the Eppendorf tubes of precipitated LDL 
(native, iodinated, and Au-labelled), accompanied by water, lipid, 9 mg/ml iodine, 18 mg/mL 
iodine, 4 mg/mL gold chloride (AuCl3) and 8 mg/mL AuCl3. For the final scan, the sample 
holder contained the PCR tubes of cells treated with n-LDL, I-LDL and Au-LDL, along with 
samples of water, lipid, 9 mg/ml iodine, 18 mg/mL iodine, 4 mg/mL AuCl3 and 8 mg/mL 
AuCl3. 
The above experiments were imaged using a Factory Al Protocol with a filtration of 2mm of 
aluminium, which blocks low energy photons which would typically not penetrate the skin in 
a human scan. Using this filtration helps improve the ability to translate this research directly 
to human scale imaging. The samples were scanned using a tube voltage of 118 kVp, a tube 
current of 13μA, and an exposure time of 300ms per projection. There were 720 projections 
representing one full rotation of the camera gantry. Four energy bins were used, these in the 
range 18 – 29.9 keV, 29.9 – 44.9 keV, 44.9-77.9 keV, and 77.9 keV- 120 keV. This energy 
range expresses the k-edge of iodine at approximately 33.2 keV and captures the increase in 
attenuation of gold in the higher energy band, representing the k-edge of gold at approximately 
80.7 keV. 
  




8.3.1 Non-functionalized gold nanoparticle uptake in macrophages 
In previous experiments conducted in this laboratory, it was noticed that non-functionalized 
gold nanoparticles tended to clump in the cell culture media. Although it was still possible to 
get enough nanoparticle uptake, this took up to 72 hours. This experiment compared the uptake 
of non-functionalized gold nanoparticles after 24 hours of incubation with HMDM cells in the 
presence or absence of human serum (Figure 8.3). After 24 hours in the presence of serum, the 
media no longer contains the pink hue that is typical of gold nanoparticles in solution, however, 
there is no visual evidence of gold nanoparticle uptake in the HMDM cells. In HMDM cells 
incubated with gold nanoparticles in the absence of serum, the cells contain dark deposits of 
gold nanoparticles after 24 hours. This suggests that a component of the human serum is 
preventing uptake of non-functionalized gold nanoparticles. 
 
Figure 8.3 Macrophages with 10 % Human Serum and Gold Nanoparticles prior to (top) and after 
(bottom) 24 hour incubation. 
200 µm 
 




Figure 8.4 Macrophages without Human Serum and Gold Nanoparticles prior to (top) and after (bottom) 
24 hour incubation. 
The cells were then lifted from the plate using 200 µL Accutase (as described in the Methods 
in brief) and pelleted so that they could be examined by spectral CT. The cells that had been 
incubated with gold nanoparticles in the presence of human serum showed no signal for gold, 
the same as the controls which did not contain nanoparticles. The HMDMs that had been 
incubated with gold nanoparticles in the absence of serum did identify positively as containing 
gold. This suggests that there may be difficulty in using non-functionalized gold nanoparticle 
to identify macrophages in vivo. To combat this issue, the next section of this thesis investigates 








Figure 8.5 Photo of layout of vials (left) and MARS image (right) of macrophages with non-functionalized 
gold nanoparticles.  
 
8.3.2 Modified LDL as a probe for macrophage like cells 
Liquid and precipitated LDL was prepared in either its native form (control) or I-LDL. At 10 
mg/mL LDL, there was no measurable iodine in the liquid sample as measured by MARS 
scanning and subsequent material decomposition. In the precipitate, both the control (n-LDL) 
and the I-LDL gave a significant iodine signal in the material decomposition of the spectral 
images. All further precipitations were carried out using ACN. Precipitates containing 10 mg 
of Au-LDL or I-LDL produced a significant signal. To investigate whether the uptake of I-
LDL or Au-LDL could be measured in monocyte-like and macrophage-like cells, we incubated 
un-differentiated and PMA-treated Au-LDL and I-LDL at 2 mg/mL.  There was little colour 
change seen in pelleted U937 cells (2 million per pellet), whether the cells were differentiated 
to be macrophage-like using PMA or not. The colour of the cell media had not changed as it 
typically would if labelled-LDL was being taken up. This suggests there was poor uptake of 
the I-LDL and Au-LDL in U937 cells. Examination of the U937 cells by microscopy shows 
that cells have changed morphology due to the addition of PMA to increase LDL uptake (Figure 
8.6). There is no evidence of gold clustering inside the cells (Figure 8.7) as was seen with the 
non-functionalized gold nanoparticles in HMDMs. Cells incubated with I-LDL appear to have 
undergone significant lysis, suggesting there may be a toxicity issue (Figure 8.8). Therefore, it 
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is not surprising that the MARS image of the pelleted cells did not indicate the presence of gold 




Figure 8.6 PMA-treated U937 cells before (left) and after (right) 24 hours incubation with n-LDL 
 
 
Figure 8.7 PMA- treated U937 cells before (left) and after (right) 24 hours incubation with Au-LDL 
 
 















Non-functionalized gold nanoparticles can be measured in macrophages in the absence of 
serum with a shorter incubation of 24 hours, but the presence of serum slows the uptake of the 
nanoparticles. Non-functionalized gold nanoparticles have been used successfully to 
investigate tumour neovascularization in a mouse model with spectral CT (unpublished). There 
was no evidence of the non-functionalised gold lodging in macrophages during the experiments 
conducted in this thesis however there were some key differences in that a much smaller 
nanoparticle was used for the tumour experiment, and the incubation time was longer. The 
tumour experiment also had the advantage that the leaky vessels enhanced the retention of gold 
nanoparticles. It is most likely that for gold-nanoparticles to be useful for in vivo experiments 
investigating macrophages they will need a form of targeting, such as to a cell surface receptor 
like CD68 or CD36.  
LDL showed some promise as a low-cost way to target macrophages, however, getting the 
contrast enhanced LDL to be taken up in U937 cells proved difficult. The reason for using LDL 
was that it is already an approved therapy. Whilst oxLDL would be more effectively taken up 
by the cell due to unregulated uptake via CD36, oxLDL is toxic to cells, limiting its value for 
use in humans. There was an expectation that LDL may be sufficient to introduce the 
nanoparticle into the cell, and then for the LDL to be recycled via ABCAI.  It is worth noting 
the maximum concentration of LDL that could be added to the cells was 2 mg/mL which is 
much lower than the 10mg/mL used for the precipitates. It was thought that if the cells had 
taken up the labelled LDL, there may have been a concentrating effect. It is possible that the 
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modification of LDL means that it is no longer recognized by the LDL receptor on U937 cells 
or that LDL uptake is severely limited by the number of receptors available (Tontonoz, Nagy, 
Alvarez, Thomazy, & Evans, 1998). An alternative possibility is that normal cell feedback 
mechanisms that are part of the regulation of cholesterol metabolism prevented significant 
uptake (Brown & Goldstein, 1983). Cormode et al. (2010) have used an alternative method that 
involves dissolving the lipid membrane of the LDL particle to insert the gold nanoparticles 
inside the LDL, and could see the uptake of these nanoparticles into the cell using TEM. This 
may be worth trialling with the MARS system. Otherwise, it may be possible to use modified 
LDL, such as acetylated-LDL or oxLDL which would avoid the normal regulation of 
cholesterol metabolism, and increase the amount accumulated in the cell (Jerome, Cox, Griffin, 
& Ullery, 2008).  
8.5 Conclusion 
Gold nanoparticles show promise as a contrast agent due to their ability to collect within 
macrophages which makes detection easier using tools such as MARS spectral CT. Developing 
viable methods for delivering gold nanoparticles targeted to macrophages or areas of increased 
inflammation is an ongoing research area. 
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9 General Discussion and Future Directions 
 
Assessing how this work sits alongside the current literature is a difficult task. For many of 
these experiments, for example, the plaque culture, there are no directly comparable results to 
draw upon. Spectral CT is such a new technology that whilst groups in the US are also 
experimenting with using it to investigate plaque specimens, no results are currently available. 
For neopterin, despite the fact it is routinely used to assess inflammation there are no studies 
investigating the mechanism of its formation. 
9.1 Biomarkers of inflammation 
One of the specific aims of this thesis was to investigate the inflammatory response of 
macrophages within excised atherosclerotic plaque and the relation of the clinical biomarker 
neopterin, and its parent compound, 7,8-dihydroneopterin, to the morphology of the plaque. In 
addition, to explore the role of superoxide, a reactive oxygen species produced by NADPH 
oxidase in macrophages, in the oxidation of 7,8-dihydroneopterin to neopterin. 
Neopterin is generated from superoxide induced oxidation of 7,8-dihydroneopterin, possibly 
via a stable charged intermediate. It is worth exploring the possibility of this intermediate 
further using techniques such as mass spectrometry, as this may be crucial to elucidating a 
mechanism for neopterin production in vivo that does not involve hypochlorite. One aspect that 
was not tested here was the effect of pH on the efficiency of neopterin generation. It is known 
that in the plaque environment there is a wide range of pH, anywhere from pH 6 - 8 (Naghavi 
et al., 2002), and this may help to explain why some sections of the plaque produce more 
neopterin than others. 
A further goal of this thesis was to investigate the relationship between plaque morphology and 
its biochemical response, particularly release of neopterin and 7,8-dihydroneopterin, to stimuli. 
Plaque total neopterin output (macrophage activation) is correlated to plasma lactate values, 
which are known to be associated with the degree of carotid atherosclerosis present, and 
inversely correlated to calcium volume. The results here indicate that there is new information 
to be obtained by measuring total neopterin in a clinical setting. This has recently been 
demonstrated in the case of patients with muscular dystrophy (Angus Lindsay, Schmiechen, 
Chamberlain, Ervasti, & Lowe, 2018). Further research is needed to understand how high levels 
of total neopterin in patient plasma contribute to positive or negative clinical outcomes. 
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9.2 Future of MARS imaging 
Another goal of this project was to develop techniques in conjunction with others that will 
identify macrophages and regions of interest within the plaque. In this thesis it has now been 
shown that key hallmarks of vulnerable plaque can be identified using MARS imaging. Much 
of this work has been focused on the identification of the markers as opposed to quantification. 
This project is now at a stage where it can move into characterizing and cataloguing plaques 
based on their morphology and composition. The next steps for this work are to assess how 
plaque vulnerability markers change across the population based on the vulnerable plaques that 
have already been collected. This work can move beyond the intrinsic markers discussed here 
to investigating macrophage density or phenotype using suitable nanoparticle-based contrast 
agents with specific antibodies bound. It is worth noting that some of this work has already 
been attempted by others using methods such as histology. The distinct value to repeating this 
work using MARS imaging is the ability to capture all the information from each plaque. 
However, a common criticism of this type of work is that by their nature all these plaques are 
vulnerable. Accessing plaques from autopsy is a possibility but as the patient is no longer alive, 
there is no way to know whether the plaque would have been vulnerable or not. These are two 
of the main reasons why establishing the triggers of plaque vulnerability has been so difficult 
in the past. MARS imaging is likely to solve this issue in the future, as the results obtained 
using excised specimens in the small animal scanner are directly translatable to human scale 
imaging. Within the next 5 to 10 years it should be possible to conduct a long-term study to 
follow plaque development and vulnerability in a clinical setting within minimal harm to those 
involved. In the meantime, cataloguing of existing plaques will help to identify which features 
should be explored first when the human scale technology is available. 
9.3 Conclusion 
This thesis investigated the relationship between plaque morphology and the biochemical 
markers of inflammation, 7,8-dihydroneopterin and neopterin. It was found that plaque total 
neopterin is inversely related to calcium deposition. This finding is significant as this is the 
first evidence that plaque morphology may influence inflammatory biomarkers. The 
biochemical response of plaque tissue is likely to be varied due to differences in morphology, 
which has implications for treatment of plaques in vivo. In addition, this thesis explored the 
role of superoxide in the oxidation of 7,8-dihydroneopterin to neopterin. It was found that 
oxidation to neopterin did occur, but this could be modulated using SOD and catalase. A 
possible mechanism for the oxidation to neopterin was hypothesized based on the evidence 
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presented here. This new evidence that superoxide has a role in neopterin formation is 
significant, as it adds to the evidence that both total neopterin and neopterin should be 
considered as clinical biomarkers for atherosclerosis. Finally, it has been shown here that using 
MARS spectral CT, images of plaque with regions of interest such as necrotic core, intraplaque 
haemorrhage and microcalcification can be obtained. This demonstrates this work is now ready 
for translation to human scale imaging where non-invasive images of the key hallmarks of 
vulnerable plaque will have an impact on how atherosclerosis is diagnosed and treated in the 
future. 
9.4 Summary 
Understanding the complex reactions that form neopterin from 7,8-dihydroneopterin are 
important for the utility of both neopterin and 7,8-dihydroneopterin as biomarkers of 
inflammation. Plaque culture experiments showed that modulation of oxidants influenced the 
balance of both neopterin and 7,8-dihydroneopterin, and that there is a differential response 
across the plaque tissue, dependent on the level of calcification. This is significant as this is a 
first step towards being able to relate macrophage activity in vulnerable tissue to plasma 
markers which would help to improve clinical assessment of atherosclerosis. 
MARS imaging of plaque tissue produces high quality images with excellent differentiation of 
key hallmarks of plaque vulnerability, including lipid pools within the necrotic core and 
microcalcification, which are highly consistent with visual inspection of the tissue. Intraplaque 
haemorrhage can be identified and differentiated from calcification in ex-vivo plaque tissue. 
This is significant as iron and calcium cannot be distinguished using traditional CT methods, 
and it provides a further tool to assess plaque vulnerability. 
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